articleURL: 0
10.1021/acs.jmedchem.9b00350
{"compound": "g associated kinase ( gak ) /epidermal growth factor receptor ( egfr ) inhibitor set to interrogate the relationship of egfr and gak in chordoma we describe the design of a set of inhibitors to investigate the relationship between cyclin g associated kinase ( gak ) and epidermal growth factor receptor ( egfr ) in chordoma bone cancers . these compounds were characterized both in vitro and using in cell target engagement assays . the most potent chordoma inhibitors were further characterized in a kinome-wide screen demonstrating narrow spectrum profiles .", "ic50_mc": "2 . 9 μm", "selectivity_mc": "1", "ic50_ce": "2", "ed50_an": "1-f][1 , 2 , 4]triazine ( bms 6 9 0 5 1 4 ) were screened directly against two chordoma cell lines , u-ch1 and u-ch2 ( table 1 ) , the latter of which is notably less sensitive to egfr inhibitors . ( 6 ) the combination of the literature kinase cross-screening and chordoma cellular results enabled us to identify several kinases , including gak as targets of interest , with egfr and gak the most prevalent across the series of inhibitors ( si , table s1 ) . ( 9−15 ) there was not a linear relationship between egfr and/or gak inhibition and antiproliferative effects .", "t_half_an": "3", "compound_drug": "bms 6 9 0 5 1"}


{"id": 0, "paper_title": "Design of a Cyclin G Associated Kinase (GAK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Set to Interrogate the Relationship of EGFR and GAK in Chordoma", "paper_author": ["Christopher R. M. Asquith", "Kaleb M. Naegeli", "Michael P. East", "Tuomo Laitinen", "Tammy M. Havener", "Carrow I. Wells", "Gary L. Johnson", "David H. Drewry", "William J. Zuercher", "David C. Morris"], "paper_year": 2019, "paper_institution": "Structural Genomics Consortium, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States", "paper_cited": 16, "doi": "10.1021/acs.jmedchem.9b00350", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.9b00350/20190502/images/large/jm-2019-003508_0006.jpeg", "compound_count": 19, "compound_name": "15", "compound_name_drug": "", "compound_smiles": "", "medicinal_chemistry_metrics": {"Ki": "", "Kd": "", "IC50": 2900.0, "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": "32", "IC50": 2.0, "EC50": "", "selectivity": "", "hERG": "", "solubility": ""}, "pharm_metrics_vivo": {"ED50": 0.002, "AUC": "", "solubility": "", "t_half": 3.0, "bioavailability": ""}, "clinical_statistics": {}}
articleURL: 1
10.1021/acs.jmedchem.5b01985
{"compound": "4 7", "selectivity_mc": "1", "herg_ce": "1 0 μm", "bioavailability_an": "3 0 %", "compound_drug": "egf816"}


{"id": 1, "paper_title": "Discovery of (R,E)-N-(7-Chloro-1-(1-[4-(dimethylamino)but-2-enoyl]azepan-3-yl)-1H-benzo[d]imidazol-2-yl)-2-methylisonicotinamide (EGF816), a Novel, Potent, and WT Sparing Covalent Inhibitor of Oncogenic (L858R, ex19del) and Resistant (T790M) EGFR Mutants for the Treatment of EGFR Mutant Non-Small-Cell Lung Cancers", "paper_author": ["Gérald Lelais", "Robert Epple", "Thomas H. Marsilje", "Yun O. Long", "Matthew McNeill", "Bei Chen", "Wenshuo Lu", "Jaganmohan Anumolu", "Sangamesh Badiger", "Badry Bursulaya", "Michael DiDonato", "Rina Fong", "Jose Juarez", "Jie Li", "Mari Manuia", "Daniel E. Mason", "Perry Gordon", "Todd Groessl", "Kevin Johnson", "Yong Jia", "Shailaja Kasibhatla", "Chun Li", "John Isbell", "Glen Spraggon", "Steven Bender", "Pierre-Yves Michellys"], "paper_year": 2016, "paper_institution": "Genomics Institute of the Novartis Research Foundation, 10675 John J. Hopkins Drive, San Diego, California 92121, United States", "paper_cited": 49, "doi": "10.1021/acs.jmedchem.5b01985", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.5b01985/20160722/images/large/jm-2015-01985j_0013.jpeg", "compound_count": 48, "compound_name": "47", "compound_name_drug": "", "compound_smiles": "", "medicinal_chemistry_metrics": {"Ki": "", "Kd": "", "IC50": "", "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": "", "IC50": "", "EC50": "", "selectivity": "", "hERG": 10.0, "solubility": ""}, "pharm_metrics_vivo": {"ED50": "", "AUC": "", "solubility": "", "t_half": "", "bioavailability": 30.0}, "clinical_statistics": {}}
articleURL: 2
10.1021/jm0580196
{"compound": "5a", "ic50_mc": "1 . 5", "selectivity_mc": "1", "ed50_an": "9 are outlined in scheme 1 . 6-nitroquinazolone was reacted with thionyl chloride to produce the 4-chloro-6-nitroquinazoline . the excess of thionyl chloride was distilled out , and the product was obtained without any further purification , with 8 0 % chemical yield and 9 7 % purity , as determined by hplc . reaction of the 4-chloro-6-nitroquinazoline was performed with either of the following aniline derivatives: 3 , 4-dichloro-6-fluoroaniline ( a ) , meta-bromoaniline ( b ) or meta-iodoaniline ( c ) in i-proh at reflux . the products were obtained as a bright yellow precipitate . after filtration , compounds 1a−c were obtained with 75%−80% yield . in the next step , the nitro group at the 6-position of the quinazoline ring was reduced to amine . it should be noted that an undesired reduction of the halogen position at the anilino moiety was observed only with the iodo derivative . therefore , the reduction step of this derivative was performed at 0 °c . yet , even at this temperature , we observed 1 0 % formation of the reduction side product that was separated from the desired product by silica chromatography . compounds 2a−c were used as basic starting materials for the preparation of the three different groups of inhibitors . they were reacted with α-methoxyacetyl chloride to yield group a compounds , 3a−c , with 7 1 % , 6 9 % , and 6 4", "compound_drug": "<unk> . in this paragraph , can you find out the result of compound_drug ? [SEP] results chemistry . the syntheses of compounds 3−5 and 9 are outlined in scheme 1 . 6-nitroquinazolone was reacted with thionyl chloride to produce the 4-chloro-6-nitroquinazoline . the excess of thionyl chloride was distilled out , and the product was obtained without any further purification , with 8 0 % chemical yield and 9 7 % purity , as determined by hplc . reaction of the 4-chloro-6-nitroquinazoline was performed with either of the following aniline derivatives: 3 , 4-dichloro-6-fluoroaniline ( a ) , meta-bromoaniline ( b ) or meta-iodoaniline ( c ) in i-proh at reflux . the products were obtained as a bright yellow precipitate . after filtration , compounds 1a−c were obtained with 75%−80% yield . in the next step , the nitro group at the 6-position of the quinazoline ring was reduced to amine . it should be noted that an undesired reduction of the halogen position at the anilino moiety was observed only with the iodo derivative . therefore , the reduction step of this derivative was performed at 0 °c . yet , even at this temperature , we observed 1 0 % formation of the reduction side product that was separated from the desired product by silica chromatography . compounds 2a−c were used as basic starting materials for the preparation of the three different groups of inhibitors . they were reacted with α-methoxyacetyl chloride to yield group a compounds , 3a−c"}


{"id": 2, "paper_title": "High-Affinity Epidermal Growth Factor Receptor (EGFR) Irreversible Inhibitors with Diminished Chemical Reactivities as Positron Emission Tomography (PET)-Imaging Agent Candidates of EGFR Overexpressing Tumors", "paper_author": ["Eyal Mishani", "Galith Abourbeh", "Orit Jacobson", "Samar Dissoki", "Revital Ben Daniel", "Yulia Rozen", "Mazal Shaul", "Alexander Levitzki"], "paper_year": 2005, "paper_institution": "Department of Medical Biophysics and Nuclear Medicine, Hadassah Hebrew University, Jerusalem 91120, Israel, and Unit of Cellular Signaling, Department of Biological Chemistry, The Alexander Silberman Institute of Life Sciences, The Hebrew University, Jerusalem 91904, Israel ", "paper_cited": 59, "doi": "10.1021/jm0580196", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2005/jmcmar.2005.48.issue-16/jm0580196/production/images/large/jm0580196n00001.jpeg", "compound_count": 67, "compound_name": "5a", "compound_name_drug": "", "compound_smiles": "", "medicinal_chemistry_metrics": {"Ki": "", "Kd": "", "IC50": 1.5, "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": "", "IC50": "∼4 ", "EC50": "", "selectivity": "", "hERG": "", "solubility": ""}, "pharm_metrics_vivo": {"ED50": 0.009, "AUC": "", "solubility": "", "t_half": "", "bioavailability": ""}, "clinical_statistics": {}}
articleURL: 3
10.1021/acs.jmedchem.0c02005
{"compound": "dosimertinib . preclinical studies revealed that dosimertinib demonstrated robust in vivo antitumor efficacy and favorable pk profiles , but with lower toxicity than osimertinib . these preclinical data support further clinical development of dosimertinib for the treatment of nsclc . dosimertinib has received official approval in china to initiate the phase i clinical trial ( registration numbers: cxhl2000060", "ic50_mc": "1 . 8 ± 0 . 3", "selectivity_mc": "1", "ic50_ce": "3", "selectivity_ce": "9", "t_half_an": "1 2", "compound_drug": "cxhl2000060"}


{"id": 3, "paper_title": "Discovery of Dosimertinib, a Highly Potent, Selective, and Orally Efficacious Deuterated EGFR Targeting Clinical Candidate for the Treatment of Non-Small-Cell Lung Cancer", "paper_author": ["Yonggang Meng", "Bin Yu", "He Huang", "Youmei Peng", "Ertong Li", "Yongfang Yao", "Chuanjun Song", "Wenquan Yu", "Kaikai Zhu", "Kai Wang", "Dongxu Yi", "Jinfa Du", "Junbiao Chang"], "paper_year": 2021, "paper_institution": "College of Chemistry, Zhengzhou University, Zhengzhou 450001, China", "paper_cited": 5, "doi": "10.1021/acs.jmedchem.0c02005", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-2/acs.jmedchem.0c02005/20210121/images/large/jm0c02005_0009.jpeg", "compound_count": 12, "compound_name": "2h", "compound_name_drug": "dosimertinib.preclinicalstudiesrevealedthatdosimertinibdemonstratedrobustinvivoantitumorefficacyandfavorablepkprofiles,butwithlowertoxicitythanosimertinib.thesepreclinicaldatasupportfurtherclinicaldevelopmentofdosimertinibforthetreatmentofnsclc.dosimertinibhasreceivedofficialapprovalinchinatoinitiatethephaseiclinicaltrial(registrationnumbers:cxhl2000060", "compound_smiles": "", "medicinal_chemistry_metrics": {"Ki": "", "Kd": "", "IC50": 1.8, "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": "", "IC50": 3.0, "EC50": "", "selectivity": "28.4 ± 2.6", "hERG": "", "solubility": ""}, "pharm_metrics_vivo": {"ED50": "", "AUC": "", "solubility": "", "t_half": 12.0, "bioavailability": ""}, "clinical_statistics": {}}
articleURL: 4
10.1021/acs.jmedchem.6b01907
{"compound": "1 9", "selectivity_mc": "1", "solubility_ce": "2", "bioavailability_an": "1 0 . 2 9 %", "compound_drug": "chmfl-egfr-202"}


{"id": 4, "paper_title": "Discovery of (R)-1-(3-(4-Amino-3-(3-chloro-4-(pyridin-2-ylmethoxy)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one (CHMFL-EGFR-202) as a Novel Irreversible EGFR Mutant Kinase Inhibitor with a Distinct Binding Mode", "paper_author": ["Aoli Wang", "Xixiang Li", "Hong Wu", "Fengming Zou", "Xiao-E Yan", "Cheng Chen", "Chen Hu", "Kailin Yu", "Wenchao Wang", "Peng Zhao", "Jiaxin Wu", "Ziping Qi", "Wei Wang", "Beilei Wang", "Li Wang", "Tao Ren", "Shanchun Zhang", "Cai-Hong Yun", "Jing Liu", "Qingsong Liu"], "paper_year": 2017, "paper_institution": "High Magnetic Field Laboratory, Chinese Academy of Sciences, Mailbox 1110, 350 Shushanhu Road, Hefei, Anhui 230031, P. R. China", "paper_cited": 15, "doi": "10.1021/acs.jmedchem.6b01907", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01907/20170407/images/large/jm-2016-01907c_0016.jpeg", "compound_count": 45, "compound_name": "19", "compound_name_drug": "", "compound_smiles": "", "medicinal_chemistry_metrics": {"Ki": "", "Kd": "", "IC50": "pEGFR T790M/L8SSR: ECso: 7 nM", "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": "", "IC50": "", "EC50": "", "selectivity": "", "hERG": "", "solubility": 2.0}, "pharm_metrics_vivo": {"ED50": "", "AUC": "", "solubility": "", "t_half": "", "bioavailability": 10.29}, "clinical_statistics": {}}
articleURL: 5
10.1021/acs.jmedchem.9b01566
{"compound": "6", "selectivity_ce": "1", "ed50_an": "8 ) through several linkers ( figure 2 ) .", "t_half_an": "3 . 5", "compound_drug": "ms154"}


{"id": 5, "paper_title": "Discovery of Potent and Selective Epidermal Growth Factor Receptor (EGFR) Bifunctional Small-Molecule Degraders", "paper_author": ["Meng Cheng", "Xufen Yu", "Kaylene Lu", "Ling Xie", "Li Wang", "Fanye Meng", "Xiaoran Han", "Xian Chen", "Jing Liu", "Yue Xiong", "Jian Jin"], "paper_year": 2020, "paper_institution": "Curriculum in Genetics and Molecular Biology,  Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States", "paper_cited": 30, "doi": "10.1021/acs.jmedchem.9b01566", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b01566/20200207/images/large/jm9b01566_0003.jpeg", "compound_count": 33, "compound_name": "6", "compound_name_drug": "", "compound_smiles": "", "medicinal_chemistry_metrics": {"Ki": "", "Kd": "", "IC50": "", "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": "", "IC50": "", "EC50": "", "selectivity": "", "hERG": "", "solubility": ""}, "pharm_metrics_vivo": {"ED50": 8.0, "AUC": "", "solubility": "", "t_half": 3.5, "bioavailability": ""}, "clinical_statistics": {}}
articleURL: 6
10.1021/acs.jmedchem.0c00489
{"compound": "", "ic50_mc": "1", "ki_mc": "0 . 7 nm ) and e4 ( kd = 0 . 1 3 nm", "kd_mc": "2", "ec50_ce": "2 9", "herg_ce": "1 μm", "solubility_ce": "3", "ed50_an": "7 nm ) and e4 ( kd = 0 . 1 3 nm ) were selected due to their lack of cysteines . cysteine-free proteins generally result in faster purification , higher protein yields , and the potential to incorporate site-specific cysteines for further conjugation . ( 1 4 ) e1 and e4 were fused to the n terminus of the dhfr2 ( 1dd ) construct , yielding e1-1dd and e4-1dd . both fusion proteins were expressed in e . coli as soluble proteins , allowing much faster protein purification protocols", "t_half_an": "7", "bioavailability_an": "2 8", "compound_drug": "csans"}


{"id": 6, "paper_title": "Anti-EGFR Fibronectin Bispecific Chemically Self-Assembling Nanorings (CSANs) Induce Potent T Cell-Mediated Antitumor Responses and Downregulation of EGFR Signaling and PD-1/PD-L1 Expression", "paper_author": ["Ozgun Kilic", "Marcos R. Matos de Souza", "Abdulaziz A. Almotlak", "Yiao Wang", "Jill M. Siegfried", "Mark D. Distefano", "Carston R. Wagner"], "paper_year": 2020, "paper_institution": "Department of Medicinal Chemistry, University of Minnesota, Minneapolis, Minnesota 55455, United States", "paper_cited": 1, "doi": "10.1021/acs.jmedchem.0c00489", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00489/20200918/images/large/jm0c00489_0008.jpeg", "compound_count": 0, "compound_name": "CSANs", "compound_name_drug": "", "compound_smiles": "", "medicinal_chemistry_metrics": {"Ki": 0.7, "Kd": 2.0, "IC50": 1.0, "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": "", "IC50": "", "EC50": 29.0, "selectivity": "", "hERG": 1.0, "solubility": 3.0}, "pharm_metrics_vivo": {"ED50": 0.007, "AUC": "", "solubility": "", "t_half": 7.0, "bioavailability": 28.0}, "clinical_statistics": {}}
articleURL: 7
10.1021/acs.jmedchem.0c00891
{"compound": "7 9", "ic50_mc": "9", "kd_mc": "2", "ed50_an": "2a , b ) . these simulations started from the unbound state , with three azd9291 molecules arbitrarily placed in the simulation system . the simulations were conducted without using any structural information ( experimental or otherwise ) about the small-molecule binding poses or the location of the binding site . such binding simulations have previously produced kinase-ligand binding poses highly consistent with the corresponding crystal structure poses . ( 1 8 , 1 9 ) the formation or breaking of covalent bonds cannot be simulated with standard biomolecular md force fields , including the one used here , so the simulations show binding , but not bond formation , between azd9291 and egfr .", "t_half_an": "1", "compound_drug": "<unk> . in this paragraph , can you find out the result of compound_drug ? [SEP] results md simulations suggest a flipped azd9291 binding pose with t790m but not with the wt gatekeeper to study the interaction between azd9291 and egfr kinase , we performed unbiased md simulations of the spontaneous binding of azd9291 to l858r/t790m and to l858r ( figure 2a , b"}


{"id": 7, "paper_title": "Structural Basis of AZD9291 Selectivity for EGFR T790M", "paper_author": ["Xiao-E Yan", "Pelin Ayaz", "Su-Jie Zhu", "Peng Zhao", "Ling Liang", "Casey H. Zhang", "Ya-Chuang Wu", "Je-Luen Li", "Hwan Geun Choi", "Xin Huang", "Yibing Shan", "David E. Shaw", "Cai-Hong Yun"], "paper_year": 2020, "paper_institution": "Department of Biochemistry and Biophysics,  Department of Integration of Chinese and Western Medicine, School of Basic Medical Sciences, Peking University Health Science Center, Beijing 100191, China", "paper_cited": 13, "doi": "10.1021/acs.jmedchem.0c00891", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00891/20200806/images/large/jm0c00891_0007.jpeg", "compound_count": 0, "compound_name": "79", "compound_name_drug": "AZD9291", "compound_smiles": "", "medicinal_chemistry_metrics": {"Ki": "", "Kd": 2.0, "IC50": 9.0, "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": "", "IC50": "", "EC50": "", "selectivity": "", "hERG": "", "solubility": ""}, "pharm_metrics_vivo": {"ED50": 0.018, "AUC": "", "solubility": "", "t_half": 1.0, "bioavailability": ""}, "clinical_statistics": {"p1_company_num": 94, "p1_stat_company_num": [2, 8, 0, 7, 0, 0, 76, 0, 1], "p1_company": [["Institute of oncology Dr. Rosell", "Ohio State University Comprehensive Cancer Center"], ["AbbVie", "Emory University", "Daiichi Sankyo, Inc.", "University Hospital of Cologne", "Huntsman Cancer Institute", "Hunan Provincial Tumor Hospital", "University of California, Davis", "Ohio State University Comprehensive Cancer Center LAO"], [], ["University Health Network Princess Margaret Cancer Center LAO", "Columbia University", "City of Hope Comprehensive Cancer Center LAO", "Dana-Farber - Harvard Cancer Center LAO", "Dana-Faber Cancer Institute", "Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center", "Centro Integral Oncologico Clara Campal"], [], [], ["Duke University", "501 Smyth Road, Ottawa, Canada", "Janssen Research & Development, LLC", "Guangdong General Hospita", "MedImmune LLC", "Memorial Sloan Kettering Cancer Center", "Karolinska University Hospital", "International Coordinating Investigator", "Sun Yat-sen University Cancer Center (SYSUCC)", "Department of Oncology, Herlev and Gentofte Hospital", "M.D. Anderson Cancer Center", "Vanderbilt University, Nashville, USA", "Dana-Farber Cancer Institute", "Soroka University Medical Center", "University of California, San Francisco", "Tianjin Medical University Cancer Institute and Hospital", "Spectrum Pharmaceuticals, Inc", "UCLA / Jonsson Comprehensive Cancer Center", "Yale University Cancer Center LAO", "First Affiliated Hospital of Zhejiang University", "Building 2, 199 Liangjing Road, Zhangjiang Hi-tech Park, Shanghai 201203, China", "Massachusetts General Hospital", "Dizal (Jiangsu) Pharmaceutical Co., Ltd.", "Dana Farber Cancer Institute, 450 Brookline Avenue, LC4114, Boston, MA 02215, USA", "Shandong Cancer Hospital and Institute", "Nantes University Hospital", "Quotient Clinical Ltd", "Washington University School of Medicine", "Guangdong General Hospital, Guangdong, 510030, China", "Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA", "Jiangsu Province People's Hospital", "Merck Sharp & Dohme Corp.", "Drammen Hospital - Vestre Viken", "Samsung Medical Center", "PI", "Fudan University", "Incyte Corporation", "AstraZeneca", "Lawson Health Research Institute", "MD Anderson", "Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany", "Chonnam National University Hospital", "Memorial Sloan Kettering, USA", "Sun Yat-sen University", "National Cancer Institute (NCI)", "Emory University School of Medicine, Atlanta, U.S.", "Seoul National University Hospital", "Second Affiliated Hospital of Nanchang University", "Guangdong Provincial People's Hospital", "National University Hospital, Singapore", "University of Birmingham", "Centre Hospitalier Universitaire Vaudois", "The Affiliated Cancer Hospital of Chongqing University", "Peter MacCallum Cancer Centre, Australia", "Hellenic Oncology Research Group", "Istituto Nazionale Tumori IRCCS Fondazione Pascale", "Shanghai Chest Hospital", "ECOG-ACRIN Cancer Research Group", "Eli Lilly and Company", "BC Cancer, Vancouver Centre", "Revolution Medicines, Inc.", "Quintiles 6700 W 115th Street, Kansas, US", "Senior Medical Director", "Executive VP and COO", "Zeno Pharmaceuticals", "Clifford Hospital", "Asan Medical Center", "University of Texas Southwestern Medical Center", "Mecical University of Gdansk, Poland", "University Hospital, Zürich", "G1 Therapeutics, Inc.", "Quotient Clinical Ltd, Mere Way, Ruddington Fields, Nottingham, United Kingdom. NG11 6JS", "NKI-AvL", "Associate Director for Clinical Research, Lombardi Comprehensive Cancer Center", "Shaare Zedek Medical Center", "Institute of Oncology Dr. Rosell (IOR)"], [], ["Peking University Third Hospital"]], "p1_terminate_reason": {}, "p1_withdraw_reason": {}, "p1_adverse_event": {"AstraZeneca": 0.04411764705882353}, "p2_company_num": 71, "p2_stat_company_num": [8, 27, 2, 13, 0, 0, 19, 0, 2], "p2_company": [["Washington University School of Medicine", "PI", "First Affiliated Hospital of Zhejiang University", "University Hospital, Zürich", "Executive VP and COO", "Second Affiliated Hospital of Nanchang University", "M.D. Anderson Cancer Center", "The Affiliated Cancer Hospital of Chongqing University"], ["Duke University", "Sun Yat-sen University", "Memorial Sloan Kettering Cancer Center", "University of Birmingham", "Department of Oncology, Herlev and Gentofte Hospital", "Dana-Farber Cancer Institute", "Soroka University Medical Center", "Peter MacCallum Cancer Centre, Australia", "University of California, San Francisco", "Istituto Nazionale Tumori IRCCS Fondazione Pascale", "Spectrum Pharmaceuticals, Inc", "BC Cancer, Vancouver Centre", "UCLA / Jonsson Comprehensive Cancer Center", "Massachusetts General Hospital", "Senior Medical Director", "Zeno Pharmaceuticals", "Clifford Hospital", "University of Texas Southwestern Medical Center", "Nantes University Hospital", "Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA", "Jiangsu Province People's Hospital", "Drammen Hospital - Vestre Viken", "MD Anderson", "NKI-AvL", "Fudan University", "Lawson Health Research Institute", "Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany"], ["Samsung Medical Center", "Tianjin Medical University Cancer Institute and Hospital"], ["Mecical University of Gdansk, Poland", "501 Smyth Road, Ottawa, Canada", "National Cancer Institute (NCI)", "Yale University Cancer Center LAO", "Associate Director for Clinical Research, Lombardi Comprehensive Cancer Center", "Revolution Medicines, Inc.", "Shaare Zedek Medical Center", "Seoul National University Hospital", "MedImmune LLC", "G1 Therapeutics, Inc.", "Incyte Corporation", "AstraZeneca", "Centre Hospitalier Universitaire Vaudois"], [], [], ["Asan Medical Center", "Chonnam National University Hospital", "Memorial Sloan Kettering, USA", "Institute of Oncology Dr. Rosell (IOR)", "Shanghai Chest Hospital", "Janssen Research & Development, LLC", "ECOG-ACRIN Cancer Research Group", "Emory University School of Medicine, Atlanta, U.S.", "Eli Lilly and Company", "Guangdong General Hospital, Guangdong, 510030, China", "Guangdong General Hospita", "Merck Sharp & Dohme Corp.", "International Coordinating Investigator", "Guangdong Provincial People's Hospital", "Dizal (Jiangsu) Pharmaceutical Co., Ltd.", "Sun Yat-sen University Cancer Center (SYSUCC)", "Dana Farber Cancer Institute, 450 Brookline Avenue, LC4114, Boston, MA 02215, USA", "Vanderbilt University, Nashville, USA", "Shandong Cancer Hospital and Institute"], [], ["Hellenic Oncology Research Group", "National University Hospital, Singapore"]], "p2_terminate_reason": {}, "p2_withdraw_reason": {}, "p2_adverse_event": {"International Coordinating Investigator": 0.0}, "p3_company_num": 14, "p3_stat_company_num": [4, 4, 0, 4, 0, 0, 1, 0, 1], "p3_company": [["Sun Yat-sen University Cancer Center (SYSUCC)", "Shanghai Chest Hospital", "Guangdong Provincial People's Hospital", "Janssen Research & Development, LLC"], ["Memorial Sloan Kettering, USA", "Emory University School of Medicine, Atlanta, U.S.", "Dana Farber Cancer Institute, 450 Brookline Avenue, LC4114, Boston, MA 02215, USA", "ECOG-ACRIN Cancer Research Group"], [], ["Merck Sharp & Dohme Corp.", "Vanderbilt University, Nashville, USA", "Guangdong General Hospital, Guangdong, 510030, China", "Eli Lilly and Company"], [], [], ["Guangdong General Hospita"], [], ["Shandong Cancer Hospital and Institute"]], "p3_terminate_reason": {}, "p3_withdraw_reason": {}, "p3_adverse_event": {}}}
articleURL: 8
10.1021/acs.jmedchem.5b01082
{"compound": "co-1686", "ic50_mc": "1 . 8 μm", "kd_mc": "4", "ed50_an": "7 , 3 8 )", "bioavailability_an": "4 7", "compound_drug": "t338m/s345c"}


{"id": 8, "paper_title": "Targeting Drug Resistance in EGFR with Covalent Inhibitors: A Structure-Based Design Approach", "paper_author": ["Julian Engel", "André Richters", "Matthäus Getlik", "Stefano Tomassi", "Marina Keul", "Martin Termathe", "Jonas Lategahn", "Christian Becker", "Svenja Mayer-Wrangowski", "Christian Grütter", "Niklas Uhlenbrock", "Jasmin Krüll", "Niklas Schaumann", "Simone Eppmann", "Patrick Kibies", "Franziska Hoffgaard", "Jochen Heil", "Sascha Menninger", "Sandra Ortiz-Cuaran", "Johannes M. Heuckmann", "Verena Tinnefeld", "René P. Zahedi", "Martin L. Sos", "Carsten Schultz-Fademrecht", "Roman K. Thomas", "Stefan M. Kast", "Daniel Rauh"], "paper_year": 2015, "paper_institution": "Department of Chemistry and Chemical Biology, TU Dortmund University, Otto-Hahn-Straße 6, D-44227 Dortmund, Germany", "paper_cited": 60, "doi": "10.1021/acs.jmedchem.5b01082", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b01082/20150904/images/large/jm-2015-01082e_0013.jpeg", "compound_count": 59, "compound_name": "co-1686", "compound_name_drug": "co-1686", "compound_smiles": "C(C)CCCCCCCc1c(cccc1NC(=O)C=C)Oc1nc(cc(N2CCN(CC2)C)n1)Nc1c2ccccc2[nH]n1", "medicinal_chemistry_metrics": {"Ki": "1.75 ± 0.19", "Kd": 4.0, "IC50": 1800.0, "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": "", "IC50": "", "EC50": "", "selectivity": "", "hERG": "", "solubility": ""}, "pharm_metrics_vivo": {"ED50": 7.0, "AUC": "", "solubility": "", "t_half": "", "bioavailability": 47.0}, "clinical_statistics": {}}
articleURL: 9
10.1021/acs.jmedchem.5b00840
{"compound": "", "ic50_mc": "1", "kd_mc": "2", "ic50_ce": "2 0 1", "ec50_ce": "2 0", "ed50_an": "we hope that this review on the small-molecule egfr t790m inhibitors , along with their discovery strategies , will assist in the design of future t790m-containing egfr inhibitors with high levels of selectivity over wt egfr , broad kinase selectivity , and desirable physicochemical properties . . [SEP]", "compound_drug": "t790m ) mutation in the atp-binding pocket of the epidermal growth factor receptor ( egfr ) , the current generation of egfr tyrosine kinase inhibitors lost their clinical efficacy . recently , a large number of small-molecule inhibitors with striking inhibitory potency against egfr mutants with the t790m change have been identified . in particular , the inhibitors rociletinib"}


{"id": 9, "paper_title": "Challenges and Perspectives on the Development of Small-Molecule EGFR Inhibitors against T790M-Mediated Resistance in Non-Small-Cell Lung Cancer", "paper_author": ["Zhendong Song", "Yang Ge", "Changyuan Wang", "Shanshan Huang", "Xiaohong Shu", "Kexin Liu", "Youwen Zhou", "Xiaodong Ma"], "paper_year": 2016, "paper_institution": "College of Pharmacy, Dalian Medical University, Dalian 116044, P. R. China", "paper_cited": 55, "doi": "10.1021/acs.jmedchem.5b00840", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.5b00840/20160722/images/large/jm-2015-008408_0032.jpeg", "compound_count": 59, "compound_name": "3", "compound_name_drug": "", "compound_smiles": "", "medicinal_chemistry_metrics": {"Ki": "", "Kd": 2.0, "IC50": 1.0, "selectivity": "μm4"}, "pharm_metrics_vitro": {"Ki": "", "Kd": "", "IC50": 201.0, "EC50": 20.0, "selectivity": "", "hERG": "", "solubility": ""}, "pharm_metrics_vivo": {"ED50": "", "AUC": "", "solubility": "", "t_half": "", "bioavailability": ""}, "clinical_statistics": {}}
articleURL: 10
10.1021/acs.jmedchem.0c00200
{"compound": "k745", "ic50_mc": "1", "ic50_ce": "2", "ed50_an": "1 and 2 are likely agnostic with respect to the c797s mutation . the imidazole group extends away from the hinge toward k745 , the catalytic lysine , and the fluorophenyl group extends into the hydrophobic pocket positioned between the t790m gatekeeper mutation and k745 . the imidazole n3 forms an h-bond with k745 , which is also h-bonded to d855 of the dfg motif . the flexible functional groups extending from the imidazole c2 adopt subtly different conformations in the four copies", "compound_drug": "l858r/t790m/c797s"}


{"id": 10, "paper_title": "Structural Basis for EGFR Mutant Inhibition by Trisubstituted Imidazole Inhibitors", "paper_author": ["David E. Heppner", "Marcel Günther", "Florian Wittlinger", "Stefan A. Laufer", "Michael J. Eck"], "paper_year": 2020, "paper_institution": "Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, United States", "paper_cited": 4, "doi": "10.1021/acs.jmedchem.0c00200", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.0c00200/20200416/images/large/jm0c00200_0010.jpeg", "compound_count": 27, "compound_name": "k745", "compound_name_drug": "k745", "compound_smiles": "", "medicinal_chemistry_metrics": {"Ki": "", "Kd": "", "IC50": 1.0, "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": "", "IC50": 2.0, "EC50": "", "selectivity": "", "hERG": "", "solubility": ""}, "pharm_metrics_vivo": {"ED50": 0.001, "AUC": "", "solubility": "", "t_half": "", "bioavailability": ""}, "clinical_statistics": {}}
articleURL: 11
10.1021/acs.jmedchem.6b01894
{"compound": "", "ic50_mc": "1 . 9 ×", "ki_mc": "1 0", "kd_mc": "1", "selectivity_mc": "20-fold", "ic50_ce": "2", "herg_ce": "1 0 μm", "bioavailability_an": "5 0", "compound_drug": "pf-06747775"}


{"id": 11, "paper_title": "Discovery of N-((3R,4R)-4-Fluoro-1-(6-((3-methoxy-1-methyl-1H-pyrazol-4-yl)amino)-9-methyl-9H-purin-2-yl)pyrrolidine-3-yl)acrylamide (PF-06747775) through Structure-Based Drug Design: A High Affinity Irreversible Inhibitor Targeting Oncogenic EGFR Mutants with Selectivity over Wild-Type EGFR", "paper_author": ["Simon Planken", "Douglas C. Behenna", "Sajiv K. Nair", "Theodore O. Johnson", "Asako Nagata", "Chau Almaden", "Simon Bailey", "T. Eric Ballard", "Louise Bernier", "Hengmiao Cheng", "Sujin Cho-Schultz", "Deepak Dalvie", "Judith G. Deal", "Dac M. Dinh", "Martin P. Edwards", "Rose Ann Ferre", "Ketan S. Gajiwala", "Michelle Hemkens", "Robert S. Kania", "John C. Kath", "Jean Matthews", "Brion W. Murray", "Sherry Niessen", "Suvi T. M. Orr", "Mason Pairish", "Neal W. Sach", "Hong Shen", "Manli Shi", "James Solowiej", "Khanh Tran", "Elaine Tseng", "Paolo Vicini", "Yuli Wang", "Scott L. Weinrich", "Ru Zhou", "Michael Zientek", "Longqing Liu", "Yiqin Luo", "Shuibo Xin", "Chengyi Zhang", "Jennifer Lafontaine"], "paper_year": 2017, "paper_institution": "†Departments of Worldwide Medicinal Chemistry, §Pharmacokinetics, Dynamics and Metabolism, ‡Oncology Research Unit, and ∥Drug Safety, La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States", "paper_cited": 47, "doi": "10.1021/acs.jmedchem.6b01894", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01894/20170407/images/large/jm-2016-018943_0022.jpeg", "compound_count": 38, "compound_name": "21", "compound_name_drug": "PF-06747775", "compound_smiles": "O=C(N[C@@H]1CN(C[C@H]1F)c1nc2c(c(Nc3c(nn(C)c3)OC)n1)ncn2C)C=C", "medicinal_chemistry_metrics": {"Ki": 10.0, "Kd": 1.0, "IC50": 1.9, "selectivity": 20}, "pharm_metrics_vitro": {"Ki": "", "Kd": "", "IC50": 2.0, "EC50": "", "selectivity": "", "hERG": 10.0, "solubility": ""}, "pharm_metrics_vivo": {"ED50": "", "AUC": "", "solubility": "", "t_half": "", "bioavailability": 50.0}, "clinical_statistics": {"p1_company_num": 1, "p1_stat_company_num": [0, 0, 0, 0, 0, 0, 1, 0, 0], "p1_company": [[], [], [], [], [], [], ["Pfizer"], [], []], "p1_terminate_reason": {}, "p1_withdraw_reason": {}, "p1_adverse_event": {}, "p2_company_num": 1, "p2_stat_company_num": [0, 0, 0, 0, 0, 1, 0, 0, 0], "p2_company": [[], [], [], [], [], ["Pfizer"], [], [], []], "p2_terminate_reason": {"Pfizer": "Death"}, "p2_withdraw_reason": {}, "p2_adverse_event": {"Pfizer": 0.5}, "p3_company_num": 0, "p3_stat_company_num": [0, 0, 0, 0, 0, 0, 0, 0, 0], "p3_company": [[], [], [], [], [], [], [], [], []], "p3_terminate_reason": {}, "p3_withdraw_reason": {}, "p3_adverse_event": {}}}
articleURL: 12
10.1021/acs.jmedchem.8b00346
{"compound": "20g", "ic50_mc": "0 . 4", "ki_mc": "2 3 0 nm", "selectivity_mc": "1", "ed50_an": "7 , respectively . to further improve the selectivity profile , by occupying both mutant-induced subpockets ( s1 and s2 ) , compound 14a was designed with a novel scaffold: pyrimido[4 , 5-d]pyrimidine-2 , 4 ( 1h , 3h )", "t_half_an": "2 4", "bioavailability_an": "3 5 %", "compound_drug": "<unk> . in this paragraph , can you find out the result of compound_drug ? [SEP] results and discussion scaffold hopping and binding mode analysis through a structure-based design strategy targeting a hydrophobic subpocket induced by a gatekeeper mutant t790m , compound 7 ( figure 2a"}


{"id": 12, "paper_title": "Design, Synthesis, and Biological Evaluation of Pyrimido[4,5-d]pyrimidine-2,4(1H,3H)-diones as Potent and Selective Epidermal Growth Factor Receptor (EGFR) Inhibitors against L858R/T790M Resistance Mutation", "paper_author": ["Yongjia Hao", "Jiankun Lyu", "Rong Qu", "Yi Tong", "Deheng Sun", "Fang Feng", "Linjiang Tong", "Tingyuan Yang", "Zhenjiang Zhao", "Lili Zhu", "Jian Ding", "Yufang Xu", "Hua Xie", "Honglin Li"], "paper_year": 2018, "paper_institution": "Shanghai Key Laboratory of New Drug Design, State Key Laboratory of Bioreactor Engineering, School of Pharmacy, East China University of Science and Technology, Shanghai 200237, China", "paper_cited": 14, "doi": "10.1021/acs.jmedchem.8b00346", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-13/acs.jmedchem.8b00346/20180706/images/large/jm-2018-00346h_0012.jpeg", "compound_count": 36, "compound_name": "20g", "compound_name_drug": "", "compound_smiles": "", "medicinal_chemistry_metrics": {"Ki": 230.0, "Kd": "", "IC50": 0.4, "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": "", "IC50": "", "EC50": "", "selectivity": "", "hERG": "", "solubility": ""}, "pharm_metrics_vivo": {"ED50": 0.007, "AUC": "", "solubility": "", "t_half": 24.0, "bioavailability": 35.0}, "clinical_statistics": {}}
articleURL: 13
10.1021/acs.jmedchem.7b00316
{"compound": "4", "ic50_mc": "3 . 3", "ki_mc": "0 .", "ic50_ce": "7", "selectivity_ce": "1", "ed50_an": "1 and met793 when docked into an x-ray structure of egfr-l858r/t790m ( figure 2 ) . moreover , in this predicted binding mode , the 4-fluorophenyl residue extended deep into hr i , occupying this hydrophobic pocket . the phenyl ring of the aniline moiety was located in hr ii . because lead compound 1 bears a small methyl residue attached to the sulfur in the imidazole c2 position , it does not interact with the pb in our docking studies . on the basis of this model , we first studied possible substituents in the imidazole c2 position to interact with the pb , thus increasing the inhibitory activity of the resulting compounds ."}


{"id": 13, "paper_title": "Trisubstituted Pyridinylimidazoles as Potent Inhibitors of the Clinically Resistant L858R/T790M/C797S EGFR Mutant: Targeting of Both Hydrophobic Regions and the Phosphate Binding Site", "paper_author": ["Marcel Günther", "Jonas Lategahn", "Michael Juchum", "Eva Döring", "Marina Keul", "Julian Engel", "Hannah L. Tumbrink", "Daniel Rauh", "Stefan Laufer"], "paper_year": 2017, "paper_institution": "Institute of Pharmaceutical Sciences, Pharmaceutical and Medicinal Chemistry, Eberhard Karls University Tübingen, Auf der Morgenstelle 8, 72076 Tübingen, Germany", "paper_cited": 49, "doi": "10.1021/acs.jmedchem.7b00316", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00316/20170707/images/large/jm-2017-00316d_0019.jpeg", "compound_count": 107, "compound_name": "4", "compound_name_drug": "", "compound_smiles": "", "medicinal_chemistry_metrics": {"Ki": "", "Kd": "", "IC50": 3.3, "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": "", "IC50": 7.0, "EC50": "μm10 ± 1", "selectivity": "", "hERG": "", "solubility": ""}, "pharm_metrics_vivo": {"ED50": 0.001, "AUC": "", "solubility": "", "t_half": "", "bioavailability": ""}, "clinical_statistics": {}}
articleURL: 14
10.1021/acs.jmedchem.1c00607
{"compound": "m-2-5", "ic50_mc": "1 7 . 7 μm", "kd_mc": "0 . 5 5 μm", "t_half_an": "3", "compound_drug": "<unk> . in this paragraph , can you find out the result of compound_drug ? [SEP] results and discussion library synthesis and screening the obtc γ-aapeptide library was prepared on the solid phase following the previously reported protocol . ( 2 4"}


{"id": 14, "paper_title": "Discovery of Cyclic Peptidomimetic Ligands Targeting the Extracellular Domain of EGFR", "paper_author": ["Mengmeng Zheng", "Chunpu Li", "Mi Zhou", "Ru Jia", "Gang Cai", "Fengyu She", "Lulu Wei", "Shaohui Wang", "Jie Yu", "Dingyan Wang", "Laurent Calcul", "Xingmin Sun", "Xiaomin Luo", "Feng Cheng", "Qi Li", "Yan Wang", "Jianfeng Cai"], "paper_year": 2021, "paper_institution": "Department of Chemistry, University of South Florida, 4202 E. Fowler Avenue, Tampa, Florida 33620, United States", "paper_cited": -1, "doi": "10.1021/acs.jmedchem.1c00607", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00607/20210723/images/large/jm1c00607_0008.jpeg", "compound_count": 9, "compound_name": "m-2-5", "compound_name_drug": "m-2-5", "compound_smiles": "", "medicinal_chemistry_metrics": {"Ki": "", "Kd": 550.0, "IC50": 17700.0, "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": "", "IC50": "", "EC50": "", "selectivity": "", "hERG": "", "solubility": ""}, "pharm_metrics_vivo": {"ED50": "", "AUC": "", "solubility": "", "t_half": 3.0, "bioavailability": ""}, "clinical_statistics": {}}
articleURL: 15
10.1021/acs.jmedchem.8b01612
{"compound": "1f", "ic50_mc": "1 . 4", "solubility_ce": "7 5 % yield ( 5a–o , step iv ) . the alkylation of the 6-oh on compounds 5a–o were performed with two kinds of macrocyclic polyamine moieties containing bromopropyl ( step v ) . finally , the boc groups were removed with 1 2", "ed50_an": "3 , which is commercially available . after protection of 6-oh by acetic anhydride ( step i ) , carbonyl in compound 3 was chlorinated by thionyl chloride to afford 4 in 7 4 % yield ( step ii ) . subsequently , various substituted anilines were coupled to 4-cl in quinazoline ( step iii ) , and hydrolysis of the acetyl group using ammonium hydroxide gave corresponding phenol intermediates in average 7 5 % yield ( 5a–o , step iv ) . the alkylation of the 6-oh on compounds 5a–o were performed with two kinds of macrocyclic polyamine moieties containing bromopropyl ( step v ) . finally , the boc groups were removed with 1 2 m hydrochloride acid ( hcl ) in anhydrous methanol solution , to give the titled compounds 1a–o and 2a–o in average 7 0 % yield ( step vi ) , respectively .", "bioavailability_an": "1 1 . 0 8", "compound_drug": "<unk> . in this paragraph , can you find out the result of compound_drug ? [SEP] results and discussion chemistry a series of novel quinazoline derivatives linked with macrocyclic polyamine at c-6 position and different aniline at c-4 position were synthesized . the synthetic route of the titled compounds is depicted in table 1 , starting from compound 3 , which is commercially available . after protection of 6-oh by acetic anhydride ( step i ) , carbonyl in compound 3 was chlorinated by thionyl chloride to afford 4 in 7 4 % yield ( step ii ) . subsequently , various substituted anilines were coupled to 4-cl in quinazoline ( step iii ) , and hydrolysis of the acetyl group using ammonium hydroxide gave corresponding phenol intermediates in average 7 5 % yield ( 5a–o , step iv ) . the alkylation of the 6-oh on compounds 5a–o were performed with two kinds of macrocyclic polyamine moieties containing bromopropyl ( step v ) . finally , the boc groups were removed with 1 2 m hydrochloride acid ( hcl ) in anhydrous methanol solution , to give the titled compounds 1a–o"}


{"id": 15, "paper_title": "Design and Evaluation of Potent EGFR Inhibitors through the Incorporation of Macrocyclic Polyamine Moieties into the 4-Anilinoquinazoline Scaffold", "paper_author": ["Yilan Ju", "Jintao Wu", "Xi Yuan", "Luqing Zhao", "Ganlin Zhang", "Chao Li", "Renzhong Qiao"], "paper_year": 2018, "paper_institution": "State Key Laboratory of Chemical Resource Engineering, Beijing University of Chemical Technology, Beijing 100029, P. R. China", "paper_cited": 12, "doi": "10.1021/acs.jmedchem.8b01612", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b01612/20181226/images/large/jm-2018-01612b_0008.jpeg", "compound_count": 38, "compound_name": "1f", "compound_name_drug": "", "compound_smiles": "", "medicinal_chemistry_metrics": {"Ki": "", "Kd": "", "IC50": 1.4, "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": "", "IC50": "μm0.958 ± 0.034", "EC50": "", "selectivity": "", "hERG": "", "solubility": 0.075}, "pharm_metrics_vivo": {"ED50": 3000.0, "AUC": "", "solubility": "", "t_half": "", "bioavailability": 11.08}, "clinical_statistics": {}}
articleURL: 16
10.1021/jm901338g
{"compound": "pd153035", "ic50_mc": "paragraph", "selectivity_mc": "<unk> . in this paragraph , can you find out the result of selectivity_mc ? [SEP] [CLS] what is the compound in this paper ? [SEP] exploring epidermal growth factor receptor ( egfr ) inhibitor features: the role of fused dioxygenated rings on the quinazoline scaffold a number of dioxolane , dioxane , and dioxepine quinazoline derivatives have been synthetized and evaluated as egfr inhibitors . their cytotoxic activity has been tested against two cell lines overexpressing and not expressing egfr . most derivatives were able to counteract egf-induced egfr phosphorylation , and their potency was comparable to the reference compound pd153035 . the size of the fused dioxygenated ring was crucial for the biological activity , the dioxane derivatives being the most promising class of this series .", "ic50_ce": "can you find out the result of ic50_ce ? [SEP] [CLS] what is the compound in this paper ? [SEP] exploring epidermal growth factor receptor ( egfr ) inhibitor features: the role of fused dioxygenated rings on the quinazoline scaffold a number of dioxolane , dioxane , and dioxepine quinazoline derivatives have been synthetized and evaluated as egfr inhibitors . their cytotoxic activity has been tested against two cell lines overexpressing and not expressing egfr . most derivatives were able to counteract egf-induced egfr phosphorylation", "kd_ce": "<unk> . in this paragraph , can you find out the result of kd_ce", "selectivity_ce": "<unk> . in this paragraph , can you find out the result of selectivity_ce ? [SEP] [CLS] what is the compound in this paper ? [SEP] exploring epidermal growth factor receptor ( egfr ) inhibitor features: the role of fused dioxygenated rings on the quinazoline scaffold a number of dioxolane , dioxane , and dioxepine quinazoline derivatives have been synthetized and evaluated as egfr inhibitors . their cytotoxic activity has been tested against two cell lines overexpressing and not expressing egfr . most derivatives were able to counteract egf-induced egfr phosphorylation , and their potency was comparable to the reference compound pd153035 . the size of the fused dioxygenated ring was crucial for the biological activity , the dioxane derivatives being the most promising class of this series .", "solubility_ce": "can you find out the result of solubility_ce ? [SEP] [CLS] what is the compound in this paper ? [SEP] exploring epidermal growth factor receptor ( egfr ) inhibitor features: the role of fused dioxygenated rings on the quinazoline scaffold a number of dioxolane , dioxane , and dioxepine quinazoline derivatives have been synthetized and evaluated as egfr inhibitors . their cytotoxic activity has been tested against two cell lines overexpressing and not expressing egfr . most derivatives were able to counteract egf-induced egfr phosphorylation", "ed50_an": "epidermal growth factor receptor ( egfr ) inhibitor features: the role of fused dioxygenated rings on the quinazoline scaffold . the main compound is <unk> . in this paragraph , can you find out the result of ed50_an ? [SEP] [CLS] what is the compound in this paper ? [SEP] exploring epidermal growth factor receptor ( egfr ) inhibitor features: the role of fused dioxygenated rings on the quinazoline scaffold a number of dioxolane , dioxane , and dioxepine quinazoline derivatives have been synthetized and evaluated as egfr inhibitors . their cytotoxic activity has been tested against two cell lines overexpressing and not expressing egfr . most derivatives were able to counteract egf-induced egfr phosphorylation , and their potency was comparable to the reference compound pd153035 . the size of the fused dioxygenated ring was crucial for the biological activity , the dioxane derivatives being the most promising class of this series . . [SEP]", "t_half_an": "<unk> . in this paragraph , can you find out the result of t_half_an ? [SEP] [CLS] what is the compound in this paper ? [SEP] exploring epidermal growth factor receptor ( egfr ) inhibitor features: the role of fused dioxygenated rings on the quinazoline scaffold a number of dioxolane , dioxane", "bioavailability_an": ") inhibitor features: the role of fused dioxygenated rings on the quinazoline scaffold a number of dioxolane , dioxane"}


{"id": 16, "paper_title": "Exploring Epidermal Growth Factor Receptor (EGFR) Inhibitor Features: The Role of Fused Dioxygenated Rings on the Quinazoline Scaffold", "paper_author": ["Adriana Chilin", "Maria Teresa Conconi", "Giovanni Marzaro", "Adriano Guiotto", "Luca Urbani", "Francesca Tonus", "Pierpaolo Parnigotto"], "paper_year": 2010, "paper_institution": "Dipartimento di Scienze Farmaceutiche, Università di Padova, via Marzolo 5, 35131 Padova, Italy", "paper_cited": 41, "doi": "10.1021/jm901338g", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm901338g/production/images/large/jm-2009-01338g_0001.jpeg", "compound_count": 19, "compound_name": "pd153035", "compound_name_drug": "", "compound_smiles": "Cc1ccccc1", "medicinal_chemistry_metrics": {"Ki": "", "Kd": "", "IC50": "", "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": "", "IC50": "μm4.40 ± 1.3", "EC50": "", "selectivity": "", "hERG": "", "solubility": ""}, "pharm_metrics_vivo": {"ED50": "", "AUC": "", "solubility": "", "t_half": "", "bioavailability": ""}, "clinical_statistics": {}}
articleURL: 17
10.1021/jm5014659
{"compound": "5a", "ic50_mc": "0 . 2 0 and 6 . 6 7", "kd_mc": "3 3 . 3", "selectivity_ce": "1", "herg_ce": "1 0 μm", "bioavailability_an": "1 6 . 5 %", "compound_drug": "<unk> . in this paragraph , can you find out the result of compound_drug ? [SEP] results and discussion chemistry attenuated electrophiles have a reduced likelihood of reacting irreversibly with off-target proteins . ( 14a , 14b ) because of the high electronegativity , small size , and special chemical reactivity with respect to hydrogen , we hypothesized the replacement of hydrogen at the α-position of acrylamide with fluorine would chemically tune the michael-type conjugate addition . to test this hypothesis , two simple michael acceptors , n-phenylacrylamide ( a ) and 2-fluoro-n-phenylacrylamide ( b"}


{"id": 17, "paper_title": "A Chemical Tuned Strategy to Develop Novel Irreversible EGFR-TK Inhibitors with Improved Safety and Pharmacokinetic Profiles", "paper_author": ["Guangxin Xia", "Wenteng Chen", "Jing Zhang", "Jiaan Shao", "Yong Zhang", "Wei Huang", "Leduo Zhang", "Weixing Qi", "Xing Sun", "Bojun Li", "Zhixiong Xiang", "Chen Ma", "Jia Xu", "Hailin Deng", "Yufeng Li", "Ping Li", "Hong Miao", "Jiansheng Han", "Yanjun Liu", "Jingkang Shen", "Yongping Yu"], "paper_year": 2014, "paper_institution": "Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Science, Zhejiang University, 866 Yuhangtang Road Zijin Campus, Hangzhou 310058, China", "paper_cited": 40, "doi": "10.1021/jm5014659", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm5014659/20141205/images/large/jm-2014-014659_0001.jpeg", "compound_count": 27, "compound_name": "5a", "compound_name_drug": "", "compound_smiles": "C1[C@@H](COC1)Oc1c(NC(=O)[C]2(=CCN(C)C)CC(C=C=C=CCCCC2)C)cc2c(Nc3ccc(F)c(Cl)c3)ncnc2c1", "medicinal_chemistry_metrics": {"Ki": "", "Kd": 33.3, "IC50": 0.2, "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": "", "IC50": "", "EC50": "", "selectivity": "", "hERG": 10.0, "solubility": ""}, "pharm_metrics_vivo": {"ED50": "", "AUC": "", "solubility": "", "t_half": "", "bioavailability": 16.5}, "clinical_statistics": {}}
articleURL: 18
10.1021/acs.jmedchem.7b01310
{"compound": "", "ic50_mc": ", a high percentage of these treated patients developed a tertiary cystein-797 to serine-790 ( c797s ) mutation in the egfr kinase domain . this c797s mutation is thought to induce resistance to all current irreversible egfr tkis . in this miniperspective , we present key mechanisms of resistance in response to third-generation egfr tkis , and emerging reports on novel egfr tkis to combat the resistance . specifically", "ki_mc": "growth factor receptor ( egfr ) has been a particular interest for drug development for treatment of non-small-cell lung cancer ( nsclc ) . the current third-generation egfr small-molecule inhibitors , especially osimertinib , are at the forefront clinically for treatment of patients with nsclc . however , a high percentage of these treated patients developed a tertiary cystein-797 to serine-790 ( c797s ) mutation in the egfr kinase domain . this c797s mutation is thought to induce resistance to all current irreversible egfr tkis . in this miniperspective , we present key mechanisms of resistance in response to third-generation egfr tkis , and emerging reports on novel egfr tkis to combat the resistance", "kd_ce": "<unk> . in this paragraph , can you find out the result of kd_ce ? [SEP] [CLS] what is the compound in this paper ? [SEP] recent progress of small-molecule epidermal growth factor receptor ( egfr ) inhibitors against c797s resistance in non-small-cell lung cancer the epidermal growth factor receptor ( egfr ) has been a particular interest for drug development for treatment of non-small-cell lung cancer ( nsclc ) . the current third-generation egfr small-molecule inhibitors , especially osimertinib , are at the forefront clinically for treatment of patients with nsclc . however , a high percentage of these treated patients developed a tertiary cystein-797 to", "selectivity_ce": "cystein-797", "solubility_ce": "<unk> . in this paragraph , can you find out the result of solubility_ce ? [SEP] [CLS] what is the compound in this paper ? [SEP] recent progress of small-molecule epidermal growth factor receptor ( egfr ) inhibitors against c797s resistance in non-small-cell lung cancer the epidermal growth factor receptor ( egfr ) has been a particular interest for drug development for treatment of non-small-cell lung cancer ( nsclc ) . the current third-generation egfr small-molecule inhibitors , especially osimertinib , are at the forefront clinically for treatment of patients with nsclc . however , a high percentage of these treated patients developed a tertiary cystein-797 to serine-790 ( c797s ) mutation in the egfr kinase domain . this c797s mutation is thought to induce resistance to all current irreversible egfr tkis . in this miniperspective , we present key mechanisms of resistance in response to third-generation egfr tkis , and emerging reports on novel egfr tkis to combat the resistance . specifically , we analyze the allosteric and atp-competitive inhibitors in terms of drug discovery , binding mechanism , and their potency and selectivity against egfr harboring c797s mutations", "ed50_an": "third-generation egfr small-molecule inhibitors , especially osimertinib , are at the forefront clinically for treatment of patients with nsclc . however , a high percentage of these treated patients developed a tertiary cystein-797 to serine-790 ( c797s ) mutation in the egfr kinase domain . this c797s mutation is thought to induce resistance to all current irreversible egfr tkis . in this miniperspective , we present key mechanisms of resistance in response to third-generation egfr tkis , and emerging reports on novel egfr tkis to combat the resistance . specifically , we analyze the allosteric and atp-competitive inhibitors in terms of drug discovery , binding mechanism , and their potency and selectivity against egfr harboring c797s mutations . lastly , we provide some perspectives on new challenges and future directions in this field . . [SEP]", "t_half_an": "<unk> . in this paragraph , can you find out the result of t_half_an ? [SEP] [CLS] what is the compound in this paper ? [SEP] recent progress of small-molecule epidermal growth factor receptor ( egfr ) inhibitors against c797s resistance in non-small-cell lung cancer the epidermal growth factor receptor ( egfr ) has been a particular interest for drug development for treatment of non-small-cell lung cancer ( nsclc ) . the current third-generation egfr small-molecule inhibitors , especially osimertinib , are at the forefront clinically for treatment of patients with nsclc . however , a high percentage of these treated patients developed a tertiary cystein-797 to serine-790 ( c797s ) mutation in the egfr kinase domain . this c797s mutation is thought to induce resistance to all current irreversible egfr tkis . in this miniperspective , we present key mechanisms of resistance in response to third-generation egfr tkis , and emerging reports on novel egfr tkis to combat the resistance", "compound_drug": "c797s"}


{"id": 18, "paper_title": "Recent Progress of Small-Molecule Epidermal Growth Factor Receptor (EGFR) Inhibitors against C797S Resistance in Non-Small-Cell Lung Cancer", "paper_author": ["Lingfeng Chen", "Weitao Fu", "Lulu Zheng", "Zhiguo Liu", "Guang Liang"], "paper_year": 2017, "paper_institution": "Chemical Biology Research Center at School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang 325035, China", "paper_cited": 45, "doi": "10.1021/acs.jmedchem.7b01310", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.7b01310/20180517/images/large/jm-2017-01310k_0009.jpeg", "compound_count": 29, "compound_name": "10", "compound_name_drug": "", "compound_smiles": "", "medicinal_chemistry_metrics": {"Ki": "", "Kd": "", "IC50": "", "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": "", "IC50": "", "EC50": "", "selectivity": "", "hERG": "", "solubility": ""}, "pharm_metrics_vivo": {"ED50": "", "AUC": "", "solubility": "", "t_half": "", "bioavailability": ""}, "clinical_statistics": {}}
articleURL: 19
10.1021/acs.jmedchem.7b00178
{"compound": "45a", "ic50_mc": "6 7 . 9", "kd_mc": "2", "ed50_an": "1; for details , see supporting information , scheme s1 ) .", "compound_drug": "<unk> . in this paragraph , can you find out the result of compound_drug ? [SEP] results and discussion chemistry the first set of reversible egfr inhibitors ( 11a–f , table 1 ) was synthesized using the optimized stille cross-coupling route for trisubstituted imidazoles , published by selig et al . ( 2 6"}


{"id": 19, "paper_title": "Trisubstituted Imidazoles with a Rigidized Hinge Binding Motif Act As Single Digit nM Inhibitors of Clinically Relevant EGFR L858R/T790M and L858R/T790M/C797S Mutants: An Example of Target Hopping", "paper_author": ["Michael Juchum", "Marcel Günther", "Eva Döring", "Adrian Sievers-Engler", "Michael Lämmerhofer", "Stefan Laufer"], "paper_year": 2017, "paper_institution": "Department of Pharmaceutical Chemistry, Institute of Pharmaceutical Sciences, Eberhard Karls Universität Tübingen, Auf der Morgenstelle 8, 72076 Tübingen, Germany", "paper_cited": 31, "doi": "10.1021/acs.jmedchem.7b00178", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.7b00178/20170602/images/large/jm-2017-001787_0019.jpeg", "compound_count": 72, "compound_name": "45a", "compound_name_drug": "", "compound_smiles": "c1(c2c([nH]c1)nccc2c1c(c2ccc(F)cc2)nc([nH]1)CCCO)c1cccc(NC(=O)C=C)c1", "medicinal_chemistry_metrics": {"Ki": "", "Kd": 2.0, "IC50": 67.9, "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": "", "IC50": "", "EC50": "", "selectivity": "", "hERG": "", "solubility": ""}, "pharm_metrics_vivo": {"ED50": "", "AUC": "", "solubility": "", "t_half": "", "bioavailability": ""}, "clinical_statistics": {}}
articleURL: 20
10.1021/jm401045n
{"compound": "3q", "ic50_mc": "3 . 8 2", "kd_ce": "3", "selectivity_ce": "1", "ed50_an": "1 via virtual screening was identified as a moderately effective egfr kinase inhibitor , which shares the same pyrimidine scaffold as the recently developed irreversible egfr t790m mutant inhibitor wz4002 . therefore , a similar strategy could likely be applied to convert compound 1 into a potential egfr mutant inhibitor by introducing a michael addition receptor group . however , because wz4002-based irreversible inhibitors have been previously reported and patented , the pyridine scaffold had to be replaced with a different scaffold that could bind the egfr pocket in a similar manner prior to michael addition receptor decoration . shape-based molecular 3d superposition proved to be a powerful tool for computational scaffold hopping because shape complementation plays a pivotal role in ligand–protein recognition . ( 3 9 ) we have developed an in-house molecular 3d similarity calculation method called shafts . shafts adopts a hybrid similarity metric combined with molecular shape and colored ( labeled ) chemistry groups annotated by pharmacophore features for 3d similarity calculation and ranking , which is designed to integrate the strength of pharmacophore matching and volumetric overlay approaches . a featured triplet hashing method is used for fast molecular-alignment poses enumeration , and the optimal superposition between the target and the query molecules can be prioritized by calculating corresponding “hybrid similarities” . shafts is suitable for large-scale virtual screening with single or multiple bioactive compounds as", "compound_drug": "wz4002"}


{"id": 20, "paper_title": "Discovery of Pteridin-7(8H)-one-Based Irreversible Inhibitors Targeting the Epidermal Growth Factor Receptor (EGFR) Kinase T790M/L858R Mutant", "paper_author": ["Wei Zhou", "Xiaofeng Liu", "Zhengchao Tu", "Lianwen Zhang", "Xin Ku", "Fang Bai", "Zhenjiang Zhao", "Yufang Xu", "Ke Ding", "Honglin Li"], "paper_year": 2013, "paper_institution": "Shanghai Key Laboratory of New Drug Design, State Key Laboratory of Bioreactor Engineering, School of Pharmacy, East China University of Science & Technology, Shanghai 200237, China", "paper_cited": 45, "doi": "10.1021/jm401045n", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-20/jm401045n/production/images/large/jm-2013-01045n_0013.jpeg", "compound_count": 45, "compound_name": "3q", "compound_name_drug": "", "compound_smiles": "", "medicinal_chemistry_metrics": {"Ki": "", "Kd": "", "IC50": 3.82, "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": 3.0, "IC50": "4.02 ± 1.52", "EC50": "", "selectivity": "", "hERG": "", "solubility": ""}, "pharm_metrics_vivo": {"ED50": 0.001, "AUC": "", "solubility": "", "t_half": "", "bioavailability": ""}, "clinical_statistics": {}}
articleURL: 21
10.1021/acs.jmedchem.9b01169
{"compound": "bi-4020", "ic50_mc": "9", "ed50_an": "1 0", "bioavailability_an": "1 2 1", "compound_drug": "<unk> . in this paragraph , can you find out the result of compound_drug ? [SEP] results and discussion selectivity first: screening for a highly selective rather than a highly active starting point at the outset of the project , we decided to start a screening campaign to find chemical starting points , which provided selectivity for the mutated egfr proteins over egfrwt protein rather than a high activity . we hypothesized that it would be easier to improve upon the activity of an egfrwt selective molecule than it would be to rationally design egfrwt selectivity of a potent but unselective inhibitor . a structure-based design approach to generate selectivity for the egfr primary activation mutation l858r and del19 over egfrwt was further ruled out as no structural differences between the binding pockets from the publicly available x-ray structures of the egfrl858r and egfrwt proteins were observable ."}


{"id": 21, "paper_title": "Start Selective and Rigidify: The Discovery Path toward a Next Generation of EGFR Tyrosine Kinase Inhibitors", "paper_author": ["Harald Engelhardt", "Dietrich Böse", "Mark Petronczki", "Dirk Scharn", "Gerd Bader", "Anke Baum", "Andreas Bergner", "Eugene Chong", "Sandra Döbel", "Georg Egger", "Christian Engelhardt", "Peter Ettmayer", "Julian E. Fuchs", "Thomas Gerstberger", "Nina Gonnella", "Andreas Grimm", "Elisabeth Grondal", "Nizar Haddad", "Barbara Hopfgartner", "Roland Kousek", "Mariusz Krawiec", "Monika Kriz", "Lyne Lamarre", "Joyce Leung", "Moriz Mayer", "Nitinchandra D. Patel", "Biljana Peric Simov", "Jonathan T. Reeves", "Renate Schnitzer", "Andreas Schrenk", "Bernadette Sharps", "Flavio Solca", "Heinz Stadtmüller", "Zhulin Tan", "Tobias Wunberg", "Andreas Zoephel", "Darryl B. McConnell"], "paper_year": 2019, "paper_institution": "Boehringer Ingelheim RCV GmbH & Co KG, Dr-Boehringer-Gasse 5-11, Vienna 1120, Austria", "paper_cited": 21, "doi": "10.1021/acs.jmedchem.9b01169", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01169/20191122/images/large/jm9b01169_0023.jpeg", "compound_count": 56, "compound_name": "bi-4020", "compound_name_drug": "bi-4020", "compound_smiles": "", "medicinal_chemistry_metrics": {"Ki": "", "Kd": "", "IC50": 9.0, "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": "", "IC50": "", "EC50": "", "selectivity": "", "hERG": "", "solubility": ""}, "pharm_metrics_vivo": {"ED50": 10.0, "AUC": "", "solubility": "", "t_half": "", "bioavailability": 121.0}, "clinical_statistics": {}}
articleURL: 22
10.1021/jm030065n
{"compound": "d", "ed50_an": "7 to ser , his 7 4 9 to tyr and ile 7 6 5 to val , that do not expose their side chains to the atp could be possibly contributing to the differences in selectivity of these enzymes toward various inhibitors . the effects of these residues in terms of their effects on dynamics of the atp site is difficult to model using static docking on the receptor", "compound_drug": "1m14 and 1m17"}


{"id": 22, "paper_title": "Receptor-Guided Alignment-Based Comparative 3D-QSAR Studies of Benzylidene Malonitrile Tyrphostins as EGFR and HER-2 Kinase Inhibitors", "paper_author": ["Shantaram Kamath", "John K. Buolamwini"], "paper_year": 2003, "paper_institution": "Department of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee Health Sciences Center, 847 Monroe Avenue Suite 327, Memphis, Tennessee 38163 ", "paper_cited": 48, "doi": "10.1021/jm030065n", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2003/jmcmar.2003.46.issue-22/jm030065n/production/images/large/jm030065nn00001.jpeg", "compound_count": 55, "compound_name": "II", "compound_name_drug": "", "compound_smiles": "", "medicinal_chemistry_metrics": {"Ki": "", "Kd": "", "IC50": "", "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": "", "IC50": "", "EC50": "", "selectivity": "", "hERG": "", "solubility": ""}, "pharm_metrics_vivo": {"ED50": 0.007, "AUC": "", "solubility": "", "t_half": "", "bioavailability": ""}, "clinical_statistics": {}}
articleURL: 23
10.1021/jm400822z
{"compound": "", "ic50_mc": "0 . 0 0 9 μm", "ki_mc": "egfr", "kd_mc": "3", "selectivity_mc": "1", "ic50_ce": "2", "ec50_ce": "7", "herg_ce": "1 5", "solubility_ce": "7 . 4", "ed50_an": "7 ) however , the set of compounds that was of particular interest were the examples from internal astrazeneca projects that had shown activity against kinases with a methionine gatekeeper .", "t_half_an": "2 5 min", "bioavailability_an": "reactivity-based development of covalent inhibitors of the activating and gatekeeper mutant forms of the epidermal growth factor receptor ( egfr", "compound_drug": "<unk> . in this paragraph , can you find out the result of compound_drug ? [SEP] results and discussion chemistry where possible , compounds were prepared according to the general strategy outlined in scheme 1 from commercially available pyrimidines ( a ) . installation of the reactive warhead , where present , at the last or penultimate step was desirable because it was not expected to be robust enough during further chemical manipulation . although scheme 1 captures the synthesis approach to the majority of the key examples from this manuscript ( shown in table 1 ) , because of the structural diversity of the compounds reported , some examples were not synthesized using this approach . however , the full synthesis of all compounds can be found in the experimental section or in the supporting information ."}


{"id": 23, "paper_title": "Structure- and Reactivity-Based Development of Covalent Inhibitors of the Activating and Gatekeeper Mutant Forms of the Epidermal Growth Factor Receptor (EGFR)", "paper_author": ["Richard A. Ward", "Mark J. Anderton", "Susan Ashton", "Paul A. Bethel", "Matthew Box", "Sam Butterworth", "Nicola Colclough", "Christopher G. Chorley", "Claudio Chuaqui", "Darren A. E. Cross", "Les A. Dakin", "Judit É. Debreczeni", "Cath Eberlein", "M. Raymond V. Finlay", "George B. Hill", "Matthew Grist", "Teresa C. M. Klinowska", "Clare Lane", "Scott Martin", "Jonathon P. Orme", "Peter Smith", "Fengjiang Wang", "Michael J. Waring"], "paper_year": 2013, "paper_institution": "AstraZeneca, Oncology & Discovery Sciences Innovative Medicines, Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, United Kingdom", "paper_cited": 131, "doi": "10.1021/jm400822z", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400822z/production/images/large/jm-2013-00822z_0052.jpeg", "compound_count": 53, "compound_name": "15", "compound_name_drug": "", "compound_smiles": "", "medicinal_chemistry_metrics": {"Ki": "", "Kd": 3.0, "IC50": 9.0, "selectivity": "μm237"}, "pharm_metrics_vitro": {"Ki": "", "Kd": "", "IC50": 2.0, "EC50": 7.0, "selectivity": "", "hERG": 15.0, "solubility": 7.4}, "pharm_metrics_vivo": {"ED50": 7.0, "AUC": "", "solubility": "", "t_half": 0.4166666666666667, "bioavailability": ""}, "clinical_statistics": {}}
articleURL: 24
10.1021/jm0600390
{"compound": "2 3", "ic50_mc": "2 . 2 . 2", "solubility_ce": "2 5", "ed50_an": "9 were synthesized as per the procedure described by tsou et al . 1 4 briefly , anthranilonitrile 1 was condensed with dmf−acetal giving amidine 3 , which was cyclized in refluxing acetic acid in the presence of corresponding aniline to provide 6-nitroquinazolines 5 and 6 . reduction of these nitro compounds with fe gave the targeted amines 8 and 9 in good yield . 6-aminoquinazolines 7−9 were converted to their n-methyl analogues 10−12 following a slightly modified procedure published by bridges et al . 1 5 first , amines 7−9 were treated with ethyl chloroformate , and then the resulting carbamates were reduced with lialh4 . the aminoquinazolines 7−12 thus generated were treated with 2-chloroethylisocyanate to provide ureas 13−18 , which were subsequently nitrosated with nobf4/acoh to give nitrosoureas 19−24 . the latter compounds were purified by column chromatography on silica gel with a mixture of ethyl acetate/petroleum ether as eluent . the", "t_half_an": "4 1 h", "compound_drug": "<unk> . in this paragraph , can you find out the result of compound_drug ? [SEP] 2 . results and discussion 2 . 1 . chemistry . the synthesis of the series proceeded as depicted in schemes 2 and 3 . 6-aminoquinazolines 7−9 were prepared in three steps from nitroanthranilonitrile 1 as previously described . 1 1 briefly , anthranilonitrile 1 was heated at reflux in formic acid containing concentrated h2so4 to give 4-oxoquinazoline 2 , 1 1 which was chlorinated with pcl5 in fusion . 1 2 the resulting 4-chloroquinazoline was treated with 3-methylaniline to yield 6-nitroquinazoline 4 which was catalytically reduced to amine 7 . 1 3 aminoquinazolines 8"}


{"id": 24, "paper_title": "The Combi-Targeting Concept:  Synthesis of Stable Nitrosoureas Designed to Inhibit the Epidermal Growth Factor Receptor (EGFR)", "paper_author": ["Juozas Domarkas", "Fabienne Dudouit", "Christopher Williams", "Qiu Qiyu", "Ranjita Banerjee", "Fouad Brahimi", "Bertrand Jacques Jean-Claude"], "paper_year": 2006, "paper_institution": "Cancer Drug Research Laboratory, Department of Medicine, Division of Medical Oncology, McGill University Health Center/ Royal Victoria Hospital, Montreal, H3A1A1, Quebec, Canada ", "paper_cited": 55, "doi": "10.1021/jm0600390", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2006/jmcmar.2006.49.issue-12/jm0600390/production/images/large/jm0600390n00001.jpeg", "compound_count": 83, "compound_name": "23", "compound_name_drug": "", "compound_smiles": "", "medicinal_chemistry_metrics": {"Ki": "", "Kd": "", "IC50": "μm11.7", "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": "", "IC50": "", "EC50": "", "selectivity": "", "hERG": "", "solubility": 25.0}, "pharm_metrics_vivo": {"ED50": 0.009, "AUC": "", "solubility": "", "t_half": 41.0, "bioavailability": ""}, "clinical_statistics": {}}
articleURL: 25
10.1021/acs.jmedchem.6b00403
{"compound": "17d", "ic50_mc": "1 . 1", "selectivity_mc": "7", "ed50_an": "9 ( figure 1 ) was identified by scaffold hopping as a potent irreversible egfr kinase inhibitor , which exhibited competitive inhibitory enzymatic activities with single nanomolar ic50 values against both wild-type and l858r/t790m mutant egfrs ( 3 . 8 nm vs 1 . 1 nm ) . ( 3 3 ) on the basis of molecular modeling studies , 9 irreversibly binds to the t790m mutant egfr ( pdb code 3ika ) by targeting the cys797 residue in the atp binding site via the formation of a covalent bond , and the n-methylpiperazine motif on the left-hand side is directed toward the solvent exposed region . the pteridin-7 ( 8h ) -one core forms an expected bidentate hydrogen-bonded interaction with the hinge residue met793 , while the double-ring system contacts the mutant gatekeeper met790 residue . besides , the egfr l858r mutation adjacent to the activation loop is far from the ligand and would not affect the binding site ( figure 2a and figure 2b ) . the crystal structure of compound 4 , which exhibited similar binding modes but mutant-selective activity , encouraged us to do the comparative crystal structure analysis for egfrt790m mutant over egfrwt . as shown in figure 2b , overlay of the structure of wt egfr ( pdb code 4g5j ) into t790m mutant egfr shows that selectivity of compound 4 for the gatekeeper egfrt790m mutant was obtained through the", "bioavailability_an": "4 8 %", "compound_drug": "<unk> . in this paragraph , can you find out the result of compound_drug ? [SEP] results and discussion lead compound and design strategy in our previous studies , compound 9 ( figure 1"}


{"id": 25, "paper_title": "Discovery and Structural Optimization of N5-Substituted 6,7-Dioxo-6,7-dihydropteridines as Potent and Selective Epidermal Growth Factor Receptor (EGFR) Inhibitors against L858R/T790M Resistance Mutation", "paper_author": ["Yongjia Hao", "Xia Wang", "Tao Zhang", "Deheng Sun", "Yi Tong", "Yuqiong Xu", "Haiyang Chen", "Linjiang Tong", "Lili Zhu", "Zhenjiang Zhao", "Zhuo Chen", "Jian Ding", "Hua Xie", "Yufang Xu", "Honglin Li"], "paper_year": 2016, "paper_institution": "Shanghai Key Laboratory of New Drug Design, Shanghai Key Laboratory of Chemical Biology, State Key Laboratory of Bioreactor Engineering, School of Pharmacy, East China University of Science and Technology, Shanghai, 200237, China", "paper_cited": 18, "doi": "10.1021/acs.jmedchem.6b00403", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-15/acs.jmedchem.6b00403/20160811/images/large/jm-2016-00403e_0012.jpeg", "compound_count": 30, "compound_name": "17d", "compound_name_drug": "", "compound_smiles": "N1(CCN(CC1)C)c1cc(OC)c(Nc2ncc3c(n(c4cccc(NC(=O)C=C)c4)c(=O)c(=O)n3CC(C)C)n2)cc1", "medicinal_chemistry_metrics": {"Ki": "", "Kd": "", "IC50": 1.1, "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": "", "IC50": "", "EC50": "", "selectivity": "", "hERG": "", "solubility": ""}, "pharm_metrics_vivo": {"ED50": 0.009, "AUC": "", "solubility": "", "t_half": "", "bioavailability": 48.0}, "clinical_statistics": {}}
articleURL: 26
10.1021/jm0608762
{"compound": "1", "selectivity_mc": "growth factor receptor ( egfr ) and to exert proapoptotic effects† . the main compound is <unk> . in this paragraph , can you find out the result of selectivity_mc ? [SEP] [CLS] what is the compound in this paper ? [SEP] multitarget-directed drug design strategy: a novel molecule designed to block epidermal growth factor receptor ( egfr ) and to exert proapoptotic effects† the multifactorial mechanistic nature of cancer calls for the development of multifunctional therapeutic tools , i . e . , single compounds able to interact with multiple altered pathogenetic pathways . following this rationale , we designed compounds able to irreversibly block epidermal growth factor receptor ( egfr ) , and to induce apoptosis in tumor cell lines . the novel molecules were synthesized by combining the structural features of the egfr inhibitor pd153035 ( <b> 1", "ic50_ce": "<unk> . in this paragraph , can you find out the result of ic50_ce ? [SEP] [CLS] what is the compound in this paper ? [SEP] multitarget-directed drug design strategy: a novel molecule designed to block epidermal growth factor receptor ( egfr ) and to exert proapoptotic effects† the multifactorial mechanistic nature of cancer calls for the development of multifunctional therapeutic tools , i . e .", "kd_ce": "<unk> . in this paragraph , can you find out the result of kd_ce ? [SEP] [CLS] what is the compound in this paper ? [SEP] multitarget-directed drug design strategy: a novel molecule designed to block epidermal growth factor receptor ( egfr", "ed50_an": "1 </b> ) and lipoic acid , which among other therapeutic effects triggers apoptosis in human cancer cells . . [SEP]", "bioavailability_an": "growth factor receptor ( egfr", "compound_drug": "pd153035"}


{"id": 26, "paper_title": "Multitarget-Directed Drug Design Strategy:  A Novel Molecule Designed To Block Epidermal Growth Factor Receptor (EGFR) and To Exert Proapoptotic Effects†", "paper_author": ["Alessandra Antonello", "Andrea Tarozzi", "Fabiana Morroni", "Andrea Cavalli", "Michela Rosini", "Patrizia Hrelia", "Maria Laura Bolognesi", "Carlo Melchiorre"], "paper_year": 2006, "paper_institution": "Department of Pharmaceutical Sciences, Alma Mater Studiorum, University of Bologna, Via Belmeloro 6, 40126 Bologna, Italy, and Department of Pharmacology, Alma Mater Studiorum, University of Bologna, Via Irnerio 48, 40126 Bologna, Italy ", "paper_cited": 59, "doi": "10.1021/jm0608762", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2006/jmcmar.2006.49.issue-23/jm0608762/production/images/large/jm0608762n00001.jpeg", "compound_count": 12, "compound_name": "1", "compound_name_drug": "", "compound_smiles": "", "medicinal_chemistry_metrics": {"Ki": "", "Kd": "", "IC50": "", "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": "", "IC50": "μm0.028 ± 0.004 ", "EC50": "", "selectivity": "", "hERG": "", "solubility": ""}, "pharm_metrics_vivo": {"ED50": 0.001, "AUC": "", "solubility": "", "t_half": "", "bioavailability": ""}, "clinical_statistics": {}}
articleURL: 27
10.1021/jm500973a
{"compound": ". we describe herein the evolution of an early , mutant selective lead to the clinical candidate azd9291", "selectivity_mc": "1", "ic50_ce": "2 0", "t_half_an": "2", "bioavailability_an": "5 1 . 7", "compound_drug": "azd9291"}


{"id": 27, "paper_title": "Discovery of a Potent and Selective EGFR Inhibitor (AZD9291) of Both Sensitizing and T790M Resistance Mutations That Spares the Wild Type Form of the Receptor", "paper_author": ["M. Raymond V. Finlay", "Mark Anderton", "Susan Ashton", "Peter Ballard", "Paul A. Bethel", "Matthew R. Box", "Robert H. Bradbury", "Simon J. Brown", "Sam Butterworth", "Andrew Campbell", "Christopher Chorley", "Nicola Colclough", "Darren A. E. Cross", "Gordon S. Currie", "Matthew Grist", "Lorraine Hassall", "George B. Hill", "Daniel James", "Michael James", "Paul Kemmitt", "Teresa Klinowska", "Gillian Lamont", "Scott G. Lamont", "Nathaniel Martin", "Heather L. McFarland", "Martine J. Mellor", "Jonathon P. Orme", "David Perkins", "Paula Perkins", "Graham Richmond", "Peter Smith", "Richard A. Ward", "Michael J. Waring", "David Whittaker", "Stuart Wells", "Gail L. Wrigley"], "paper_year": 2014, "paper_institution": "†Oncology Innovative Medicines, ‡Drug Safety and Metabolism, §Global Medicines Development, and ∥Discovery Sciences, AstraZeneca, Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, U.K.", "paper_cited": 292, "doi": "10.1021/jm500973a", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/large/jm-2014-00973a_0029.jpeg", "compound_count": 25, "compound_name": "8", "compound_name_drug": ".wedescribehereintheevolutionofanearly,mutantselectiveleadtotheclinicalcandidateazd9291", "compound_smiles": "", "medicinal_chemistry_metrics": {"Ki": "", "Kd": "", "IC50": "μm0.912", "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": "", "IC50": 20.0, "EC50": "", "selectivity": "", "hERG": "", "solubility": ""}, "pharm_metrics_vivo": {"ED50": "", "AUC": "", "solubility": "", "t_half": 2.0, "bioavailability": 51.7}, "clinical_statistics": {}}
articleURL: 28
10.1021/jm100607r
{"compound": "1 9", "ic50_mc": "7", "selectivity_mc": "1", "ic50_ce": "2", "ed50_an": "7 through increasing the side chain length ( 7a ) , substitution in the phenyl ring ( 7b , c ) , or converting the fused cyclohexyl ring to cyclopentyl ring ( 7d ) led to decreased egfr kinase activity ( table 1 ) . meanwhile , through a concurrent program for the development of aurora kinase inhibitors , we have synthesized a set of kinase-targeted compound library based on furanopyrimidine scaffold . this library was counter-screened for egfr kinase inhibition , leading to the identification of an egfr kinase selective furanopyrimidine inhibitor 8 ( figure 2 ) with an egfr kinase ic50 = 2 2 3 nm ( aurora a kinase ic50 > 1 0 μm ) . ( 6 )", "compound_drug": "<unk> . in this paragraph , can you find out the result of compound_drug ? [SEP] results and discussion initial attempts to improve the activity of 7 through increasing the side chain length ( 7a ) , substitution in the phenyl ring ( 7b , c ) , or converting the fused cyclohexyl ring to cyclopentyl ring ( 7d ) led to decreased egfr kinase activity ( table 1 ) . meanwhile , through a concurrent program for the development of aurora kinase inhibitors , we have synthesized a set of kinase-targeted compound library based on furanopyrimidine scaffold . this library was counter-screened for egfr kinase inhibition , leading to the identification of an egfr kinase selective furanopyrimidine inhibitor 8 ( figure 2"}


{"id": 28, "paper_title": "Design and Synthesis of Tetrahydropyridothieno[2,3-d]pyrimidine Scaffold Based Epidermal Growth Factor Receptor (EGFR) Kinase Inhibitors: The Role of Side Chain Chirality and Michael Acceptor Group for Maximal Potency", "paper_author": ["Chia-Hsien Wu", "Mohane Selvaraj Coumar", "Chang-Ying Chu", "Wen-Hsing Lin", "Yi-Rong Chen", "Chiung-Tong Chen", "Hui-Yi Shiao", "Shaik Rafi", "Sing-Yi Wang", "Hui Hsu", "Chun-Hwa Chen", "Chun-Yu Chang", "Teng-Yuan Chang", "Tzu-Wen Lien", "Ming-Yu Fang", "Kai-Chia Yeh", "Ching-Ping Chen", "Teng-Kuang Yeh", "Su-Huei Hsieh", "John T.-A. Hsu", "Chun-Chen Liao", "Yu-Sheng Chao", "Hsing-Pang Hsieh"], "paper_year": 2010, "paper_institution": "Institute of Biotechnology and Pharmaceutical Research", "paper_cited": 80, "doi": "10.1021/jm100607r", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-20/jm100607r/production/images/large/jm-2010-00607r_0010.jpeg", "compound_count": 64, "compound_name": "19", "compound_name_drug": "", "compound_smiles": "", "medicinal_chemistry_metrics": {"Ki": "", "Kd": "", "IC50": 7.0, "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": "", "IC50": 2.0, "EC50": "", "selectivity": "", "hERG": "", "solubility": ""}, "pharm_metrics_vivo": {"ED50": 0.007, "AUC": "", "solubility": "", "t_half": "", "bioavailability": ""}, "clinical_statistics": {}}
articleURL: 29
10.1021/jm300185p
{"compound": "51m", "ic50_mc": "4", "kd_mc": "2 . 0", "selectivity_mc": "1 0", "ic50_ce": "7 9", "kd_ce": "2", "ec50_ce": "1", "ed50_an": "2 . among the compounds cyclized at the c-3 and c-4 positions ( 42a–d ) , the 6-substituted-2 , 3-dihydro-1h-isoindol-1-one derivative 42a showed the most potent her2/egfr inhibitory activities and growth inhibition ( gi ) activity in bt-474 cells . the other compounds , 42b–d , showed reduced potencies against her2/egfr kinases as well as reduced gi activity . it was confirmed that suitable interaction of the carboxamide moiety in the bicyclic amide ring with the her2/egfr proteins is important for high-level inhibitory activity .", "compound_drug": "<unk> . in this paragraph , can you find out the result of compound_drug ? [SEP] results and discussion among the compounds cyclized at the c-3 and c-2 positions ( 42e–h ) , compound 42e exhibited reduced potency against the her2/egfr kinases , but 42f–h showed potent her2/egfr kinase inhibitory activities similar to those of 42a . interestingly , among the compounds 42f–h , only 42f exhibited a reduction of gi activity in bt-474 cells . however , 4-substituted-1 , 3-dihydro-2h-indol-2-one ( 42h"}


{"id": 29, "paper_title": "Design and Synthesis of Pyrrolo[3,2-d]pyrimidine Human Epidermal Growth Factor Receptor 2 (HER2)/Epidermal Growth Factor Receptor (EGFR) Dual Inhibitors: Exploration of Novel Back-Pocket Binders", "paper_author": ["Youichi Kawakita", "Hiroshi Banno", "Tomohiro Ohashi", "Toshiya Tamura", "Tadashi Yusa", "Akiko Nakayama", "Hiroshi Miki", "Hidehisa Iwata", "Hidenori Kamiguchi", "Toshimasa Tanaka", "Noriyuki Habuka", "Satoshi Sogabe", "Yoshikazu Ohta", "Tomoyasu Ishikawa"], "paper_year": 2012, "paper_institution": "Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited: 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan", "paper_cited": 27, "doi": "10.1021/jm300185p", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300185p/production/images/large/jm-2012-00185p_0001.jpeg", "compound_count": 98, "compound_name": "51m", "compound_name_drug": "", "compound_smiles": "", "medicinal_chemistry_metrics": {"Ki": "", "Kd": 2.0, "IC50": 4.0, "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": 2.0, "IC50": 79.0, "EC50": 1.0, "selectivity": "", "hERG": "", "solubility": ""}, "pharm_metrics_vivo": {"ED50": 0.002, "AUC": "", "solubility": "", "t_half": "", "bioavailability": ""}, "clinical_statistics": {}}
articleURL: 31
10.1021/acs.jmedchem.7b00794
{"compound": ". because the concomitant inhibition of both hh and met pathways restores the sensitivity to anti-egfr drugs , here we aimed at discovering the first compounds that block simultaneously met and smo . by using an “in silico drug repurposing” approach and by validating our predictions both in vitro and in vivo , we identified a set of compounds with the desired dual inhibitory activity and enhanced antiproliferative activity on egfr tki-resistant nsclc . the identification of the known met tkis , glesatinib", "ic50_mc": "1", "ki_mc": "1 2 . 2 ± 1 . 7 nm", "ic50_ce": "2", "ed50_an": "7 ) .", "compound_drug": "bindingdb database . ( 1 1"}


{"id": 30, "paper_title": "Dual MET and SMO Negative Modulators Overcome Resistance to EGFR Inhibitors in Human Nonsmall Cell Lung Cancer", "paper_author": ["Floriana Morgillo", "Giorgio Amendola", "Carminia Maria Della Corte", "Chiara Giacomelli", "Lorenzo Botta", "Salvatore Di Maro", "Anna Messere", "Vincenza Ciaramella", "Sabrina Taliani", "Luciana Marinelli", "Maria Letizia Trincavelli", "Claudia Martini", "Ettore Novellino", "Fortunato Ciardiello", "Sandro Cosconati"], "paper_year": 2017, "paper_institution": "Oncologia Medica, Dipartimento Medico-Chirurgico di Internistica Clinica e Sperimentale “F. Magrassi e A. Lanzara”, Università della Campania “Luigi Vanvitelli”, Via Pansini 6, 80131 Naples, Italy", "paper_cited": 13, "doi": "10.1021/acs.jmedchem.7b00794", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-17/acs.jmedchem.7b00794/20170908/images/large/jm-2017-00794d_0008.jpeg", "compound_count": 17, "compound_name": "5", "compound_name_drug": "", "compound_smiles": "", "medicinal_chemistry_metrics": {"Ki": 12.2, "Kd": "", "IC50": 1.0, "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "53.1 ± 9.9", "Kd": "", "IC50": 2.0, "EC50": "", "selectivity": "", "hERG": "", "solubility": ""}, "pharm_metrics_vivo": {"ED50": 7.0, "AUC": "", "solubility": "", "t_half": "", "bioavailability": ""}, "clinical_statistics": {}}
articleURL: 32
10.1021/acs.jmedchem.1c00649
{"compound": "crbn", "ic50_mc": "4", "ic50_ce": "4 μm", "ed50_an": "1 ) . dual protac can not only degrade two targets at the same time , but also imbibe merits of both protacs and double targeting drugs , achieving similar efficacy as bispecific antibodies and still relatively conserving the advantages of small molecule drugs . to the best of our knowledge , there has been no report yet on this audacious and innovative idea . therefore , it will be very interesting to design and synthesize such a novel dual protac molecule for proof of concept .", "compound_drug": "<unk> . in this paragraph , can you find out the result of compound_drug ? [SEP] results and discussion inspired by the great success of dual-targeting drugs , especially bispecific antibodies , we envisage that by combining the concept of protac and dual targeting , a dual protac molecule with two independent inhibitor units and one e3 ligase ligand can be designed for degrading two targets simultaneously in completely different pathways ( figure 1 ) . dual protac can not only degrade two targets at the same time , but also imbibe merits of both protacs and double targeting drugs , achieving similar efficacy as bispecific antibodies and still relatively conserving the advantages of small molecule drugs . to the best of our knowledge , there has been no report yet on this audacious and innovative idea . therefore , it will be very interesting to design and synthesize such a novel dual protac molecule for proof of concept ."}


{"id": 31, "paper_title": "Rational Design and Synthesis of Novel Dual PROTACs for Simultaneous Degradation of EGFR and PARP", "paper_author": ["Mengzhu Zheng", "Junfeng Huo", "Xiaoxia Gu", "Yali Wang", "Canrong Wu", "Qingzhe Zhang", "Wang Wang", "Yang Liu", "Yu Liu", "Xuechen Zhou", "Lixia Chen", "Yirong Zhou", "Hua Li"], "paper_year": 2021, "paper_institution": "Hubei Key Laboratory of Natural Medicinal Chemistry and Resource Evaluation, School of Pharmacy, Tongji-Rongcheng Center for Biomedicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China", "paper_cited": -1, "doi": "10.1021/acs.jmedchem.1c00649", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00649/20210602/images/large/jm1c00649_0008.jpeg", "compound_count": 64, "compound_name": "DP-V-4", "compound_name_drug": "", "compound_smiles": "", "medicinal_chemistry_metrics": {"Ki": "", "Kd": "", "IC50": 4.0, "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": "", "IC50": 4000.0, "EC50": "", "selectivity": "", "hERG": "", "solubility": ""}, "pharm_metrics_vivo": {"ED50": 0.001, "AUC": "", "solubility": "", "t_half": "", "bioavailability": ""}, "clinical_statistics": {}}
articleURL: 33
10.1021/jm301365e
{"compound": "9e", "ic50_mc": "2", "selectivity_ce": "1", "ed50_an": "0 . 0 0 1 6 μm ) .", "t_half_an": "9 . 7 2", "compound_drug": "h1975"}


{"id": 32, "paper_title": "Structural Optimization and Structure–Activity Relationships of N2-(4-(4-Methylpiperazin-1-yl)phenyl)-N8-phenyl-9H-purine-2,8-diamine Derivatives, a New Class of Reversible Kinase Inhibitors Targeting both EGFR-Activating and Resistance Mutations", "paper_author": ["Jiao Yang", "Li-Jiao Wang", "Jing-Jing Liu", "Lei Zhong", "Ren-Lin Zheng", "Yong Xu", "Pan Ji", "Chun-Hui Zhang", "Wen-Jing Wang", "Xing-Dong Lin", "Lin-Li Li", "Yu-Quan Wei", "Sheng-Yong Yang"], "paper_year": 2012, "paper_institution": "State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medical School, Sichuan University, Sichuan 610041, China", "paper_cited": 32, "doi": "10.1021/jm301365e", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-23/jm301365e/production/images/large/jm-2012-01365e_0015.jpeg", "compound_count": 54, "compound_name": "9e", "compound_name_drug": "", "compound_smiles": "", "medicinal_chemistry_metrics": {"Ki": "", "Kd": "", "IC50": 2.0, "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": "", "IC50": "", "EC50": "", "selectivity": "", "hERG": "", "solubility": ""}, "pharm_metrics_vivo": {"ED50": 0.0016, "AUC": "", "solubility": "", "t_half": 9.72, "bioavailability": ""}, "clinical_statistics": {}}
articleURL: 34
10.1021/jm2008634
{"compound": "34e", "selectivity_mc": "1", "ic50_ce": "2 6 0 nm", "kd_ce": "2", "herg_ce": "1 μm", "ed50_an": "6 . 2 5", "bioavailability_an": "9 7 . 7", "compound_drug": "tak-285"}


{"id": 33, "paper_title": "Design and Synthesis of Novel Human Epidermal Growth Factor Receptor 2 (HER2)/Epidermal Growth Factor Receptor (EGFR) Dual Inhibitors Bearing a Pyrrolo[3,2-d]pyrimidine Scaffold", "paper_author": ["Tomoyasu Ishikawa", "Masaki Seto", "Hiroshi Banno", "Youichi Kawakita", "Mami Oorui", "Takahiko Taniguchi", "Yoshikazu Ohta", "Toshiya Tamura", "Akiko Nakayama", "Hiroshi Miki", "Hidenori Kamiguchi", "Toshimasa Tanaka", "Noriyuki Habuka", "Satoshi Sogabe", "Jason Yano", "Kathleen Aertgeerts", "Keiji Kamiyama"], "paper_year": 2011, "paper_institution": "Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1 Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan", "paper_cited": 98, "doi": "10.1021/jm2008634", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-23/jm2008634/production/images/large/jm-2011-008634_0015.jpeg", "compound_count": 100, "compound_name": "34e", "compound_name_drug": "", "compound_smiles": "", "medicinal_chemistry_metrics": {"Ki": "", "Kd": "", "IC50": "", "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": 2.0, "IC50": 260.0, "EC50": "", "selectivity": "", "hERG": 1.0, "solubility": ""}, "pharm_metrics_vivo": {"ED50": 6.25, "AUC": "", "solubility": "", "t_half": "", "bioavailability": 97.7}, "clinical_statistics": {}}
articleURL: 35
10.1021/jm901453q
{"compound": "8", "ic50_mc": "5 8 . 1", "selectivity_mc": "7", "herg_ce": "2 0", "solubility_ce": "2", "ed50_an": "7- ( 4- ( 3-ethynylphenylamino ) -7-methoxyquinazolin-6-yloxy ) -n-hydroxyheptanamide ( cudc-101 ) as a potent multi-acting hdac , egfr , and her2 inhibitor for the treatment of cancer . the main compound is <unk> . in this paragraph , can you find out the result of ed50_an ? [SEP] results and discussion to study structure−activity relationships , compounds were evaluated in egfr and her2 kinase activity assays , as well as an hdac enzyme assay . for the purpose of sar analysis , all compounds were assigned to four groups including chain length and phenyl ring substitution analogues , quinazoline ring substitution analogues , benzylamine analogues , and position analogues . the in vitro enzymatic inhibition assay results of these four types of compounds are summarized in tables 1−4 .", "t_half_an": "3", "compound_drug": "cudc-101"}


{"id": 34, "paper_title": "Discovery of 7-(4-(3-Ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDC-101) as a Potent Multi-Acting HDAC, EGFR, and HER2 Inhibitor for the Treatment of Cancer", "paper_author": ["Xiong Cai", "Hai-Xiao Zhai", "Jing Wang", "Jeffrey Forrester", "Hui Qu", "Ling Yin", "Cheng-Jung Lai", "Rudi Bao", "Changgeng Qian"], "paper_year": 2010, "paper_institution": "Curis Inc., 45 Moulton Street, Cambridge, Massachusetts 02138", "paper_cited": 164, "doi": "10.1021/jm901453q", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901453q/production/images/large/jm-2009-01453q_0015.jpeg", "compound_count": 74, "compound_name": "8", "compound_name_drug": "", "compound_smiles": "", "medicinal_chemistry_metrics": {"Ki": "", "Kd": "", "IC50": 58.1, "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": "", "IC50": "4.4", "EC50": "", "selectivity": "", "hERG": 20.0, "solubility": 2.0}, "pharm_metrics_vivo": {"ED50": "", "AUC": "", "solubility": "", "t_half": 3.0, "bioavailability": ""}, "clinical_statistics": {}}
articleURL: 36
10.1021/jm0005555
{"compound": "16a", "ic50_mc": "1", "ed50_an": "2 the ic50 for inhibition of egfr kinase that we measured was 3-fold higher than was found by other researchers . 9 as we pointed out in a previous publication , 2 0 we attribute this to differences in the nature of the enzyme and substrate as well as to the overall assay conditions , particularly our use of a solid-phase elisa-based assay . our enzyme consists of the purified cytoplasmic domain of egfr and we measure the inhibition of autophosphorylation of this protein . other researchers have measured inhibition using , in a soluble format , the entire enzyme , purified from a431 cells , along with an exogenous peptide substrate .", "compound_drug": "<unk> . in this paragraph , can you find out the result of compound_drug ? [SEP] results and discussion consider again the pair of compounds 1 8 and 16a"}


{"id": 35, "paper_title": "6-Substituted-4-(3-bromophenylamino)quinazolines as Putative Irreversible Inhibitors of the Epidermal Growth Factor Receptor (EGFR) and Human Epidermal Growth Factor Receptor (HER-2) Tyrosine Kinases with Enhanced Antitumor Activity", "paper_author": ["Hwei-Ru Tsou", "Nellie Mamuya", "Bernard D. Johnson", "Marvin F. Reich", "Brian C. Gruber", "Fei Ye", "Ramaswamy Nilakantan", "Ru Shen", "Carolyn Discafani", "Ronald DeBlanc", "Rachel Davis", "Frank E. Koehn", "Lee M. Greenberger", "Yu-Fen Wang", "Allan Wissner"], "paper_year": 2001, "paper_institution": "Wyeth-Ayerst Research, A Division of American Home Products, 401 N. Middletown Road, Pearl River, New York 10965-1215 ", "paper_cited": 198, "doi": "10.1021/jm0005555", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2001/jmcmar.2001.44.issue-17/jm0005555/production/images/large/jm0005555n00001.jpeg", "compound_count": 197, "compound_name": "16a", "compound_name_drug": "", "compound_smiles": "Nc1cc(ccc1)C", "medicinal_chemistry_metrics": {"Ki": "", "Kd": "", "IC50": 1.0, "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": "", "IC50": "III ", "EC50": "", "selectivity": "", "hERG": "", "solubility": ""}, "pharm_metrics_vivo": {"ED50": 0.002, "AUC": "", "solubility": "", "t_half": "", "bioavailability": ""}, "clinical_statistics": {}}
articleURL: 37
10.1021/jm020241c
{"compound": "5", "ed50_an": "7 5 . 0 3 5 . 5 0 1 2 . 3 4 19i och3h h 3-br 0 . 9 6 0 . 3 0 0 . 2 8 0 . 3 5 0 . 5 2 20i o ( ch2 ) 2och3h h 3-br 0 . 9 3 0 . 4 5 0", "compound_drug": "ekb-569"}


{"id": 36, "paper_title": "Synthesis and Structure−Activity Relationships of 6,7-Disubstituted 4-Anilinoquinoline-3-carbonitriles. The Design of an Orally Active, Irreversible Inhibitor of the Tyrosine Kinase Activity of the Epidermal Growth Factor Receptor (EGFR) and the Human Epidermal Growth Factor Receptor-2 (HER-2)", "paper_author": ["Allan Wissner", "Elsebe Overbeek", "Marvin F. Reich", "M. Brawner Floyd", "Bernard D. Johnson", "Nellie Mamuya", "Edward C. Rosfjord", "Carolyn Discafani", "Rachel Davis", "Xiaoqing Shi", "Sridhar K. Rabindran", "Brian C. Gruber", "Fei Ye", "William A. Hallett", "Ramaswamy Nilakantan", "Ru Shen", "Yu-Fen Wang", "Lee M. Greenberger", "Hwei-Ru Tsou"], "paper_year": 2002, "paper_institution": "Chemical Sciences, Oncology and Immunoinflammatory Research, and Computational Chemistry, Wyeth Research, 401 North Middletown Road, Pearl River, New York 10965 ", "paper_cited": 174, "doi": "10.1021/jm020241c", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2003/jmcmar.2003.46.issue-1/jm020241c/production/images/large/jm020241cn00001.jpeg", "compound_count": 196, "compound_name": "5", "compound_name_drug": "", "compound_smiles": "", "medicinal_chemistry_metrics": {"Ki": "", "Kd": "", "IC50": "", "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": "", "IC50": "0.08 ", "EC50": "", "selectivity": "", "hERG": "", "solubility": ""}, "pharm_metrics_vivo": {"ED50": "", "AUC": "", "solubility": "", "t_half": "", "bioavailability": ""}, "clinical_statistics": {}}
articleURL: 38
10.1021/jm100665z
{"compound": "5", "ic50_mc": "1", "ic50_ce": "2", "ec50_ce": "her2 ) , and histone deacetylase activity . the main compound is <unk> . in this paragraph , can you find out the result of ec50_ce ? [SEP] results and discussion the synthesized chimeric compounds were characterized in biochemical assays for hdac as well as protein-kinase inhibitory activity . in addition , cellular target specific activity was assessed in respective cancer cell lines", "ed50_an": "2 ( her2 ) , and histone deacetylase activity . the main compound is <unk> . in this paragraph , can you find out the result of ed50_an ? [SEP] results and discussion the synthesized chimeric compounds were characterized in biochemical assays for hdac as well as protein-kinase inhibitory activity . in addition , cellular target specific activity was assessed in respective cancer cell lines . finally , the cytotoxic activity was determined in egfr or her2 overexpressing cancer cell lines for selected analogues .", "compound_drug": "<unk> . in this paragraph , can you find out the result of compound_drug ? [SEP] results and discussion pharmacological profile in biochemical and cellular , target-specific assays to investigate the effect of the system vinylogous to benzamides , included in the hdac-inhibitory structures 6a"}


{"id": 37, "paper_title": "Novel Chimeric Histone Deacetylase Inhibitors: A Series of Lapatinib Hybrides as Potent Inhibitors of Epidermal Growth Factor Receptor (EGFR), Human Epidermal Growth Factor Receptor 2 (HER2), and Histone Deacetylase Activity", "paper_author": ["Siavosh Mahboobi", "Andreas Sellmer", "Matthias Winkler", "Emerich Eichhorn", "Herwig Pongratz", "Thomas Ciossek", "Thomas Baer", "Thomas Maier", "Thomas Beckers"], "paper_year": 2010, "paper_institution": "Department of Pharmaceutical Chemistry I, University of Regensburg, D-93040 Regensburg, Germany", "paper_cited": 64, "doi": "10.1021/jm100665z", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-24/jm100665z/production/images/large/jm-2010-00665z_0006.jpeg", "compound_count": 43, "compound_name": "5", "compound_name_drug": "", "compound_smiles": "N(c1ccccc1)[S](=O)(C([I]C)c1cccc(/C=C/C(=O)NO)c1)CC", "medicinal_chemistry_metrics": {"Ki": "", "Kd": "", "IC50": 1.0, "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": "", "IC50": 2.0, "EC50": "", "selectivity": "", "hERG": "", "solubility": ""}, "pharm_metrics_vivo": {"ED50": 0.002, "AUC": "", "solubility": "", "t_half": "", "bioavailability": ""}, "clinical_statistics": {}}
articleURL: 39
10.1021/acs.jmedchem.5b01633
{"compound": "", "ic50_mc": "1", "ki_mc": "2 5 % and 8 0 % inhibition of the initial linear ( 60–120 s", "kd_mc": "2 . 2", "ic50_ce": "2", "kd_ce": "3r , 4r", "solubility_ce": "3r , 4r ) -3-[ ( {5-chloro-2-[ ( 1-methyl-1h-pyrazol-4-yl ) amino]-7h-pyrrolo[2 , 3-d]pyrimidin-4-yl}oxy", "ed50_an": "1-methyl-1h-pyrazol-4-yl ) amino]-7h-pyrrolo[2 , 3-d]pyrimidin-4-yl}oxy ) methyl]-4-methoxypyrrolidin-1-yl}prop-2-en-1-one ( pf-06459988 ) , a potent , wt sparing , irreversible inhibitor of t790m-containing egfr mutants . the main compound is <unk> . in this paragraph , can you find out the result of ed50_an ? [SEP] results and discussion objective the inactivation of egfr occurs through a two-step process that begins with reversible binding to egfr followed by covalent bond formation with the thiol of cys797 to form a covalent adduct ( figure 3 ) . therefore , irreversible inhibitor potency can be increased by maximizing the reversible binding affinity ( ki = koff/kon ) , the specific reactivity ( kinact ) , or the inherent chemical reactivity of the electrophile . in addition to optimizing t790m potency and selectivity over wt , an equally significant emphasis was placed on reducing warhead reactivity to minimize proteome-wide reactivity and decrease the probability of idiosyncratic toxicity . to achieve these multiple objectives , a key strategy was to optimize the potency of inhibitors based on their reversible ( noncovalent ) binding affinity to egfr t790m as opposed to the chemical reactivity of the warhead . to effectively carry out this strategy , a high capacity binding kinetics assay was developed which is capable of separating the reversible binding affinity from the inactivation rate . typically , irreversible kinetic analysis to determine reversible affinity ( ki ) and specific reactivity kinact is low throughput and labor intensive . however , to truly leverage binding affinity sar , it was essential to be able to test all new inhibitors on a weekly basis . to do so , a high throughput irreversible kinetics screening assay capable of coarsely defining reversible binding affinity ( kiest ) and overall irreversible inactivation (", "bioavailability_an": "8 0 %", "compound_drug": "pf-06459988"}


{"id": 38, "paper_title": "Discovery of 1-{(3R,4R)-3-[({5-Chloro-2-[(1-methyl-1H-pyrazol-4-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}oxy)methyl]-4-methoxypyrrolidin-1-yl}prop-2-en-1-one (PF-06459988), a Potent, WT Sparing, Irreversible Inhibitor of T790M-Containing EGFR Mutants", "paper_author": ["Hengmiao Cheng", "Sajiv K. Nair", "Brion W. Murray", "Chau Almaden", "Simon Bailey", "Sangita Baxi", "Doug Behenna", "Sujin Cho-Schultz", "Deepak Dalvie", "Dac M. Dinh", "Martin P. Edwards", "Jun Li Feng", "Rose Ann Ferre", "Ketan S. Gajiwala", "Michelle D. Hemkens", "Amy Jackson-Fisher", "Mehran Jalaie", "Ted O. Johnson", "Robert S. Kania", "Susan Kephart", "Jennifer Lafontaine", "Beth Lunney", "Kevin K.-C. Liu", "Zhengyu Liu", "Jean Matthews", "Asako Nagata", "Sherry Niessen", "Martha A. Ornelas", "Suvi T. M. Orr", "Mason Pairish", "Simon Planken", "Shijian Ren", "Daniel Richter", "Kevin Ryan", "Neal Sach", "Hong Shen", "Tod Smeal", "Jim Solowiej", "Scott Sutton", "Khanh Tran", "Elaine Tseng", "William Vernier", "Marlena Walls", "Shuiwang Wang", "Scott L. Weinrich", "Shuibo Xin", "Haiwei Xu", "Min-Jean Yin", "Michael Zientek", "Ru Zhou", "John C. Kath"], "paper_year": 2016, "paper_institution": "La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States", "paper_cited": 57, "doi": "10.1021/acs.jmedchem.5b01633", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01633/20160310/images/large/jm-2015-01633b_0010.jpeg", "compound_count": 46, "compound_name": "1", "compound_name_drug": "PF-06459988", "compound_smiles": "C(=O)(C=C)N1C[C@@H]([C@@H](OC)C1)COc1nc(Nc2cnn(C)c2)nc2c1c(c[nH]2)Cl", "medicinal_chemistry_metrics": {"Ki": 25.0, "Kd": 2.2, "IC50": 1.0, "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": "", "IC50": 2.0, "EC50": "", "selectivity": "", "hERG": "", "solubility": ""}, "pharm_metrics_vivo": {"ED50": 0.003, "AUC": "", "solubility": "", "t_half": "", "bioavailability": 80.0}, "clinical_statistics": {"p1_company_num": 1, "p1_stat_company_num": [0, 0, 0, 0, 0, 0, 1, 0, 0], "p1_company": [[], [], [], [], [], [], ["Pfizer"], [], []], "p1_terminate_reason": {}, "p1_withdraw_reason": {}, "p1_adverse_event": {}, "p2_company_num": 1, "p2_stat_company_num": [0, 0, 0, 0, 0, 0, 0, 1, 0], "p2_company": [[], [], [], [], [], [], [], ["Pfizer"], []], "p2_terminate_reason": {}, "p2_withdraw_reason": {}, "p2_adverse_event": {}, "p3_company_num": 0, "p3_stat_company_num": [0, 0, 0, 0, 0, 0, 0, 0, 0], "p3_company": [[], [], [], [], [], [], [], [], []], "p3_terminate_reason": {}, "p3_withdraw_reason": {}, "p3_adverse_event": {}}}
articleURL: 40
10.1021/jm000387g
{"compound": "", "ic50_mc": "0 . 3 5 μm", "ki_mc": "5", "kd_mc": "2", "selectivity_mc": "1", "herg_ce": "1 0", "solubility_ce": "0 . 0 μm ) , methoxy ( 13d , mgm 1 5 . 4 μm ) , and hydroxy ( 13g , mgm 2 0 . 4 μm ) . lengthening the chain of 13a by one methylene unit had no appreciable effect on cytotoxicity ( 13j , mgm 1 3 . 2 μm ) , and shortening it by one methylene group also had little effect on cytotoxicity ( 13e , mgm 1 5 . 5 μm ) . the replacement of the benzene ring by a 2-pyridyl substituent (", "ed50_an": "1 4 . 8 μm , various substituents were introduced into the para position in order to determine how they affected cytotoxicity . the substituent that resulted in the greatest cytotoxicity was fluorine ( 13b , mgm 0 . 3 5 μm ) , followed by bromine ( 13c , mgm 7", "bioavailability_an": "1 4 . 8 μm , various substituents were introduced into the para position in order to determine how they affected cytotoxicity", "compound_drug": "<unk> . in this paragraph , can you find out the result of compound_drug ? [SEP] . 8 μm , various substituents were introduced into the para position in order to determine how they affected cytotoxicity . the substituent that resulted in the greatest cytotoxicity was fluorine ( 13b"}


{"id": 39, "paper_title": "Design, Synthesis, and Biological Evaluation of a Series of Lavendustin A Analogues That Inhibit EGFR and Syk Tyrosine Kinases, as Well as Tubulin Polymerization", "paper_author": ["Fanrong Mu", "Stephanie L. Coffing", "David J. Riese", "Robert L. Geahlen", "Pascal Verdier-Pinard", "Ernest Hamel", "Jill Johnson", "Mark Cushman"], "paper_year": 2001, "paper_institution": "Department of Medicinal Chemistry and Molecular Pharmacology, School of Pharmacy and Pharmacal Sciences, Purdue University, West Lafayette, Indiana 47907, Screening Technologies Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Frederick Cancer Research and Development Center, Frederick, Maryland 21702, and Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Rockville, Maryland 20852 ", "paper_cited": 34, "doi": "10.1021/jm000387g", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2001/jmcmar.2001.44.issue-3/jm000387g/production/images/large/jm000387gn00001.jpeg", "compound_count": 176, "compound_name": "N", "compound_name_drug": "", "compound_smiles": "", "medicinal_chemistry_metrics": {"Ki": 5.0, "Kd": 2.0, "IC50": 350.0, "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": "", "IC50": "", "EC50": "", "selectivity": "", "hERG": 10.0, "solubility": ""}, "pharm_metrics_vivo": {"ED50": 14.8, "AUC": "", "solubility": "", "t_half": "", "bioavailability": 14.8}, "clinical_statistics": {}}
articleURL: 41
10.1021/acs.jmedchem.0c00151
{"compound": "", "ic50_mc": "1", "ki_mc": "5 8", "kd_mc": "2", "ec50_ce": "2 0", "herg_ce": "2 0 ) we envisioned the preparation of analogues with modifications in the thf core region in an effort to complete a comprehensive sar of 1 . as the asymmetric synthesis of the thf core of 1 requires a lengthy synthetic sequence", "ed50_an": "1 . as the asymmetric synthesis of the thf core of 1 requires a lengthy synthetic sequence , ( 1 9 ) we also aimed to identify manassantin a analogues with reduced structural complexity and improved chemical tractability . we anticipated that our effort would help understand the effect of ring type and size , conformation , heteroatom , and hydrogen bonding on the hif-1 inhibition by 1 . such information will allow structural modifications to increase specificity , decrease off-target effects , and improve drug performance .", "bioavailability_an": "1 9", "compound_drug": "<unk> . in this paragraph , can you find out the result of compound_drug ? [SEP] results and discussion chemistry manassantin a ( 1 ) consists of two regions ( figure 1 ) : tetrahydrofuran ( thf ) core and side chain regions . following our previous study on the role of the manassantin a side chain regions in the hif-1 inhibition by 1 , ( 2 0 ) we envisioned the preparation of analogues with modifications in the thf core region in an effort to complete a comprehensive sar of 1 . as the asymmetric synthesis of the thf core of 1 requires a lengthy synthetic sequence , ( 1 9"}


{"id": 40, "paper_title": "Evaluation of Manassantin A Tetrahydrofuran Core Region Analogues and Cooperative Therapeutic Effects with EGFR Inhibition", "paper_author": ["Seung-Hwa Kwak", "Tesia N. Stephenson", "Hye-Eun Lee", "Yun Ge", "Hyunji Lee", "Sophia M. Min", "Jea Hyun Kim", "Do-Yeon Kwon", "You Mie Lee", "Jiyong Hong"], "paper_year": 2020, "paper_institution": "Department of Chemistry, Duke University, Durham, North Carolina 27708, United States", "paper_cited": 1, "doi": "10.1021/acs.jmedchem.0c00151", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00151/20200701/images/large/jm0c00151_0007.jpeg", "compound_count": 44, "compound_name": "15", "compound_name_drug": "", "compound_smiles": "", "medicinal_chemistry_metrics": {"Ki": 58.0, "Kd": 2.0, "IC50": 1.0, "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": "", "IC50": "", "EC50": 20.0, "selectivity": "", "hERG": 20000.0, "solubility": ""}, "pharm_metrics_vivo": {"ED50": 1000.0, "AUC": "", "solubility": "", "t_half": "", "bioavailability": 19.0}, "clinical_statistics": {}}
articleURL: 42
10.1021/acs.jmedchem.9b00631
{"compound": "2 2", "selectivity_mc": "1", "t_half_an": "3"}


{"id": 41, "paper_title": "Identification and Optimization of Novel Cathepsin C Inhibitors Derived from EGFR Inhibitors", "paper_author": ["Weijie Hou", "Huan Sun", "Yongfen Ma", "Chunyan Liu", "Zhiyuan Zhang"], "paper_year": 2019, "paper_institution": "National Institute of Biological Sciences (NIBS), 7 Science Park Road, ZGC Life Science Park, Beijing 102206, China", "paper_cited": 4, "doi": "10.1021/acs.jmedchem.9b00631", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-12/acs.jmedchem.9b00631/20190621/images/large/jm-2019-006317_0022.jpeg", "compound_count": 52, "compound_name": "22", "compound_name_drug": "", "compound_smiles": "O(C)c1c(Nc2nc(c(N3CCCCC3)cc2)Oc2cc(c(C)cc2)NC(=O)C=C)ccc(N2CCN(CC2)C)c1", "medicinal_chemistry_metrics": {"Ki": "", "Kd": "", "IC50": ": `>10 pM", "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": "", "IC50": "", "EC50": "", "selectivity": "", "hERG": "", "solubility": ""}, "pharm_metrics_vivo": {"ED50": "", "AUC": "", "solubility": "", "t_half": 3.0, "bioavailability": ""}, "clinical_statistics": {}}
articleURL: 44
10.1021/jm1000198
{"compound": "3", "ic50_mc": "1", "compound_drug": "<unk> . in this paragraph , can you find out the result of compound_drug ? [SEP] results and discussion through substructure searching for kinase-privileged fragments in our in-house compound library , we found that compound 1a ( table 1"}


{"id": 42, "paper_title": "Fast-Forwarding Hit to Lead: Aurora and Epidermal Growth Factor Receptor Kinase Inhibitor Lead Identification", "paper_author": ["Mohane Selvaraj Coumar", "Chang-Ying Chu", "Cheng-Wei Lin", "Hui-Yi Shiao", "Yun-Lung Ho", "Randheer Reddy", "Wen-Hsing Lin", "Chun-Hwa Chen", "Yi-Hui Peng", "Jiun-Shyang Leou", "Tzu-Wen Lien", "Chin-Ting Huang", "Ming-Yu Fang", "Szu-Huei Wu", "Jian-Sung Wu", "Santhosh Kumar Chittimalla", "Jen-Shin Song", "John T.-A. Hsu", "Su-Ying Wu", "Chun-Chen Liao", "Yu-Sheng Chao", "Hsing-Pang Hsieh"], "paper_year": 2010, "paper_institution": "Division of Biotechnology and Pharmaceutical Research, National Health Research Institutes, 35 Keyan Road, Zhunan, Miaoli County 350, Taiwan, ROC", "paper_cited": 52, "doi": "10.1021/jm1000198", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-13/jm1000198/production/images/large/jm-2010-000198_0013.jpeg", "compound_count": 30, "compound_name": "3", "compound_name_drug": "", "compound_smiles": "", "medicinal_chemistry_metrics": {"Ki": "", "Kd": "", "IC50": 1.0, "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": "", "IC50": "", "EC50": "", "selectivity": "", "hERG": "", "solubility": ""}, "pharm_metrics_vivo": {"ED50": "", "AUC": "", "solubility": "", "t_half": "", "bioavailability": ""}, "clinical_statistics": {}}
articleURL: 45
10.1021/acs.jmedchem.6b00995
{"compound": "2 1", "ic50_mc": "4", "kd_mc": "3", "selectivity_mc": "1", "solubility_ce": "2", "ed50_an": "2 for the t790m mutants over wtegfr and the activating mutants was attributed to the favorable hydrophobic interactions between the 4-alkoxypiperidine group and the side chain of the methionine gatekeeper ( figure 1b ) . ( 3 4 ) fluorine substitution at the 3-position of the piperidine further enhanced those favorable interactions and resulted in enhanced inhibition of the t790m mutants while sparing the activating single mutants . the 4-hydroxyl or 4-alkyoxy substitutions of the piperidine group were critical to potency as they form a hydrogen bonding interaction with the conserved , catalytic lys745 . in order to generate an inhibitor that exhibits activities against the t790m resistance double mutants as well as the activating single mutants of egfr , we hypothesized that it would be necessary to identify a replacement for the t790m-selective piperidine motif .", "bioavailability_an": "1 9 %", "compound_drug": "t790m/del746–750"}


{"id": 43, "paper_title": "Discovery of a Noncovalent, Mutant-Selective Epidermal Growth Factor Receptor Inhibitor", "paper_author": ["Bryan K. Chan", "Emily J. Hanan", "Krista K. Bowman", "Marian C. Bryan", "Daniel Burdick", "Emily Chan", "Yuan Chen", "Saundra Clausen", "Trisha Dela Vega", "Jennafer Dotson", "Charles Eigenbrot", "Richard L. Elliott", "Robert A. Heald", "Philip S. Jackson", "Jamie D. Knight", "Hank La", "Michael D. Lainchbury", "Shiva Malek", "Hans E. Purkey", "Gabriele Schaefer", "Stephen Schmidt", "Eileen M. Seward", "Steve Sideris", "Lily Shao", "Shumei Wang", "Siew Kuen Yeap", "Ivana Yen", "Christine Yu", "Timothy P. Heffron"], "paper_year": 2016, "paper_institution": "Departments of †Discovery Chemistry, ‡Structural Biology, §Drug Metabolism and Pharmacokinetics, ∥Biochemical and Cellular Pharmacology, ⊥Molecular Oncology, #Research Oncology, and ∇Protein Expression, Genentech Inc., 1 DNA Way, South San Francisco, California 94080, United States", "paper_cited": 11, "doi": "10.1021/acs.jmedchem.6b00995", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00995/20161007/images/large/jm-2016-009954_0020.jpeg", "compound_count": 40, "compound_name": "21", "compound_name_drug": "", "compound_smiles": "C1(CCN(CC1F)c1nc(Nc2ncc3nc(n([C@@H](C)C(F)(F)F)c3c2)[C@@H](C)O)ccn1)O", "medicinal_chemistry_metrics": {"Ki": "", "Kd": 3.0, "IC50": 4.0, "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": "", "IC50": "μm0.027", "EC50": "", "selectivity": "", "hERG": "", "solubility": 2.0}, "pharm_metrics_vivo": {"ED50": 0.002, "AUC": "", "solubility": "", "t_half": "", "bioavailability": 19.0}, "clinical_statistics": {}}
articleURL: 46
10.1021/jm9007938
{"compound": "", "ic50_mc": "1", "ki_mc": "growth factor receptor by bis ( thiosemicarbazonato ) metal complexes is associated with inhibition of protein tyrosine phosphatase activity . the main compound is <unk> . in this paragraph", "kd_mc": "2", "ec50_ce": "7", "herg_ce": "2 5", "solubility_ce": "2 5 μm compound 1", "ed50_an": "1 treatment induced activation of a specific cytotoxic response . our studies have shown that cuii ( btsc ) can affect endo- and exocytotic pathways ( unpublished observations ) , making the use of conventional viability assays unsuitable due to their reliance on uptake and/or exclusion of compounds . therefore , we measured whether compound 1 induced glial apoptosis by assaying caspase 3 activity in cell lysates after treatment with 2 5 μm compound 1 for 5 h . figure 3 shows that compound 1 inhibited caspase 3 activity , and this is consistent with caspase 3 and 8 activity observed in neuronal cell lines treated with compound 1 ( data not shown ) . these findings indicated that compound 1 treatment did not induce a specific apoptotic response in treated glial cells during the treatment period .", "t_half_an": "3", "bioavailability_an": "2 7", "compound_drug": "gtsm"}


{"id": 44, "paper_title": "Sustained Activation of Glial Cell Epidermal Growth Factor Receptor by Bis(thiosemicarbazonato) Metal Complexes Is Associated with Inhibition of Protein Tyrosine Phosphatase Activity", "paper_author": ["Katherine Ann Price", "Aphrodite Caragounis", "Brett M. Paterson", "Gulay Filiz", "Irene Volitakis", "Colin L. Masters", "Kevin J. Barnham", "Paul S. Donnelly", "Peter J. Crouch", "Anthony R. White"], "paper_year": 2009, "paper_institution": "Department of Pathology", "paper_cited": 33, "doi": "10.1021/jm9007938", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-21/jm9007938/production/images/large/jm-2009-007938_0002.jpeg", "compound_count": 7, "compound_name": "1", "compound_name_drug": "", "compound_smiles": "", "medicinal_chemistry_metrics": {"Ki": "", "Kd": 2.0, "IC50": 1.0, "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": "", "IC50": "", "EC50": 7.0, "selectivity": "", "hERG": 25.0, "solubility": 25.0}, "pharm_metrics_vivo": {"ED50": 0.001, "AUC": "", "solubility": "", "t_half": 3.0, "bioavailability": 27.0}, "clinical_statistics": {}}
articleURL: 47
10.1021/acs.jmedchem.6b01626
{"compound": "", "ic50_mc": "1 4 8 . 7", "ki_mc": "3", "selectivity_mc": "1", "ec50_ce": "1 0 0", "herg_ce": "and the gatekeeper residue , without undergoing steric clashes with the methionine side chain", "solubility_ce": "3 0", "ed50_an": "7 to the closely related 5-methyl-3-aminopyrazole inhibitor in complex with drug-resistant csrc ( pdb id: 5d11 ) to allow for the aminoindazole to form", "bioavailability_an": "2 8 . 0", "compound_drug": "cys797"}


{"id": 45, "paper_title": "Indazole-Based Covalent Inhibitors To Target Drug-Resistant Epidermal Growth Factor Receptor", "paper_author": ["Stefano Tomassi", "Jonas Lategahn", "Julian Engel", "Marina Keul", "Hannah L. Tumbrink", "Julia Ketzer", "Thomas Mühlenberg", "Matthias Baumann", "Carsten Schultz-Fademrecht", "Sebastian Bauer", "Daniel Rauh"], "paper_year": 2017, "paper_institution": "Faculty of Chemistry and Chemical Biology, TU Dortmund University, Otto-Hahn-Straße 4a, Dortmund D-44227, Germany", "paper_cited": 28, "doi": "10.1021/acs.jmedchem.6b01626", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-6/acs.jmedchem.6b01626/20170317/images/large/jm-2016-016266_0007.jpeg", "compound_count": 48, "compound_name": "6l", "compound_name_drug": "", "compound_smiles": "", "medicinal_chemistry_metrics": {"Ki": 3.0, "Kd": "", "IC50": 148.7, "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": "", "IC50": "", "EC50": 100.0, "selectivity": "", "hERG": "", "solubility": 30.0}, "pharm_metrics_vivo": {"ED50": 7.0, "AUC": "", "solubility": "", "t_half": "", "bioavailability": 28.0}, "clinical_statistics": {}}
articleURL: 48
10.1021/jm500007h
{"compound": "6a", "ic50_mc": "4", "ic50_ce": "5 5 1 nm", "ed50_an": "1 . 0 nm ic50 value , ( 4 2 , 4 3 ) but its potency on b-raf is minor .", "t_half_an": "3", "compound_drug": "<unk> . in this paragraph , can you find out the result of compound_drug ? [SEP] results and discussion in order to identify novel b-raf/egfr dual inhibitors for overcoming the intrinsic resistance of colorectal cancers against the current b-raf inhibitor therapy , we conducted a random screening on our self-constructed-kinase-inhibitor focused library . compound 4 was discovered to display good inhibitory activities against both b-rafv600e and egfr , with ic50 values of 5 5 1 nm and 5 5 0 nm , respectively ( table 1 ) . similar to the reported data , drug 1 potently inhibits the kinase activity of b-raf v600e mutant with an ic 5 0 value of 2 6 nm , ( 4 1 ) but it is almost totally inactive against egfr . however , gefitinib ( 3"}


{"id": 46, "paper_title": "Identification and Optimization of New Dual Inhibitors of B-Raf and Epidermal Growth Factor Receptor Kinases for Overcoming Resistance against Vemurafenib", "paper_author": ["Huimin Cheng", "Yu Chang", "Lianwen Zhang", "Jinfeng Luo", "Zhengchao Tu", "Xiaoyun Lu", "Qingwen Zhang", "Jibu Lu", "Xiaomei Ren", "Ke Ding"], "paper_year": 2014, "paper_institution": "Institute of Chemical Biology, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, #190 Kaiyuan Avenue, Guangzhou 510530, China", "paper_cited": 18, "doi": "10.1021/jm500007h", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-6/jm500007h/production/images/large/jm-2014-00007h_0009.jpeg", "compound_count": 49, "compound_name": "6a", "compound_name_drug": "", "compound_smiles": "", "medicinal_chemistry_metrics": {"Ki": "", "Kd": "", "IC50": 4.0, "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": "", "IC50": 551.0, "EC50": "", "selectivity": "", "hERG": "", "solubility": ""}, "pharm_metrics_vivo": {"ED50": 0.001, "AUC": "", "solubility": "", "t_half": 3.0, "bioavailability": ""}, "clinical_statistics": {}}
articleURL: 49
10.1021/jm901558p
{"compound": "", "ic50_mc": "1 . 7 nm .", "ki_mc": "1 . 7 nm", "kd_mc": "2", "selectivity_mc": "1", "ec50_ce": "3", "herg_ce": "1 0", "solubility_ce": "9 0 % after an 8 h washout . on the other hand , compounds 7−8 and 10−14 were only partially irreversible under the tested conditions , with percent inhibition of egfr autophosphorylation between 2 4 % and 8 0 % . as expected , the reference reversible compound 3 , which completely inhibited egfr activity after 1", "ed50_an": "1 . 7 nm . substitution of the acrylamide warhead of 2 with an epoxy ( 4−6 ) , a carbonylic ( carbamate 1 0 and nitrile 1 1 ) , or a ( benzo ) isothiazolinonic ( 1 2 and 1 3 ) one generally produced equally potent or more potent inhibitors . on the contrary , the phenoxyacetamide derivatives ( 7−9 ) proved less effective than 2 but yet maintained ic50 values in the low nanomolar range . only the introduction of a thiadiazole warhead ( 1 4 ) notably reduced egfr tyrosine kinase inhibition potency .", "bioavailability_an": "8 0", "compound_drug": "<unk> . in this paragraph , can you find out the result of compound_drug ? [SEP] results and discussion the newly synthesized 4- ( 3-bromoanilino ) quinazoline derivatives were tested as egfr inhibitors in enzyme-based and cell-based assays . the effects of the compounds on the kinase activity of human egfr were quantified by measuring the phosphorylation of a peptide substrate , using time-resolved fluorometry ( see experimental section ) . results are reported in table 1 . in accordance with our docking hypothesis and with the sar profile of the 4-anilinoquinazoline ring , ( 2 3 , 47-49"}


{"id": 47, "paper_title": "Novel Irreversible Epidermal Growth Factor Receptor Inhibitors by Chemical Modulation of the Cysteine-Trap Portion", "paper_author": ["Caterina Carmi", "Andrea Cavazzoni", "Stefano Vezzosi", "Fabrizio Bordi", "Federica Vacondio", "Claudia Silva", "Silvia Rivara", "Alessio Lodola", "Roberta R. Alfieri", "Silvia La Monica", "Maricla Galetti", "Andrea Ardizzoni", "Pier Giorgio Petronini", "Marco Mor"], "paper_year": 2010, "paper_institution": "Dipartimento Farmaceutico, Università degli Studi di Parma, V.le G.P. Usberti 27/A, I-43124 Parma, Italy", "paper_cited": 35, "doi": "10.1021/jm901558p", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901558p/production/images/large/jm-2009-01558p_0012.jpeg", "compound_count": 37, "compound_name": "6", "compound_name_drug": "", "compound_smiles": "", "medicinal_chemistry_metrics": {"Ki": 1.7, "Kd": 2.0, "IC50": 1.7, "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": "", "IC50": "μm1.72 ± 0.47", "EC50": 3.0, "selectivity": "", "hERG": 10.0, "solubility": 90.0}, "pharm_metrics_vivo": {"ED50": 0.0017, "AUC": "", "solubility": "", "t_half": "", "bioavailability": 80.0}, "clinical_statistics": {}}
articleURL: 50
10.1021/jm800829v
{"compound": "2", "ic50_mc": "0 . 1 7 nm", "ed50_an": "1 5 egfr tk complexes . in order to extend the analysis to a larger number of tk−inhibitor complexes , using the blastp server , a sequence similarity search was carried out so that the docking analysis was also performed on the 2 7 tk−inhibitor complexes with the highest percentage of sequence homology with respect to the egfr catalytic domain ."}


{"id": 48, "paper_title": "Computational Studies of Epidermal Growth Factor Receptor: Docking Reliability, Three-Dimensional Quantitative Structure−Activity Relationship Analysis, and Virtual Screening Studies", "paper_author": ["Concettina La Motta", "Stefania Sartini", "Tiziano Tuccinardi", "Erika Nerini", "Federico Da Settimo", "Adriano Martinelli"], "paper_year": 2009, "paper_institution": "Dipartimento di Scienze Farmaceutiche, Università di Pisa, Via Bonanno 6, 56126 Pisa, Italy", "paper_cited": 28, "doi": "10.1021/jm800829v", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-4/jm800829v/production/images/large/jm-2008-00829v_0004.jpeg", "compound_count": 4, "compound_name": "2", "compound_name_drug": "", "compound_smiles": "c1c(ccc(c1)n1c(SCc2nc(no2)COc2c(cccc2Cl)Cl)nnc1)C(F)(F)F", "medicinal_chemistry_metrics": {"Ki": "", "Kd": "", "IC50": 0.17, "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": "", "IC50": "", "EC50": "", "selectivity": "", "hERG": "", "solubility": ""}, "pharm_metrics_vivo": {"ED50": 0.015, "AUC": "", "solubility": "", "t_half": "", "bioavailability": ""}, "clinical_statistics": {}}
articleURL: 51
10.1021/jm400463q
{"compound": "12k", "kd_mc": "3 . then the nitro group of 3 was reduced to yield arylamine 4 . meanwhile , aryl ether 6 was obtained by regioselective coupling of 3-nitrophenol ( 5 ) to the 4-position of 2 , 4 , 5-trichloropyrimidine . subsequent reduction of the nitro group of 6 afforded arylamine 7 . acylation of the amino group of 7 led to acrylamide 8 . coupling of 4 with 8 in the presence of trifluoroacetic acid offered anilinopyrimidine 9 , which was converted to the corresponding acid 1 0 by hydrolysis . finally , condensation of 1 0 with various mono ( phenylsulfonyl ) furoxans 11a–k , synthesized in a four-step sequence as described previously by us , ( 3", "ic50_ce": "7", "ed50_an": "7 . acylation of the amino group of 7 led to acrylamide 8 . coupling of 4 with 8 in the presence of trifluoroacetic acid offered anilinopyrimidine 9 , which was converted to the corresponding acid 1 0 by hydrolysis . finally , condensation of 1 0 with various mono ( phenylsulfonyl ) furoxans 11a–k , synthesized in a four-step sequence as described previously by us , ( 3 3 ) provided the target compounds 12a–k .", "t_half_an": "2 4", "compound_drug": "<unk> . in this paragraph , can you find out the result of compound_drug ? [SEP] results and discussion kinase inhibitory activity the inhibitory activity of the target compounds 12a–k against two mutant egfrs ( l858r"}


{"id": 49, "paper_title": "Novel Hybrids of (Phenylsulfonyl)furoxan and Anilinopyrimidine as Potent and Selective Epidermal Growth Factor Receptor Inhibitors for Intervention of Non-Small-Cell Lung Cancer", "paper_author": ["Chun Han", "Zhangjian Huang", "Chao Zheng", "Ledong Wan", "Lianwen Zhang", "Sixun Peng", "Ke Ding", "Hongbin Ji", "Jide Tian", "Yihua Zhang"], "paper_year": 2013, "paper_institution": "†State Key Laboratory of Natural Medicines and ‡Center of Drug Discovery, China Pharmaceutical University, Nanjing 210009, People’s Republic of China", "paper_cited": 42, "doi": "10.1021/jm400463q", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm400463q/production/images/large/jm-2013-00463q_0007.jpeg", "compound_count": 34, "compound_name": "12k", "compound_name_drug": "", "compound_smiles": "", "medicinal_chemistry_metrics": {"Ki": "", "Kd": 3.0, "IC50": "μm0.305 ± 0.008", "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": "", "IC50": 7.0, "EC50": "", "selectivity": "", "hERG": "", "solubility": ""}, "pharm_metrics_vivo": {"ED50": 0.007, "AUC": "", "solubility": "", "t_half": 24.0, "bioavailability": ""}, "clinical_statistics": {}}
articleURL: 52
10.1021/jm070144p
{"compound": "6a", "ic50_mc": "1", "ki_mc": "8 </b> to release an inhibitor of egfr tk and a bifunctional alkylator . the combi-molecules blocked egfr tk with potency increasing with the basicity of the mustard moiety", "ic50_ce": "1 8", "ec50_ce": "1 8 </b> to release an inhibitor of egfr tk and a bifunctional alkylator . the combi-molecules blocked egfr tk with potency increasing with the basicity of the mustard moiety . they selectively killed cells transfected with egfr and were potent against the du145 prostate cancer cells", "solubility_ce": "8", "t_half_an": "1 8 </b> to release an inhibitor of egfr tk and a bifunctional alkylator . the combi-molecules blocked egfr tk with potency increasing with the basicity of the mustard moiety", "bioavailability_an": "1 8 </b> to release an inhibitor of egfr tk and a bifunctional alkylator . the combi-molecules blocked egfr tk with potency increasing with the basicity of the mustard moiety . they selectively killed cells transfected with egfr and were potent against the du145 prostate cancer cells . combi-molecule <b> 6a </b> blocked egfr phosphorylation in an irreversible manner , induced dna-cross-links , and arrested the cells in mid-s . . [SEP]"}


{"id": 50, "paper_title": "Novel Nitrogen Mustard-Armed Combi-Molecules for the Selective Targeting of Epidermal Growth Factor Receptor Overexperessing Solid Tumors:  Discovery of an Unusual Structure−Activity Relationship", "paper_author": ["Zakaria Rachid", "Fouad Brahimi", "Qiyu Qiu", "Christopher Williams", "Janet M. Hartley", "John A. Hartley", "Bertrand J. Jean-Claude"], "paper_year": 2007, "paper_institution": "Cancer Drug Research Laboratory, Department of Medicine, Division of Medical Oncology, McGill University Health Center/Royal Victoria Hospital, Montreal, H3A 1A1, Quebec, Canada, Chemical Computing Group Inc., 1010 Sherbrooke Street West, Suite 910, Montreal, H3A 2R7, Québec, Canada, and Drug-DNA Interactions Research Group, Department of Oncology, UCL, Cancer Research UK, 91 Riding House Street, London W1W 7BS, U.K. ", "paper_cited": 37, "doi": "10.1021/jm070144p", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2007/jmcmar.2007.50.issue-11/jm070144p/production/images/large/jm070144pn00001.jpeg", "compound_count": 27, "compound_name": "6a", "compound_name_drug": "", "compound_smiles": "", "medicinal_chemistry_metrics": {"Ki": 8.0, "Kd": "", "IC50": 1.0, "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": "", "IC50": 18.0, "EC50": 18.0, "selectivity": "", "hERG": "", "solubility": 8.0}, "pharm_metrics_vivo": {"ED50": "", "AUC": "", "solubility": "", "t_half": 18.0, "bioavailability": 18.0}, "clinical_statistics": {}}
articleURL: 53
10.1021/jm201507x
{"compound": "5", "ic50_mc": "1 . 7", "selectivity_mc": "1", "herg_ce": "1 μm", "ed50_an": "1 . 7 nm . ( 3 4 ) within the series of quinazoline derivatives with the same driving portion as 3 ( series a in table 1 ) , substitution of the acrylamide warhead with a substituted 3-aminopropanamide ( 5–8 ) produced a generalized increase in inhibitor potency , with ic50 values in the subnanomolar range . these values are likely to result from a complex inhibition mechanism , including reversible competition with atp and covalent interaction with egfr in different proportions for different compounds . we therefore consider these values as rough measures of the relative propensity to interact with the target . methylation of the amide nitrogen of 5 to the tertiary amide 9 notably reduced egfr-tk inhibition potency ( ic50 = 1 7 nm ) . b-series quinazoline compounds 10–13 , carrying 4- ( 4-fluoro-3-chloroanilino ) and 7-ethoxy substituents , did not show significant changes in kinase inhibition potencies when the electrophilic warhead in 1 0 was replaced with 3- ( dimethylamino ) propanamide in 1 1 , 3-piperidinopropanamide in 1 2 , or", "compound_drug": "<unk> . in this paragraph , can you find out the result of compound_drug ? [SEP] results and discussion kinase and cellular inhibitory activities compounds 3–21 ( table 1"}


{"id": 51, "paper_title": "Irreversible Inhibition of Epidermal Growth Factor Receptor Activity by 3-Aminopropanamides", "paper_author": ["Caterina Carmi", "Elena Galvani", "Federica Vacondio", "Silvia Rivara", "Alessio Lodola", "Simonetta Russo", "Stefania Aiello", "Fabrizio Bordi", "Gabriele Costantino", "Andrea Cavazzoni", "Roberta R. Alfieri", "Andrea Ardizzoni", "Pier Giorgio Petronini", "Marco Mor"], "paper_year": 2012, "paper_institution": "Dipartimento Farmaceutico, Università degli Studi di Parma, V.le G.P. Usberti 27/A, I-43124 Parma, Italy", "paper_cited": 43, "doi": "10.1021/jm201507x", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-5/jm201507x/production/images/large/jm-2011-01507x_0005.jpeg", "compound_count": 45, "compound_name": "5", "compound_name_drug": "", "compound_smiles": "", "medicinal_chemistry_metrics": {"Ki": "", "Kd": "", "IC50": 1.7, "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": "", "IC50": "", "EC50": "", "selectivity": "", "hERG": 1.0, "solubility": ""}, "pharm_metrics_vivo": {"ED50": 0.0017, "AUC": "", "solubility": "", "t_half": "", "bioavailability": ""}, "clinical_statistics": {}}
articleURL: 54
10.1021/jm030142e
{"compound": "", "ic50_mc": "0 . 0 3 9 μm", "ki_mc": "important to note that monoalkyltriazenes are unstable molecules that rapidly decompose under acidic conditions . the 6-alkyltriazene-substituted quinazolines reported herein degraded on silica gel", "kd_mc": "1 4", "selectivity_mc": "1", "ic50_ce": "7", "kd_ce": "2 was obtained as described by roth et al . 1 3 by treating the 5-nitroanthranilonitrile 1 with a sulfuric acid/formic acid mixture . the resulting quinazoline 2 was heated with phosphorus pentachloride to provide 3 , which was treated with benzylamine or substituted anilines . the nitro groups of the resulting compounds were reduced by catalytic hydrogenation to give 6-aminoquinazolines 4−8 . amine 4 bearing x = br was obtained by reduction with fe in ethanol as previously described . 1", "ec50_ce": "1 3 by treating the 5-nitroanthranilonitrile 1 with a sulfuric acid/formic acid mixture . the resulting quinazoline 2 was heated with phosphorus pentachloride to provide 3 , which was treated with benzylamine or substituted anilines . the nitro groups of the resulting compounds were reduced by catalytic hydrogenation to give 6-aminoquinazolines 4−8 . amine 4 bearing x = br was obtained by reduction with fe in ethanol as previously described . 1 4 diazotization of amines 4−8 using nobf4 in acetonitrile followed by addition of a series of primary or secondary amines and neutralization with triethylamine gave 9−24 as pure solids after purification by column chromatography on basic alumina . their structures were confirmed by 1h , 13c nmr and high-resolution mass spectrometry ( hrms ) . scheme 3 aa reagents: ( i ) h2so4/formic acid/heat; ( ii ) pcl5/heat; ( iii", "herg_ce": "1 . 4 × 10-2 , 0 . 7 1", "solubility_ce": "2", "ed50_an": "3 , which was treated with benzylamine or substituted anilines . the nitro groups of the resulting compounds were reduced by catalytic hydrogenation to give 6-aminoquinazolines 4−8 . amine 4 bearing x = br was obtained by reduction with fe in ethanol as previously described . 1 4 diazotization of amines 4−8 using nobf4 in acetonitrile followed by addition of a series of primary or secondary amines and neutralization with triethylamine gave 9−24 as pure solids after purification by column chromatography on basic alumina . their structures were confirmed by 1h , 13c nmr and high-resolution mass spectrometry ( hrms ) . scheme 3 aa reagents: ( i ) h2so4/formic acid/heat; ( ii ) pcl5/heat; ( iii ) arnh2/iproh/rt; ( iv ) bnnh2/iproh/rt; ( v ) h2/pd−c or fe/ethanol/acoh/heat; ( vi ) ch3cn/nobf4/−5 °c/ether/et3n/alkylamine . high resolution imagedownload ms powerpoint slide", "bioavailability_an": "1 3 by treating the 5-nitroanthranilonitrile 1 with a sulfuric acid/formic acid mixture . the resulting quinazoline 2 was heated with phosphorus pentachloride to provide 3 , which was treated with benzylamine or substituted anilines . the nitro groups of the resulting compounds were reduced by catalytic hydrogenation to give 6-aminoquinazolines 4−8 . amine 4 bearing x = br was obtained by reduction with fe in ethanol as previously described . 1 4 diazotization of amines 4−8 using nobf4 in acetonitrile followed by addition of a series of primary or secondary amines and neutralization with triethylamine gave 9−24 as pure solids after purification by column chromatography on basic alumina . their structures were confirmed by 1h , 13c nmr and high-resolution mass spectrometry ( hrms ) . scheme 3 aa reagents: ( i ) h2so4/formic acid/heat; ( ii ) pcl5/heat; ( iii ) arnh2/iproh/rt; ( iv ) bnnh2/iproh/rt; ( v ) h2/pd−c or fe/ethanol/acoh/heat; ( vi", "compound_drug": "<unk> . in this paragraph , can you find out the result of compound_drug ? [SEP] results and discussion it is important to note that monoalkyltriazenes are unstable molecules that rapidly decompose under acidic conditions . the 6-alkyltriazene-substituted quinazolines reported herein degraded on silica gel and even neutralization of the eluent with triethylamine did not improve the yield of purification . it was found that only a rapid elution on basic alumina could provide pure compounds in a reasonable yield . on the other hand , diazotization of the aminoquinazoline in acetonitrile with nobf4 has proven more effective than aqueous reaction with nano2/h+ , perhaps due to a greater stability of the diazonium tetrafluoroborate complex in an organic solvent ."}


{"id": 52, "paper_title": "The Combi-Targeting Concept:  Chemical Dissection of the Dual Targeting Properties of a Series of “Combi-Triazenes”", "paper_author": ["Zakaria Rachid", "Fouad Brahimi", "Athanasia Katsoulas", "Nicole Teoh", "Bertrand J. Jean-Claude"], "paper_year": 2003, "paper_institution": "Cancer Drug Research Laboratory, Department of Medicine, Division of Medical Oncology, McGill University Health Center/Royal Victoria Hospital, Montreal, H3A1A1, Quebec, Canada ", "paper_cited": 35, "doi": "10.1021/jm030142e", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2003/jmcmar.2003.46.issue-20/jm030142e/production/images/large/jm030142en00001.jpeg", "compound_count": 70, "compound_name": "−", "compound_name_drug": "", "compound_smiles": "c1c2c(cc(c1)/N=N/N)c(C)ncn2", "medicinal_chemistry_metrics": {"Ki": "", "Kd": 14.0, "IC50": 39.0, "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": 2.0, "IC50": 7.0, "EC50": 13.0, "selectivity": "", "hERG": 1.4, "solubility": 2.0}, "pharm_metrics_vivo": {"ED50": 0.003, "AUC": "", "solubility": "", "t_half": "", "bioavailability": 13.0}, "clinical_statistics": {}}
articleURL: 55
10.1021/jm400072p
{"compound": "4b", "compound_drug": "<unk> . in this paragraph , can you find out the result of compound_drug ? [SEP] results and discussion sar studies compound 2a , ( 3 8"}


{"id": 53, "paper_title": "Protein Kinase Inhibitor Design by Targeting the Asp-Phe-Gly (DFG) Motif: The Role of the DFG Motif in the Design of Epidermal Growth Factor Receptor Inhibitors", "paper_author": ["Yi-Hui Peng", "Hui-Yi Shiao", "Chih-Hsiang Tu", "Pang-Min Liu", "John Tsu-An Hsu", "Prashanth Kumar Amancha", "Jian-Sung Wu", "Mohane Selvaraj Coumar", "Chun-Hwa Chen", "Sing-Yi Wang", "Wen-Hsing Lin", "Hsu-Yi Sun", "Yu-Sheng Chao", "Ping-Chiang Lyu", "Hsing-Pang Hsieh", "Su-Ying Wu"], "paper_year": 2013, "paper_institution": "Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, 35 Keyan Road, Zhunan Town, Miaoli County 350, Taiwan, ROC", "paper_cited": 57, "doi": "10.1021/jm400072p", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-10/jm400072p/production/images/large/jm-2013-00072p_0010.jpeg", "compound_count": 28, "compound_name": "4b", "compound_name_drug": "", "compound_smiles": "", "medicinal_chemistry_metrics": {"Ki": "", "Kd": "", "IC50": "EGFR(WT) ICs0= 393 nM", "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": "", "IC50": "", "EC50": "", "selectivity": "", "hERG": "", "solubility": ""}, "pharm_metrics_vivo": {"ED50": "", "AUC": "", "solubility": "", "t_half": "", "bioavailability": ""}, "clinical_statistics": {}}
articleURL: 56
10.1021/acs.jmedchem.8b01391
{"compound": "6g", "ic50_mc": "4", "selectivity_ce": "1", "herg_ce": "1 0", "ed50_an": "7a–d , respectively , was accomplished using the general convergent synthetic route shown in scheme 1 . cyclization of methyl 5-aryl/heteroayl-3-aminothiophene-2-carboxylate and ethyl 2-anilino-4-aminothiazole-5-carboxylate 9a–j and 9k–n , respectively , with formamide ( hconh2 ) yielded the corresponding 6-aryl/heteroaryl-thieno[3 , 2-d]pyrimidin-4 ( 3h ) -ones 10a–j and 2-arylaminothiazolo[4 , 5-d]pyrimidin-7 ( 6h ) -ones 10k–n . the subsequent chlorination of the carbonyl group with phosphorus oxychloride ( pocl3 ) provided 4-chlorothieno[3 , 2-d]pyrimidine and 7-chlorothiazolo[4 , 5-d]pyrimidine derivatives 11a–j and 11k–n , respectively . finally , the nucleophilic substitution with 3 , 4 , 5-trimethoxyaniline in refluxing isopropanol furnished the final compounds 6a–j and 7a–d , respectively ."}


{"id": 54, "paper_title": "Design, Synthesis, and Biological Evaluation of 6-Substituted Thieno[3,2-d]pyrimidine Analogues as Dual Epidermal Growth Factor Receptor Kinase and Microtubule Inhibitors", "paper_author": ["Romeo Romagnoli", "Filippo Prencipe", "Paola Oliva", "Stefania Baraldi", "Pier Giovanni Baraldi", "Santiago Schiaffino Ortega", "Mariem Chayah", "Maria Kimatrai Salvador", "Luisa Carlota Lopez-Cara", "Andrea Brancale", "Salvatore Ferla", "Ernest Hamel", "Roberto Ronca", "Roberta Bortolozzi", "Elena Mariotto", "Elena Mattiuzzo", "Giampietro Viola"], "paper_year": 2019, "paper_institution": "Dipartimento di Scienze Chimiche e Farmaceutiche, Università degli Studi di Ferrara, Via Luigi Borsari 46, 44121 Ferrara, Italy", "paper_cited": 11, "doi": "10.1021/acs.jmedchem.8b01391", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-3/acs.jmedchem.8b01391/20190211/images/large/jm-2018-01391c_0015.jpeg", "compound_count": 50, "compound_name": "6g", "compound_name_drug": "", "compound_smiles": "", "medicinal_chemistry_metrics": {"Ki": "", "Kd": "", "IC50": 4.0, "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": "", "IC50": "μm0.019 ± 0.008", "EC50": "", "selectivity": "", "hERG": 10.0, "solubility": ""}, "pharm_metrics_vivo": {"ED50": 0.001, "AUC": "", "solubility": "", "t_half": "", "bioavailability": ""}, "clinical_statistics": {}}
articleURL: 57
10.1021/acs.jmedchem.9b00722
{"compound": "7 8", "ic50_ce": "2", "bioavailability_an": "4 1 . 5", "compound_drug": "dbpr112"}


{"id": 55, "paper_title": "Discovery of a Furanopyrimidine-Based Epidermal Growth Factor Receptor Inhibitor (DBPR112) as a Clinical Candidate for the Treatment of Non-Small Cell Lung Cancer", "paper_author": ["Shu-Yu Lin", "Yung Chang Hsu", "Yi-Hui Peng", "Yi-Yu Ke", "Wen-Hsing Lin", "Hsu-Yi Sun", "Hui-Yi Shiao", "Fu-Ming Kuo", "Pei-Yi Chen", "Tzu-Wen Lien", "Chun-Hwa Chen", "Chang-Ying Chu", "Sing-Yi Wang", "Kai-Chia Yeh", "Ching-Ping Chen", "Tsu-An Hsu", "Su-Ying Wu", "Teng-Kuang Yeh", "Chiung-Tong Chen", "Hsing-Pang Hsieh"], "paper_year": 2019, "paper_institution": "Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, 35 Keyan Road, Zhunan, Miaoli County 35053, Taiwan, ROC", "paper_cited": 5, "doi": "10.1021/acs.jmedchem.9b00722", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b00722/20191122/images/large/jm9b00722_0015.jpeg", "compound_count": 67, "compound_name": "78", "compound_name_drug": "DBPR112", "compound_smiles": "", "medicinal_chemistry_metrics": {"Ki": "", "Kd": "", "IC50": "", "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": "", "IC50": 2.0, "EC50": "", "selectivity": "", "hERG": "", "solubility": ""}, "pharm_metrics_vivo": {"ED50": "", "AUC": "", "solubility": "", "t_half": "", "bioavailability": 41.5}, "clinical_statistics": {"p1_company_num": 0, "p1_stat_company_num": [0, 0, 0, 0, 0, 0, 0, 0, 0], "p1_company": [[], [], [], [], [], [], [], [], []], "p1_terminate_reason": {}, "p1_withdraw_reason": {}, "p1_adverse_event": {}, "p2_company_num": 0, "p2_stat_company_num": [0, 0, 0, 0, 0, 0, 0, 0, 0], "p2_company": [[], [], [], [], [], [], [], [], []], "p2_terminate_reason": {}, "p2_withdraw_reason": {}, "p2_adverse_event": {}, "p3_company_num": 0, "p3_stat_company_num": [0, 0, 0, 0, 0, 0, 0, 0, 0], "p3_company": [[], [], [], [], [], [], [], [], []], "p3_terminate_reason": {}, "p3_withdraw_reason": {}, "p3_adverse_event": {}}}
articleURL: 58
10.1021/jm050607w
{"compound": "", "ic50_mc": "0 . 4−51 nm", "ki_mc": "5 . 5 % yield . 3 3 this was inadequate for the preparation of a series of the diethoxy analogues . thus , we produced the 4 , 5-diethoxyanthranilic acid 4 by two methods ( scheme 1 ) . initially , a small amount of methyl 2-amino-4 , 5-diethoxybenzoate 3 was commercially available from aldrich specialty chemical . the benzoate 3 was directly converted to 4 by saponification of the methyl ester . alternatively , when the commercial supply was depleted , 4 , 5-diethoxybenzoic acid 1 was nitrated to give 2", "kd_mc": "3", "selectivity_mc": "1", "ic50_ce": "2", "ec50_ce": "3 3 this was inadequate for the preparation of a series of the diethoxy analogues . thus , we produced the 4 , 5-diethoxyanthranilic acid 4 by two methods ( scheme 1 ) . initially , a small amount of methyl 2-amino-4 , 5-diethoxybenzoate 3 was commercially available from aldrich specialty chemical . the benzoate 3 was directly converted to 4 by saponification of the methyl ester . alternatively , when the commercial supply was depleted , 4", "herg_ce": "1 0", "solubility_ce": "7 0 % hno3/glacial acetic acid/2 h/rt; ( ii ) sncl2/hcl/2 h/rt; ( iii ) naoh/reflux/1 h , then hcl . high resolution imagedownload ms powerpoint slide scheme 2", "ed50_an": "9 with the appropriate substituted aniline or benzylamine ( scheme 3 ) . the 4-chloro-6 , 7-dimethoxyquinazoline was synthesized as previously reported from the 4 , 5-dimethoxyanthranilic acid 5 . 3 3 as the 4- ( 3‘-bromoanilino ) -6 , 7-diethoxyquinazoline was reported33 to possess more potent biological activity than the corresponding 6 , 7-dimethoxy analogue , we were interested in finding a convergent synthetic route suitable for the preparation of several diethoxy analogues . the previously reported two-step conversion of the dimethoxybromoanilinoquinazoline 11c to the diethoxy analogue 10c ( scheme 3 ) , using a pyridinium hydrochloride melt to give the bishydroxy intermediate followed by o-alkylation with iodoethane , proceeded in a low 5 . 5 % yield . 3 3 this was inadequate for the preparation of a series of the diethoxy analogues . thus , we produced the 4 , 5-diethoxyanthranilic acid 4 by two methods ( scheme 1 ) . initially , a small amount of methyl 2-amino-4 , 5-diethoxybenzoate 3 was commercially available from aldrich specialty chemical . the benzoate 3 was directly converted to 4 by saponification of the methyl ester . alternatively , when the commercial supply was depleted , 4 , 5-diethoxybenzoic acid 1 was nitrated to give 2 followed by reduction of the nitro group to form the desired aminobenzoic acid 4 in moderate overall yield . scheme 1 aa", "bioavailability_an": "3 3", "compound_drug": "<unk> . in this paragraph , can you find out the result of compound_drug ? [SEP] results chemistry . a small library of anilino- and benzyldialkoxyquinazoline compounds , 10−17 , was prepared by coupling 4-chlorodialkoxyquinazoline 8 or 9 with the appropriate substituted aniline or benzylamine ( scheme 3 ) . the 4-chloro-6 , 7-dimethoxyquinazoline was synthesized as previously reported from the 4 , 5-dimethoxyanthranilic acid 5 . 3 3 as the 4- ( 3‘-bromoanilino ) -6 , 7-diethoxyquinazoline was reported33 to possess more potent biological activity than the corresponding 6 , 7-dimethoxy analogue , we were interested in finding a convergent synthetic route suitable for the preparation of several diethoxy analogues . the previously reported two-step conversion of the dimethoxybromoanilinoquinazoline 11c to the diethoxy analogue 10c ( scheme 3"}


{"id": 56, "paper_title": "Anilinodialkoxyquinazolines:  Screening Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Potential Tumor Imaging Probes", "paper_author": ["Henry F. VanBrocklin", "John K. Lim", "Stephanie L. Coffing", "Darren L. Hom", "Kitaw Negash", "Michele Y. Ono", "Jennifer L. Gilmore", "Ianthe Bryant", "David J. Riese"], "paper_year": 2005, "paper_institution": "Department of Functional Imaging, Lawrence Berkeley National Laboratory, Berkeley, California 94720-8119, Department of Radiology, University of California, San Francisco, California 94143, and Department of Medicinal Chemistry and Molecular Pharmacology, Purdue University, 1333 Heine Pharmacy Building, West Lafayette, Indiana 47907 ", "paper_cited": 31, "doi": "10.1021/jm050607w", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2005/jmcmar.2005.48.issue-23/jm050607w/production/images/large/jm050607wn00001.jpeg", "compound_count": 77, "compound_name": "d", "compound_name_drug": "", "compound_smiles": "c1(O)c(O)cc2c(C)ncnc2c1", "medicinal_chemistry_metrics": {"Ki": 5.5, "Kd": 3.0, "IC50": 0.4, "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": "", "IC50": 2.0, "EC50": 33.0, "selectivity": "", "hERG": 10.0, "solubility": 70.0}, "pharm_metrics_vivo": {"ED50": 0.009, "AUC": "", "solubility": "", "t_half": "", "bioavailability": 33.0}, "clinical_statistics": {}}
articleURL: 59
10.1021/jm070436q
{"compound": "", "ed50_an": "8-substituted-4-anilino-6-aminoquinoline-3-carbonitriles tumor progression loci-2 ( tpl2 ) ( cot/map3k8 ) is a serine/threonine kinase in the map3k family directly upstream of mek . recent studies using tpl2 knockout mice have indicated an important role for tpl2 in the lipopolysaccharide ( lps ) induced production of tumor necrosis factor α ( tnf-α ) and other proinflammatory cytokines involved in diseases such as rheumatoid arthritis", "compound_drug": "tpl2"}


{"id": 57, "paper_title": "Inhibitors of Tumor Progression Loci-2 (Tpl2) Kinase and Tumor Necrosis Factor α (TNF-α) Production:  Selectivity and in Vivo Antiinflammatory Activity of Novel 8-Substituted-4-anilino-6-aminoquinoline-3-carbonitriles", "paper_author": ["Neal Green", "Yonghan Hu", "Kristin Janz", "Huan-Qiu Li", "Neelu Kaila", "Satenig Guler", "Jennifer Thomason", "Diane Joseph-McCarthy", "Steve Y. Tam", "Rajeev Hotchandani", "Junjun Wu", "Adrian Huang", "Qin Wang", "Louis Leung", "Jefferey Pelker", "Suzana Marusic", "Sang Hsu", "Jean-Baptiste Telliez", "J. Perry Hall", "John W. Cuozzo", "Lih-Ling Lin"], "paper_year": 2007, "paper_institution": "Chemical and Screening Sciences, Wyeth Research, 200 Cambridge Park Drive, Cambridge, Massachusetts 02140, Drug Safety and Metabolism and Pharmacokinetics, Wyeth Research, Building G, Andover, Massachusetts, and Collegeville, Pennsylvania, and Inflammation Signaling, Wyeth Research, 200 Cambridge Park Drive, Cambridge, Massachusetts 02140 ", "paper_cited": 36, "doi": "10.1021/jm070436q", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2007/jmcmar.2007.50.issue-19/jm070436q/production/images/large/jm070436qn00001.jpeg", "compound_count": 233, "compound_name": "12", "compound_name_drug": "", "compound_smiles": "", "medicinal_chemistry_metrics": {"Ki": "", "Kd": "", "IC50": "10 ", "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": "", "IC50": "", "EC50": "", "selectivity": "", "hERG": "", "solubility": ""}, "pharm_metrics_vivo": {"ED50": "", "AUC": "", "solubility": "", "t_half": "", "bioavailability": ""}, "clinical_statistics": {}}
articleURL: 62
10.1021/jm901146p
{"compound": "19d", "ic50_mc": "8", "selectivity_mc": "1", "ic50_ce": "7", "ed50_an": "8 ) as linker moieties with conformational rigidity .", "bioavailability_an": "1 4 . 6", "compound_drug": "<unk> . in this paragraph , can you find out the result of compound_drug ? [SEP] results biological effect of the structures of carboxamides and quinazolines having various linker moieties with restricted conformational flexibility all synthesized analogs were initially tested for their ability to inhibit cellular proliferation in two representative egfr-positive cell lines: a431 ( her-1-overexpressing human vaginal epidermoid cancer cell line ) ( 2 0 ) and sk-br3"}


{"id": 58, "paper_title": "Discovery of A Novel Her-1/Her-2 Dual Tyrosine Kinase Inhibitor for the Treatment of Her-1 Selective Inhibitor-Resistant Non-small Cell Lung Cancer", "paper_author": ["Mi Young Cha", "Kwang-Ok Lee", "Jong Woo Kim", "Chang Gon Lee", "Ji Yeon Song", "Young Hoon Kim", "Gwan Sun Lee", "Seung Bum Park", "Maeng Sup Kim"], "paper_year": 2009, "paper_institution": "Department of Drug Discovery, Hanmi Research Center, 377-1 Yeongcheon-ri, Dongtan-myeon, Hwaseong, Gyeonggi-do, 445-813, Korea", "paper_cited": 29, "doi": "10.1021/jm901146p", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-21/jm901146p/production/images/large/jm-2009-01146p_0009.jpeg", "compound_count": 38, "compound_name": "19d", "compound_name_drug": "", "compound_smiles": "", "medicinal_chemistry_metrics": {"Ki": "", "Kd": "", "IC50": 8.0, "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": "", "IC50": 7.0, "EC50": "", "selectivity": "", "hERG": "", "solubility": ""}, "pharm_metrics_vivo": {"ED50": 8.0, "AUC": "", "solubility": "", "t_half": "", "bioavailability": 14.6}, "clinical_statistics": {}}
articleURL: 63
10.1021/acs.jmedchem.5b01412
{"compound": "", "ic50_mc": "1", "ki_mc": "3 . 2 å", "kd_mc": "3", "ic50_ce": "2", "ed50_an": "1 ) . the tmlr enzyme assay alone was used primarily for optimization , as a very strong correlation was found for tmlr vs tmdel affinity . generally , the potency of these analogues correlated with lipophilicity , which could be expected based on the lipophilic nature of the ribose pocket . ligand efficiency was retained in comparison with the unsubstituted analogue 2 . the isopropyl group appeared near-optimal at this stage and was retained in the preparation of further analogues due to the combination of good potency and le but without excessive lipophilicity ( log d ) and the absence of a chiral center .", "bioavailability_an": "chiefly solubility . initially we carried out a survey of the effect of the azabenzimidazole n-substituent changes on enzyme affinity ( table 1 ) . the tmlr enzyme assay alone was used primarily for optimization , as a very strong correlation was found for tmlr vs tmdel affinity . generally , the potency of these analogues correlated with lipophilicity , which could be expected based on the lipophilic nature of the ribose pocket . ligand efficiency was retained in comparison with the unsubstituted analogue 2 . the isopropyl group appeared near-optimal at this stage and was retained in the preparation of further analogues due to the combination of good potency and le but without excessive lipophilicity ( log d", "compound_drug": "<unk> . in this paragraph , can you find out the result of compound_drug ? [SEP] results and discussion the azabenzimidazole subseries was chosen over other 5 , 6- and 6 , 6-systems due to superior physicochemical properties , chiefly solubility . initially we carried out a survey of the effect of the azabenzimidazole n-substituent changes on enzyme affinity ( table 1 ) . the tmlr enzyme assay alone was used primarily for optimization , as a very strong correlation was found for tmlr vs tmdel affinity . generally , the potency of these analogues correlated with lipophilicity , which could be expected based on the lipophilic nature of the ribose pocket . ligand efficiency was retained in comparison with the unsubstituted analogue 2 . the isopropyl group appeared near-optimal at this stage and was retained in the preparation of further analogues due to the combination of good potency and le but without excessive lipophilicity ( log d ) and the absence of a chiral center ."}


{"id": 59, "paper_title": "Noncovalent Mutant Selective Epidermal Growth Factor Receptor Inhibitors: A Lead Optimization Case Study", "paper_author": ["Robert Heald", "Krista K. Bowman", "Marian C. Bryan", "Daniel Burdick", "Bryan Chan", "Emily Chan", "Yuan Chen", "Saundra Clausen", "Belen Dominguez-Fernandez", "Charles Eigenbrot", "Richard Elliott", "Emily J. Hanan", "Philip Jackson", "Jamie Knight", "Hank La", "Michael Lainchbury", "Shiva Malek", "Sam Mann", "Mark Merchant", "Kyle Mortara", "Hans Purkey", "Gabriele Schaefer", "Stephen Schmidt", "Eileen Seward", "Steve Sideris", "Lily Shao", "Shumei Wang", "Kuen Yeap", "Ivana Yen", "Christine Yu", "Timothy P. Heffron"], "paper_year": 2015, "paper_institution": "Argenta, Early Discovery Charles River, 7/9 Spire Green Centre, Flex Meadow, Harlow, Essex CM19 5TR, United Kingdom", "paper_cited": 27, "doi": "10.1021/acs.jmedchem.5b01412", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/acs.jmedchem.5b01412/20151119/images/large/jm-2015-01412m_0021.jpeg", "compound_count": 63, "compound_name": "42", "compound_name_drug": "", "compound_smiles": "", "medicinal_chemistry_metrics": {"Ki": 3.2, "Kd": 3.0, "IC50": 1.0, "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": "", "IC50": 2.0, "EC50": "", "selectivity": "", "hERG": "", "solubility": ""}, "pharm_metrics_vivo": {"ED50": 0.001, "AUC": "", "solubility": "", "t_half": "", "bioavailability": 1.0}, "clinical_statistics": {}}
articleURL: 65
10.1021/acs.jmedchem.1c00876
{"compound": "7 9 7", "kd_mc": "9", "selectivity_mc": "200-fold", "kd_ce": "7 9 0 methionine ( t790m ) resistance while sparing the wild-type epidermal growth factor receptor ( wt egfr ) . it is nearly 200-fold more selective toward the mutant egfr as compared to the wt egfr . a tertiary cystein 7 9 7 to serine 7", "ec50_ce": "7 9 7 to serine 7 9", "selectivity_ce": "200-fold more", "solubility_ce": "7 9 0 methionine ( t790m ) resistance while sparing the wild-type epidermal growth factor receptor ( wt egfr ) . it is nearly 200-fold more selective toward the mutant egfr as compared to the wt egfr . a tertiary cystein 7 9 7 to serine 7 9", "ed50_an": "7 9 0 methionine ( t790m ) resistance while sparing the wild-type epidermal growth factor receptor ( wt egfr ) . it is nearly 200-fold more selective toward the mutant egfr as compared to the wt egfr . a tertiary cystein 7 9 7 to serine 7 9 7 ( c797s ) mutation in the egfr kinase domain has hampered osimertinib treatment in patients with advanced egfr-mutated non-small-cell lung cancer ( nsclc ) . this c797s mutation is presumed to induce a tertiary-acquired resistance to all current reversible and irreversible egfr tkis . this review summarizes the molecular mechanisms of resistance to osimertinib as well as different strategies for overcoming the egfr-dependent and egfr-independent mechanisms of resistance , new challenges , and a future direction . . [SEP]", "t_half_an": "7", "compound_drug": "c797s"}


{"id": 60, "paper_title": "Emerging Approaches to Overcome Acquired Drug Resistance Obstacles to Osimertinib in Non-Small-Cell Lung Cancer", "paper_author": ["Matin Shaikh", "Yashodeep Shinde", "Rahul Pawara", "Malleshappa Noolvi", "Sanjay Surana", "Iqrar Ahmad", "Harun Patel"], "paper_year": 2021, "paper_institution": "H. R. Patel Institute of Pharmaceutical Education and Research, Shirpur, Maharashtra, India 425405", "paper_cited": -1, "doi": "10.1021/acs.jmedchem.1c00876", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00876/20210729/images/large/jm1c00876_0064.jpeg", "compound_count": 84, "compound_name": "797", "compound_name_drug": "", "compound_smiles": "", "medicinal_chemistry_metrics": {"Ki": "", "Kd": 9.0, "IC50": "", "selectivity": 200}, "pharm_metrics_vitro": {"Ki": "", "Kd": 790.0, "IC50": "", "EC50": 797.0, "selectivity": 200, "hERG": "", "solubility": 0.79}, "pharm_metrics_vivo": {"ED50": 0.79, "AUC": "", "solubility": "", "t_half": 7.0, "bioavailability": ""}, "clinical_statistics": {}}
articleURL: 66
10.1021/jm501578n
{"compound": "6", "ed50_an": "3 have a higher level of selectivity ( 11–53 times ) . in order to advance these initial hits into a viable lead series , a number of parameters required optimization . first , these compounds were originally identified as potent inhibitors of jak2 and tyk2 with ki values between 1 and 1 6 nm , and it was desirable to minimize the inhibition of jak family kinases ( see table s1 of the supporting information for the jak family activity of 1–3 ) . ( 3 6 ) broader kinase selectivity was promising: when tested at 1 μm against a panel of 2 9 6 kinases , 3 inhibited only 5 other kinases at >80% . ( 3 7 ) second , compounds 1–3 are highly lipophilic , resulting in both poor solubility and rapid turnover in liver microsomes ( clhep > 1 5", "compound_drug": "<unk> . in this paragraph , can you find out the result of compound_drug ? [SEP] liver microsomes ) . with the dual goals of increasing potency and decreasing lipophilicity , the lipophilic ligand efficiency ( lle ) was a useful parameter for measuring progress during compound optimization . ( 38-40"}


{"id": 61, "paper_title": "Discovery of Selective and Noncovalent Diaminopyrimidine-Based Inhibitors of Epidermal Growth Factor Receptor Containing the T790M Resistance Mutation", "paper_author": ["Emily J. Hanan", "Charles Eigenbrot", "Marian C. Bryan", "Daniel J. Burdick", "Bryan K. Chan", "Yuan Chen", "Jennafer Dotson", "Robert A. Heald", "Philip S. Jackson", "Hank La", "Michael D. Lainchbury", "Shiva Malek", "Hans E. Purkey", "Gabriele Schaefer", "Stephen Schmidt", "Eileen M. Seward", "Steve Sideris", "Christine Tam", "Shumei Wang", "Siew Kuen Yeap", "Ivana Yen", "Jianping Yin", "Christine Yu", "Inna Zilberleyb", "Timothy P. Heffron"], "paper_year": 2014, "paper_institution": "Departments of †Discovery Chemistry, ‡Structural Biology, §Drug Metabolism and Pharmacokinetics, ∥Biochemical and Cellular Pharmacology, ⊥Molecular Oncology, and #Protein Expression, Genentech Inc., 1 DNA Way, South San Francisco, California 94080, United States", "paper_cited": 35, "doi": "10.1021/jm501578n", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm501578n/20151110/images/large/jm-2014-01578n_0013.jpeg", "compound_count": 33, "compound_name": "6", "compound_name_drug": "", "compound_smiles": "", "medicinal_chemistry_metrics": {"Ki": " ", "Kd": "", "IC50": "107", "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": "", "IC50": "", "EC50": "", "selectivity": "", "hERG": "", "solubility": ""}, "pharm_metrics_vivo": {"ED50": 0.003, "AUC": "", "solubility": "", "t_half": "", "bioavailability": ""}, "clinical_statistics": {}}
articleURL: 68
10.1021/jm201544y
{"compound": "5b", "ic50_mc": "1 . 0", "ic50_ce": "1 3 3 . 3 ± 2 8 . 7", "t_half_an": "2 4", "compound_drug": "48-52"}


{"id": 62, "paper_title": "Phthalocyanine–Peptide Conjugates for Epidermal Growth Factor Receptor Targeting", "paper_author": ["Benson G. Ongarora", "Krystal R. Fontenot", "Xiaoke Hu", "Inder Sehgal", "Seetharama D. Satyanarayana-Jois", "M. Graça H. Vicente"], "paper_year": 2012, "paper_institution": "Louisiana State University, Department of Chemistry, Baton Rouge Louisiana 70803, United States ", "paper_cited": 61, "doi": "10.1021/jm201544y", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm201544y/production/images/large/jm-2011-01544y_0009.jpeg", "compound_count": 12, "compound_name": "5b", "compound_name_drug": "", "compound_smiles": "", "medicinal_chemistry_metrics": {"Ki": "", "Kd": "", "IC50": 1.0, "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": "", "IC50": 133.3, "EC50": "", "selectivity": "", "hERG": "", "solubility": ""}, "pharm_metrics_vivo": {"ED50": "", "AUC": "", "solubility": "", "t_half": 24.0, "bioavailability": ""}, "clinical_statistics": {}}
articleURL: 69
10.1021/jm4012388
{"compound": "2v", "ic50_mc": "0 . 7", "kd_mc": "1 . 4", "selectivity_mc": "1", "bioavailability_an": "4 4 %", "compound_drug": "<unk> . in this paragraph , can you find out the result of compound_drug ? [SEP] results and discussion our previous investigations have demonstrated that the “u-shaped” configuration of rings a–d ( figure 1 ) , together with the aniline ring ( c ) bearing a hydrophilic group and the acrylamide moiety , is necessary to maintain the egfr inhibitory activity . ( 16a"}


{"id": 63, "paper_title": "Design, Synthesis, and Biological Evaluation of 2-Oxo-3,4-dihydropyrimido[4,5-d]pyrimidinyl Derivatives as New Irreversible Epidermal Growth Factor Receptor Inhibitors with Improved Pharmacokinetic Properties", "paper_author": ["Shilin Xu", "Tianfeng Xu", "Lianwen Zhang", "Zhang Zhang", "Jinfeng Luo", "Yingxue Liu", "Xiaoyun Lu", "Zhengchao Tu", "Xiaomei Ren", "Ke Ding"], "paper_year": 2013, "paper_institution": "Institute of Chemical Biology, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, #190 Kaiyuan Avenue, Guangzhou 510530, China", "paper_cited": 20, "doi": "10.1021/jm4012388", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-21/jm4012388/production/images/large/jm-2013-012388_0007.jpeg", "compound_count": 44, "compound_name": "2v", "compound_name_drug": "", "compound_smiles": "C1CN(CCN1C)c1cc(OC)c(Nc2ncc3c(N(c4cccc(NC(=O)C=C)c4)C(=O)N(Cc4ccccc4)C3)n2)cc1", "medicinal_chemistry_metrics": {"Ki": "", "Kd": 1.4, "IC50": 0.7, "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": "", "IC50": "μm16.0 ± 8.9", "EC50": "", "selectivity": "", "hERG": "", "solubility": ""}, "pharm_metrics_vivo": {"ED50": "", "AUC": "1640", "solubility": "", "t_half": "", "bioavailability": 44.0}, "clinical_statistics": {}}
articleURL: 70
10.1021/acs.jmedchem.8b01746
{"compound": "", "ic50_mc": "1", "ki_mc": "9 4 μm", "kd_mc": "2 . 6 3 5 ×", "ic50_ce": "2", "ec50_ce": "3 0", "herg_ce": "1 0 0 μm", "solubility_ce": "8 0", "ed50_an": "9 ) among these , the bodipy conjugate bearing the larllt peptide was found to have enhanced egfr-binding ability . on the basis of this work , we decided to synthesize a further red-shifted bodipy bearing two isothiocyanate functional groups for conjugation to two peptides rather than one or to one peptide and another biomolecule . by inducing a bathochromic shift in both the excitation and emission wavelengths of the bodipy through functionalization at the 3 , 5-positions with aryl groups , as well as benzo-fusion to the β , β′-pyrrolic positions , we anticipated to lower tissue absorption and increase tissue penetration . the novel incorporation of a second isothiocyanate group to the bodipy framework affords a second conjugation site for an additional peptide or biomolecule to further enhance tumor selectivity , solubility , and cell permeability .", "bioavailability_an": "1 0 0", "compound_drug": "<unk> . in this paragraph , can you find out the result of compound_drug ? [SEP] 2 . results and discussion 2 . 1 . synthesis and characterization the precursor bodipy 1 0 bearing two p-isothiocyanatophenyl groups at the 3- and 5-positions was prepared in nine steps as shown in scheme 1 . the synthetic route to bodipy 1 0 began with a barton–zard ( 1 0 ) reaction between 1-nitrocyclohexene and ethyl isocyanoacetate to form the ester functionalized tetrahydro-2h-isoindole 2 in 8 0 % yield , using 1 , 8-diazabicyclo ( 5 . 4 . 0 ) undec-7-ene ( dbu ) as a base . this was followed by a lindsey condensation ( 1 1"}


{"id": 64, "paper_title": "Synthesis, Characterization, and Evaluation of Near-IR Boron Dipyrromethene Bioconjugates for Labeling of Adenocarcinomas by Selectively Targeting the Epidermal Growth Factor Receptor", "paper_author": ["Nichole E. M. Kaufman", "Qianli Meng", "Kaitlin E. Griffin", "Sitanshu S. Singh", "Achyut Dahal", "Zehua Zhou", "Frank R. Fronczek", "J. Michael Mathis", "Seetharama D. Jois", "M. Graça H. Vicente"], "paper_year": 2019, "paper_institution": "Department of Chemistry, Louisiana State University, Baton Rouge, Louisiana 70803, United States", "paper_cited": 12, "doi": "10.1021/acs.jmedchem.8b01746", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.8b01746/20190404/images/large/jm-2018-01746a_0010.jpeg", "compound_count": 18, "compound_name": "12", "compound_name_drug": "", "compound_smiles": "", "medicinal_chemistry_metrics": {"Ki": 94000.0, "Kd": 2.635, "IC50": 1.0, "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": "", "IC50": 2.0, "EC50": 30.0, "selectivity": "", "hERG": 100.0, "solubility": 80.0}, "pharm_metrics_vivo": {"ED50": 0.009, "AUC": "", "solubility": "", "t_half": "", "bioavailability": 100.0}, "clinical_statistics": {}}
articleURL: 71
10.1021/acs.jmedchem.7b00515
{"compound": "", "ic50_mc": "3", "ki_mc": "3 5 , 38-40", "selectivity_mc": "9", "ic50_ce": "3 5", "ec50_ce": "9 6", "selectivity_ce": "2", "herg_ce": "iii ) an electrophile optimized with respect to geometry and orientation for the efficient alkylation of cys797 as a critical element to overcome t790m drug resistance . ( 35-37 ) we focused our design efforts on the well-studied 4-amino pyrazolopyrimidine as a core element as this moiety supplies an appropriate hinge-binding element and allows for the rapid and straightforward synthesis of a focused collection of small molecules for exploring the efficiency of potent inhibition of the kinase activity of egfr-t790m , the selectivity profiles , and covalent binding characteristics . ( 3 5 , 38-40", "ed50_an": "5 , 38-40 ) we identified n1 of the", "compound_drug": "h1975"}


{"id": 65, "paper_title": "Structure-Guided Development of Covalent and Mutant-Selective Pyrazolopyrimidines to Target T790M Drug Resistance in Epidermal Growth Factor Receptor", "paper_author": ["Julian Engel", "Steven Smith", "Jonas Lategahn", "Hannah L. Tumbrink", "Lisa Goebel", "Christian Becker", "Elisabeth Hennes", "Marina Keul", "Anke Unger", "Heiko Müller", "Matthias Baumann", "Carsten Schultz-Fademrecht", "Georgia Günther", "Jan G. Hengstler", "Daniel Rauh"], "paper_year": 2017, "paper_institution": "Faculty of Chemistry and Chemical Biology, TU Dortmund University, Otto-Hahn-Straße 4a, D-44227 Dortmund, Germany", "paper_cited": 12, "doi": "10.1021/acs.jmedchem.7b00515", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00515/20170922/images/large/jm-2017-005158_0010.jpeg", "compound_count": 59, "compound_name": "4", "compound_name_drug": "", "compound_smiles": "", "medicinal_chemistry_metrics": {"Ki": 35.0, "Kd": "", "IC50": 3.0, "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": "", "IC50": 35.0, "EC50": 96.0, "selectivity": "", "hERG": 0.035, "solubility": ""}, "pharm_metrics_vivo": {"ED50": 5.0, "AUC": "", "solubility": "", "t_half": "", "bioavailability": ""}, "clinical_statistics": {}}
articleURL: 72
10.1021/jm201591k
{"compound": "2s", "ic50_mc": "1", "ic50_ce": "3 0", "ed50_an": "0", "compound_drug": "<unk> . in this paragraph , can you find out the result of compound_drug ? [SEP] results and dicussion we were pleased to find that the conformation-constrained compound 2a also strongly suppressed the enzymatic activities of all five types of egfr kinases with potencies comparable to that of compound 1 ( table 1"}


{"id": 66, "paper_title": "Design, Synthesis, and Biological Evaluation of Novel Conformationally Constrained Inhibitors Targeting Epidermal Growth Factor Receptor Threonine790 → Methionine790 Mutant", "paper_author": ["Shaohua Chang", "Lianwen Zhang", "Shilin Xu", "Jinfeng Luo", "Xiaoyun Lu", "Zhang Zhang", "Tianfeng Xu", "Yingxue Liu", "Zhengchao Tu", "Yong Xu", "Xiaomei Ren", "Meiyu Geng", "Jian Ding", "Duanqing Pei", "Ke Ding"], "paper_year": 2012, "paper_institution": "Key Laboratory of Regenerative Biology and Institute of Chemical Biology, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, #190 Kaiyuan Avenue, Guangzhou 510530, China", "paper_cited": 68, "doi": "10.1021/jm201591k", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-6/jm201591k/production/images/large/jm-2011-01591k_0003.jpeg", "compound_count": 39, "compound_name": "2s", "compound_name_drug": "Methionine790", "compound_smiles": "", "medicinal_chemistry_metrics": {"Ki": "", "Kd": "", "IC50": 1.0, "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": "", "IC50": 30.0, "EC50": "", "selectivity": "", "hERG": "", "solubility": ""}, "pharm_metrics_vivo": {"ED50": "", "AUC": "", "solubility": "", "t_half": "", "bioavailability": ""}, "clinical_statistics": {}}
articleURL: 73
10.1021/jm901877j
{"compound": "3e", "ic50_mc": "1", "ic50_ce": "2", "ed50_an": "6 ) our previous structural and functional studies alluded toward the possibility of a steric clash between the met gatekeeper in drug resistant egfr-thr790met and", "compound_drug": "thr670ile ) , the platelet-derived growth factor receptor-α ( pdgfrα , thr674ile ) , and egfr ( thr790met ) . all of them result in tumor drug resistance . ( 1 3 , 1 4"}


{"id": 67, "paper_title": "Synthesis and Biological Evaluation of 4-Anilinoquinolines as Potent Inhibitors of Epidermal Growth Factor Receptor", "paper_author": ["Vijaykumar G. Pawar", "Martin L. Sos", "Haridas B. Rode", "Matthias Rabiller", "Stefanie Heynck", "Willem A. L. van Otterlo", "Roman K. Thomas", "Daniel Rauh"], "paper_year": 2010, "paper_institution": "Chemical Genomics Centre of the Max Planck Society, Otto-Hahn-Strasse 15, 44227 Dortmund, Germany", "paper_cited": 37, "doi": "10.1021/jm901877j", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-7/jm901877j/production/images/large/jm-2009-01877j_0006.jpeg", "compound_count": 31, "compound_name": "3e", "compound_name_drug": "", "compound_smiles": "", "medicinal_chemistry_metrics": {"Ki": "", "Kd": "", "IC50": 1.0, "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": "", "IC50": 2.0, "EC50": "", "selectivity": "", "hERG": "", "solubility": ""}, "pharm_metrics_vivo": {"ED50": 6.0, "AUC": "", "solubility": "", "t_half": "", "bioavailability": ""}, "clinical_statistics": {}}
articleURL: 74
10.1021/acs.jmedchem.9b02008
{"compound": "js230", "ic50_mc": "0 . 1 4 5 μm;", "kd_mc": "1", "ed50_an": "6 ( scheme 1 ) . compounds 5 ( quinazoline scaffold ) and 6 ( olaparib scaffold ) were carefully chosen as fragments that could maintain binding affinity for their respective targets . in silico studies were used to determine if the quinazoline and olaparib moieties of js230 could bind to their corresponding active sites ( i . e . , egfr or parp ) without steric clashes . molecular modeling showed that both the linker/olaparib and the linker/quinazoline portion of js230 had no binding hindrances to their respective site ( see the supporting information , figures s18 and s19 )"}


{"id": 68, "paper_title": "Design and Synthesis of a Trifunctional Molecular System “Programmed” to Block Epidermal Growth Factor Receptor Tyrosine Kinase, Induce High Levels of DNA Damage, and Inhibit the DNA Repair Enzyme (Poly(ADP-ribose) Polymerase) in Prostate Cancer Cells", "paper_author": ["Julie Schmitt", "Shanlong Huang", "Elliot Goodfellow", "Christopher Williams", "Bertrand J. Jean-Claude"], "paper_year": 2020, "paper_institution": "Cancer Drug Research Laboratory, Department of Medicine, The Research Institute of the McGill University Health Center/Glen Hospital, Montreal, QC H4A 3J1, Canada", "paper_cited": 1, "doi": "10.1021/acs.jmedchem.9b02008", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b02008/20200604/images/large/jm9b02008_0012.jpeg", "compound_count": 10, "compound_name": "js230", "compound_name_drug": "", "compound_smiles": "", "medicinal_chemistry_metrics": {"Ki": "", "Kd": 1.0, "IC50": 0.145, "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": "", "IC50": "", "EC50": "", "selectivity": "", "hERG": "", "solubility": ""}, "pharm_metrics_vivo": {"ED50": 0.006, "AUC": "", "solubility": "", "t_half": "", "bioavailability": ""}, "clinical_statistics": {}}
articleURL: 75
10.1021/acs.jmedchem.1c00551
{"compound": "", "ic50_mc": "1", "ki_mc": "in this paragraph", "kd_mc": "paragraph", "selectivity_mc": "100-fold", "ic50_ce": "7", "kd_ce": "4 7", "ec50_ce": "3 4 1 7", "herg_ce": "three of which are located in loop c ( cys v-vi ) , forming a specific yxgxr motif ( x , any amino acid ) ( figures 1c", "ed50_an": "paragraph , can you find out the result of ed50_an ? [SEP] and egfr agonists provided grounds for our subsequent structure–activity relationship studies .", "t_half_an": "1 5 3 h", "bioavailability_an": "2 3 . 5", "compound_drug": "bleogen pb1 as an egfr agonist to determine the “hot spot” for structure–activity relationship studies we used weblogo to show the sequence similarities of the seven related mammalian egfr agonists , including egf , tgf-α , hb-egf , betacellulin , amphiregulin , epiregulin , and epigen . these seven egfr agonists share four conserved noncysteine residues , three of which are located in loop c ( cys v-vi ) , forming a specific yxgxr motif ( x , any amino acid ) ( figures 1c and s1"}


{"id": 69, "paper_title": "Discovery of Hyperstable Noncanonical Plant-Derived Epidermal Growth Factor Receptor Agonist and Analogs", "paper_author": ["Shining Loo", "Antony Kam", "Bin Bin Li", "Nan Feng", "Xiaoliang Wang", "James P. Tam"], "paper_year": 2021, "paper_institution": "School of Biological Sciences, Nanyang Technological University, 60 Nanyang Drive, Singapore 637551, Singapore", "paper_cited": -1, "doi": "10.1021/acs.jmedchem.1c00551", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00551/20210602/images/large/jm1c00551_0011.jpeg", "compound_count": 0, "compound_name": "stability", "compound_name_drug": "", "compound_smiles": "", "medicinal_chemistry_metrics": {"Ki": "", "Kd": "", "IC50": 1.0, "selectivity": 100}, "pharm_metrics_vitro": {"Ki": "", "Kd": 47.0, "IC50": 7.0, "EC50": 3417.0, "selectivity": "", "hERG": "", "solubility": ""}, "pharm_metrics_vivo": {"ED50": "", "AUC": "", "solubility": "", "t_half": 153.0, "bioavailability": 23.5}, "clinical_statistics": {}}
articleURL: 76
10.1021/jm040159c
{"compound": "25o", "ic50_mc": "6", "ic50_ce": "8 6", "compound_drug": "hki-272"}


{"id": 70, "paper_title": "Optimization of 6,7-Disubstituted-4-(arylamino)quinoline-3-carbonitriles as Orally Active, Irreversible Inhibitors of Human Epidermal Growth Factor Receptor-2 Kinase Activity", "paper_author": ["Hwei-Ru Tsou", "Elsebe G. Overbeek-Klumpers", "William A. Hallett", "Marvin F. Reich", "M. Brawner Floyd", "Bernard D. Johnson", "Ronald S. Michalak", "Ramaswamy Nilakantan", "Carolyn Discafani", "Jonathan Golas", "Sridhar K. Rabindran", "Ru Shen", "Xiaoqing Shi", "Yu-Fen Wang", "Janis Upeslacis", "Allan Wissner"], "paper_year": 2005, "paper_institution": "Chemical and Screening Sciences, Chemical Development, and Oncology, Wyeth Research, 401 North Middletown Road, Pearl River, New York 10965 ", "paper_cited": 211, "doi": "10.1021/jm040159c", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2005/jmcmar.2005.48.issue-4/jm040159c/production/images/large/jm040159cn00001.jpeg", "compound_count": 405, "compound_name": "25o", "compound_name_drug": "", "compound_smiles": "Oc1c(NC(=O)/C=C/CN(C)C)cc2c(Nc3ccc(F)c(Cl)c3)c(C#N)cnc2c1", "medicinal_chemistry_metrics": {"Ki": "", "Kd": "", "IC50": 6.0, "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": "", "IC50": 86.0, "EC50": "", "selectivity": "", "hERG": "", "solubility": ""}, "pharm_metrics_vivo": {"ED50": "", "AUC": "", "solubility": "", "t_half": "", "bioavailability": ""}, "clinical_statistics": {}}
articleURL: 77
10.1021/acs.jmedchem.0c00507
{"compound": "", "ic50_mc": "six", "ki_mc": "we summarize the major medicinal chemistry strategies employed in the discovery of these representative smkis , such as avoiding steric hindrance , making additional interactions with mutated residues", "selectivity_mc": "<unk> . in this paragraph , can you find out the result of selectivity_mc ? [SEP] [CLS] what is the compound in this paper ? [SEP] medicinal chemistry strategies for the development of kinase inhibitors targeting point mutations clinically acquired resistance to small molecule kinase inhibitors ( smkis ) has become a major", "ic50_ce": "six smkis to be approved for the treatment of cancer patients through targeting of clinically acquired resistance caused by on-target mutations . these are mainly focused on the mutant kinases bcr-abl t315i , egfr t790m , and alk l1196m . herein", "kd_ce": "<unk> . in this paragraph , can you find out the result of kd_ce ? [SEP] [CLS] what is the compound in this paper ? [SEP] medicinal chemistry strategies for the development of kinase inhibitors targeting point mutations clinically acquired resistance to small molecule kinase inhibitors ( smkis", "ed50_an": "six smkis to be approved for the treatment of cancer patients through targeting of clinically acquired resistance caused by on-target mutations . these are mainly focused on the mutant kinases bcr-abl t315i , egfr t790m , and alk l1196m . herein , we summarize the major medicinal chemistry strategies employed in the discovery of these representative smkis , such as avoiding steric hindrance , making additional interactions with mutated residues , and forming a covalent bond with an active site cysteine to override resistance observed for reversible inhibitors . additionally , we also briefly describe allosteric kinase inhibitors and proteolysis targeting chimera ( protac ) as two other potential strategies while addressing future opportunities in this area . . [SEP]", "t_half_an": "six smkis to be approved for the treatment of cancer patients through targeting of clinically acquired resistance caused by on-target mutations . these are mainly focused on the mutant kinases bcr-abl t315i , egfr t790m , and alk l1196m . herein , we summarize the major medicinal chemistry strategies employed in the discovery of these representative smkis , such as avoiding steric hindrance , making additional interactions with mutated residues , and forming a covalent bond with an active site cysteine to override resistance observed for reversible inhibitors", "compound_drug": "<unk> . in this paragraph , can you find out the result of compound_drug ? [SEP] [CLS] what is the compound in this paper ? [SEP] medicinal chemistry strategies for the development of kinase inhibitors targeting point mutations clinically acquired resistance to small molecule kinase inhibitors ( smkis ) has become a major “unmet clinical need” in cancer therapy . to date , there are six smkis to be approved for the treatment of cancer patients through targeting of clinically acquired resistance caused by on-target mutations . these are mainly focused on the mutant kinases bcr-abl t315i , egfr t790m , and alk l1196m"}


{"id": 71, "paper_title": "Medicinal Chemistry Strategies for the Development of Kinase Inhibitors Targeting Point Mutations", "paper_author": ["Xiaoyun Lu", "Jeff B. Smaill", "Ke Ding"], "paper_year": 2020, "paper_institution": "International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Discovery of Chinese Ministry of Education (MOE), Guangzhou City Key Laboratory of Precision Chemical Drug Development, School of Pharmacy, Jinan University, 601 Huangpu Avenue West, Guangzhou 510632, China", "paper_cited": 7, "doi": "10.1021/acs.jmedchem.0c00507", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00507/20201019/images/large/jm0c00507_0013.jpeg", "compound_count": 29, "compound_name": "19", "compound_name_drug": "", "compound_smiles": "", "medicinal_chemistry_metrics": {"Ki": "", "Kd": "", "IC50": "", "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": "", "IC50": "", "EC50": "", "selectivity": "", "hERG": "", "solubility": ""}, "pharm_metrics_vivo": {"ED50": "", "AUC": "", "solubility": "", "t_half": "", "bioavailability": ""}, "clinical_statistics": {}}
articleURL: 78
10.1021/acs.jmedchem.9b00964
{"compound": "", "selectivity_mc": "defines function: clinically relevant mutations in erbb kinases . the main compound is <unk> . in this paragraph , can you find out the result of selectivity_mc ? [SEP] [CLS] what is the compound in this paper ? [SEP] structure defines function: clinically relevant mutations in erbb kinases the erbb receptor tyrosine kinase family members egfr ( epidermal growth factor receptor ) and her2 are among the prominent mutated oncogenic drivers of non-small cell lung cancer ( nsclc ) . their importance in proliferation , apoptosis , and cell death ultimately renders them hot targets in cancer therapy . small-molecule tyrosine kinase inhibitors seem well suited to be tailor-made therapeutics for egfr mutant nsclc; however , drug resistance mutations limit their success . against this background , the elucidation and visualization of the three-dimensional structure of cancer-related kinases provide valuable insights into their molecular functions . this field has undergone a revolution", "selectivity_ce": "revolution", "solubility_ce": "defines function: clinically relevant mutations in erbb kinases the erbb receptor tyrosine kinase family members egfr ( epidermal growth factor receptor ) and her2 are among the prominent mutated oncogenic drivers of non-small cell lung cancer ( nsclc ) . their importance in proliferation , apoptosis , and cell death ultimately renders them hot targets in cancer therapy . small-molecule tyrosine kinase inhibitors seem well suited to be tailor-made therapeutics for egfr mutant nsclc; however , drug resistance mutations limit their success . against this background , the elucidation and visualization of the three-dimensional structure of cancer-related kinases provide valuable insights into their molecular functions . this field has undergone a revolution because x-ray crystal structure determinations aided structure-based drug design approaches and", "ed50_an": "we present an overview of important mutations affecting egfr and her2 and highlight their influence on the kinase domain conformations and active site accessibility . . [SEP]", "t_half_an": "function: clinically relevant mutations in erbb kinases . the main compound is <unk> . in this paragraph , can you find out the result of t_half_an ? [SEP] [CLS] what is the compound in this paper ? [SEP] structure defines function: clinically relevant mutations in erbb kinases the erbb receptor tyrosine kinase family members egfr ( epidermal growth factor receptor ) and her2 are among the prominent mutated oncogenic drivers of non-small cell lung cancer ( nsclc )", "compound_drug": "defines"}


{"id": 72, "paper_title": "Structure Defines Function: Clinically Relevant Mutations in ErbB Kinases", "paper_author": ["Janina Niggenaber", "Julia Hardick", "Jonas Lategahn", "Daniel Rauh"], "paper_year": 2019, "paper_institution": "Faculty of Chemistry and Chemical Biology, TU Dortmund University, Otto-Hahn-Strasse 4a, 44227 Dortmund, (Germany)", "paper_cited": 3, "doi": "10.1021/acs.jmedchem.9b00964", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-1/acs.jmedchem.9b00964/20200106/images/large/jm9b00964_0006.jpeg", "compound_count": 0, "compound_name": "2", "compound_name_drug": "", "compound_smiles": "", "medicinal_chemistry_metrics": {"Ki": "", "Kd": "", "IC50": "", "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": "", "IC50": "", "EC50": "", "selectivity": "", "hERG": "", "solubility": ""}, "pharm_metrics_vivo": {"ED50": "", "AUC": "", "solubility": "", "t_half": "", "bioavailability": ""}, "clinical_statistics": {}}
articleURL: 79
10.1021/acs.jmedchem.5b01073
{"compound": "1m", "ic50_mc": "0 . 9 6", "selectivity_ce": "1", "bioavailability_an": "2 4 %", "compound_drug": "azd3759"}


{"id": 73, "paper_title": "Discovery and Evaluation of Clinical Candidate AZD3759, a Potent, Oral Active, Central Nervous System-Penetrant, Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor", "paper_author": ["Qingbei Zeng", "Jiabing Wang", "Ziqiang Cheng", "Kan Chen", "Peter Johnström", "Katarina Varnäs", "David Yunzhi Li", "Zhen Fan Yang", "Xiaolin Zhang"], "paper_year": 2015, "paper_institution": "Innovation Center China, Asia & Emerging Markets iMed, AstraZeneca Innovative Medicines and Early Development, 199 Liangjing Road, Zhangjiang Hi-Tech Park, Shanghai 201203, China", "paper_cited": 64, "doi": "10.1021/acs.jmedchem.5b01073", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-20/acs.jmedchem.5b01073/20151016/images/large/jm-2015-010738_0017.jpeg", "compound_count": 49, "compound_name": "1m", "compound_name_drug": "AZD3759", "compound_smiles": "Nc1c(C)c(Cl)ccc1", "medicinal_chemistry_metrics": {"Ki": "", "Kd": "", "IC50": 0.96, "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": "", "IC50": "", "EC50": "", "selectivity": "", "hERG": "", "solubility": ""}, "pharm_metrics_vivo": {"ED50": "", "AUC": "", "solubility": "", "t_half": "", "bioavailability": 24.0}, "clinical_statistics": {"p1_company_num": 3, "p1_stat_company_num": [0, 0, 0, 0, 0, 0, 3, 0, 0], "p1_company": [[], [], [], [], [], [], ["Guangdong Association of Clinical Trials", "Building 2, 199 Liangjing Road, Zhangjiang Hi-tech Park, Shanghai 201203, China", "Guangdong Provincial People's Hospital"], [], []], "p1_terminate_reason": {}, "p1_withdraw_reason": {}, "p1_adverse_event": {}, "p2_company_num": 2, "p2_stat_company_num": [0, 1, 0, 0, 0, 0, 1, 0, 0], "p2_company": [[], ["Guangdong Association of Clinical Trials"], [], [], [], [], ["Guangdong Provincial People's Hospital"], [], []], "p2_terminate_reason": {}, "p2_withdraw_reason": {}, "p2_adverse_event": {}, "p3_company_num": 1, "p3_stat_company_num": [0, 0, 0, 1, 0, 0, 0, 0, 0], "p3_company": [[], [], [], ["Guangdong Provincial People's Hospital"], [], [], [], [], []], "p3_terminate_reason": {}, "p3_withdraw_reason": {}, "p3_adverse_event": {}}}
articleURL: 80
10.1021/acs.jmedchem.6b01774
{"compound": "9b", "ic50_mc": "0 . 3 μm", "t_half_an": "7 . 8 h"}


{"id": 74, "paper_title": "First Bispecific Inhibitors of the Epidermal Growth Factor Receptor Kinase and the NF-κB Activity As Novel Anticancer Agents", "paper_author": ["Mostafa M. Hamed", "Sarah S. Darwish", "Jennifer Herrmann", "Ashraf H. Abadi", "Matthias Engel"], "paper_year": 2017, "paper_institution": "Pharmaceutical and Medicinal Chemistry, Campus C2.3, and Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Saarland University, Campus E8.1, D-66123 Saarbrücken, Germany", "paper_cited": 14, "doi": "10.1021/acs.jmedchem.6b01774", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01774/20170407/images/large/jm-2016-01774z_0016.jpeg", "compound_count": 62, "compound_name": "9b", "compound_name_drug": "", "compound_smiles": "C1=C(C)C=C(NC(=S)Nc2cc3c(Nc4cccc(Cl)c4)ncnc3cc2)OC1F", "medicinal_chemistry_metrics": {"Ki": "", "Kd": "", "IC50": 300.0, "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": "", "IC50": "", "EC50": "", "selectivity": "", "hERG": "", "solubility": ""}, "pharm_metrics_vivo": {"ED50": "", "AUC": "", "solubility": "", "t_half": 7.8, "bioavailability": ""}, "clinical_statistics": {}}
articleURL: 81
10.1021/acs.jmedchem.0c01949
{"compound": "bi-3406", "ic50_mc": "4", "kd_mc": "3", "ec50_ce": "2 4", "compound_drug": "<unk> . in this paragraph , can you find out the result of compound_drug ? [SEP] results and discussion in our efforts to identify binders to sos1 , we designed a high-throughput screen ( hts ) to search for inhibitors of the sos1::krasg12d ppi ( figure 2 ) . we implemented rigorous biochemical and biophysical triaging for the fast identification of structurally enabled starting points . the boehringer ingelheim"}


{"id": 75, "paper_title": "One Atom Makes All the Difference: Getting a Foot in the Door between SOS1 and KRAS", "paper_author": ["Juergen Ramharter", "Dirk Kessler", "Peter Ettmayer", "Marco H. Hofmann", "Thomas Gerstberger", "Michael Gmachl", "Tobias Wunberg", "Christiane Kofink", "Michael Sanderson", "Heribert Arnhof", "Gerd Bader", "Klaus Rumpel", "Andreas Zöphel", "Renate Schnitzer", "Jark Böttcher", "Jonathan C. O’Connell", "Rachel L. Mendes", "David Richard", "Nikolai Pototschnig", "Irene Weiner", "Wolfgang Hela", "Katja Hauer", "Daniela Haering", "Lyne Lamarre", "Bernhard Wolkerstorfer", "Christian Salamon", "Patrick Werni", "Silvia Munico-Martinez", "Reiner Meyer", "Matthew D. Kennedy", "Norbert Kraut", "Darryl B. McConnell"], "paper_year": 2021, "paper_institution": "Boehringer Ingelheim RCV GmbH & Co KG, Dr. Boehringer-Gasse 5-11, A-1121 Vienna, Austria", "paper_cited": 3, "doi": "10.1021/acs.jmedchem.0c01949", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.0c01949/20210520/images/large/jm0c01949_0015.jpeg", "compound_count": 14, "compound_name": "bi-3406", "compound_name_drug": "bi-3406", "compound_smiles": "", "medicinal_chemistry_metrics": {"Ki": "", "Kd": 3.0, "IC50": 4.0, "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": "", "IC50": "", "EC50": 24.0, "selectivity": "", "hERG": "", "solubility": ""}, "pharm_metrics_vivo": {"ED50": "", "AUC": "", "solubility": "", "t_half": "", "bioavailability": ""}, "clinical_statistics": {}}
articleURL: 82
10.1021/jm000372i
{"compound": "", "ic50_mc": "0 . 4−1 . 1 nm", "ki_mc": "1 . 1 8", "kd_mc": "4", "selectivity_mc": "1", "ic50_ce": "2 0", "kd_ce": "8", "ec50_ce": "5", "herg_ce": "5 0 0", "ed50_an": "3-bromoanilino ) quinazolines and pyrido[3 , 4-d]pyrimidines substituted at the 6-position with a variety of michael acceptors . we have previously shown14 that quinazoline- and pyrido[3 , 4-d]pyrimidine-6-acrylamides ( e . g . , 3 and 4 ) show broadly similar results in these assays , and the anilino ring was kept constant in order to facilitate intercomparisons of the different michael acceptors . potencies ( ic50[app] in nm ) were determined for both inhibition of phosphorylation of a random glutamic acid/tyrosine copolymer substrate by isolated egfr enzyme and inhibition of egf-stimulated autophosphorylation of efgr in a431 cells . the type of inhibition of the isolated egfr enzyme is also listed . irreversible inhibition is defined13-15 as 8 0 % or greater inhibition after a 10-min exposure to drug , followed by drug washout and re-stimulation by egf 8 h later . drugs that produced 20−80% inhibition were designated as partially irreversible ( although in reality they can almost certainly fully inactivate the enzyme via alkylation given enough time ) . those that produced less than 2 0 % inhibition were classified as reversible . for compounds capable of rapid and complete alkylation of the enzyme , the ic50 values derive essentially from titrating the enzyme activity in a stoichiometric manner and for this reason are designated as apparent ic50s ( ic50[app] ) . 1 4 , 1 5", "compound_drug": "ci-1033"}


{"id": 76, "paper_title": "Tyrosine Kinase Inhibitors. 18. 6-Substituted 4-Anilinoquinazolines and 4-Anilinopyrido[3,4-d]pyrimidines as Soluble, Irreversible Inhibitors of the Epidermal Growth Factor Receptor", "paper_author": ["Jeff B. Smaill", "H. D. Hollis Showalter", "Hairong Zhou", "Alexander J. Bridges", "Dennis J. McNamara", "David W. Fry", "James M. Nelson", "Veronika Sherwood", "Patrick W. Vincent", "Bill J. Roberts", "William L. Elliott", "William A. Denny"], "paper_year": 2000, "paper_institution": "Auckland Cancer Society Research Centre, Faculty of Medicine and Health Science, The University of Auckland, Private Bag 92019, Auckland, New Zealand, and Pfizer Global Research and Development, Ann Arbor Laboratories, 2800 Plymouth Road, Ann Arbor, Michigan 48106-1047 ", "paper_cited": 69, "doi": "10.1021/jm000372i", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2001/jmcmar.2001.44.issue-3/jm000372i/production/images/large/jm000372in00001.jpeg", "compound_count": 142, "compound_name": "N", "compound_name_drug": "", "compound_smiles": "", "medicinal_chemistry_metrics": {"Ki": 1.18, "Kd": 4.0, "IC50": 0.4, "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": 8.0, "IC50": 20.0, "EC50": 5.0, "selectivity": "", "hERG": 500.0, "solubility": ""}, "pharm_metrics_vivo": {"ED50": 0.003, "AUC": "", "solubility": "", "t_half": "", "bioavailability": ""}, "clinical_statistics": {}}
articleURL: 86
10.1021/jm030423m
{"compound": "", "ic50_mc": "1", "ki_mc": "7 0 % yield", "kd_mc": "4 2 min in serum-containing media ( table 1 ) . interestingly , its putative metabolite 5 ( scheme 3 ) showed a half-life of 4 0", "selectivity_mc": "7", "ic50_ce": "4 ± 0 . 5 5 3 . 4 ± 1 . 2 0 . 2 1 ± 0 . 0 5 8 1 5 0 . 5 ± 1 . 9 8 . 8 ± 0 . 6 0 . 0 9 ± 0 . 0 3 tem214 . 0 ± 1 1 . 1 2 0 7 . 2 ± 1 2 . 7 2 1 0 . 0 ± 1 6 ag147828 . 6 ± 3 . 6 9 . 8 ± 0 . 3 4 . 0 ± 0 . 2 tem + ag147839 . 4 ± 5 . 4 6 . 2 ± 0 . 5 1 . 1 ± 0 . 06a", "kd_ce": "2 . briefly , compound 3 was treated in acetonitrile with nobf4 to generate intermediate 4 , which was treated in situ with a 10:1 mixture of formaldehyde/methylamine . alkalinization with aqueous k2co3 led to precipitation of compound 5 , in high yield . however , this compound coprecipitated with solid k2co3 , which was removed by resuspension in thf followed by collection and evaporation of the filtrate . hydroxymethyltriazene 5 was obtained in a pure state ( 7 0 % yield ) without requirement for further purification . treatment of 5 with acetic anhydride in pyridine gave 6 as a pure solid . we have already reported the synthesis of 8", "ec50_ce": "2", "herg_ce": "7 0", "ed50_an": "3 was treated in acetonitrile with nobf4 to generate intermediate 4 , which was treated in situ with a 10:1 mixture of formaldehyde/methylamine . alkalinization with aqueous k2co3 led to precipitation of compound 5 , in high yield . however , this compound coprecipitated with solid k2co3 , which was removed by resuspension in thf followed by collection and evaporation of the filtrate . hydroxymethyltriazene 5 was obtained in a pure state ( 7 0 % yield ) without requirement for further purification . treatment of 5 with acetic anhydride in pyridine gave 6 as a pure solid . we have already reported the synthesis of 8 . 9", "t_half_an": "4 2 min", "bioavailability_an": "1 0 %", "compound_drug": "<unk> . in this paragraph , can you find out the result of compound_drug ? [SEP] results and discussion the stability of 6 and that of each of its putative metabolites were studied by allowing them to degrade in both phosphate-buffered saline ( pbs ) and serum-containing media using uv spectrophotometric analysis . compound 6 was much less stable than 2 , with a half-life of 4 2 min in serum-containing media ( table 1 ) . interestingly , its putative metabolite 5 ( scheme 3"}


{"id": 77, "paper_title": "Synthesis of a Prodrug Designed To Release Multiple Inhibitors of the Epidermal Growth Factor Receptor Tyrosine Kinase and an Alkylating Agent:  A Novel Tumor Targeting Concept", "paper_author": ["Ranjita Banerjee", "Zakaria Rachid", "James McNamee", "Bertrand J. Jean-Claude"], "paper_year": 2003, "paper_institution": "Cancer Drug Research Laboratory, Department of Medicine, Division of Medical Oncology, McGill University Health Center/Royal Victoria Hospital, Montreal, H3A 1A1 Quebec, Canada, and Consumer and Clinical Radiation Protection Bureau, Health Canada, Ottawa, Ontario, Canada ", "paper_cited": 32, "doi": "10.1021/jm030423m", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2003/jmcmar.2003.46.issue-25/jm030423m/production/images/large/jm030423mn00001.jpeg", "compound_count": 29, "compound_name": "6", "compound_name_drug": "", "compound_smiles": "n1c2c(c(nc1)Nc1cccc(C)c1)cc(/N=N/N(COC(=O)C)C)cc2", "medicinal_chemistry_metrics": {"Ki": 70.0, "Kd": 42.0, "IC50": 1.0, "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": 2.0, "IC50": 4.0, "EC50": 2.0, "selectivity": "", "hERG": 70.0, "solubility": ""}, "pharm_metrics_vivo": {"ED50": 3.0, "AUC": "", "solubility": "", "t_half": 0.7, "bioavailability": 10.0}, "clinical_statistics": {}}
articleURL: 87
10.1021/jm025540g
{"compound": ") groups for taxoid−antibody immunoconjugates were designed , synthesized and their activities evaluated . a highly cytotoxic c-10 methyldisulfanylpropanoyl taxoid was conjugated to monoclonal antibodies recognizing the", "ic50_mc": "<unk> . in this paragraph , can you find out the result of ic50_mc ? [SEP] [CLS] what is the compound in this paper ? [SEP] tumor-specific novel taxoid−monoclonal antibody conjugates taxoids bearing methyldisulfanyl ( alkanoyl ) groups for taxoid−antibody immunoconjugates were designed , synthesized and their activities evaluated . a highly cytotoxic c-10 methyldisulfanylpropanoyl taxoid was conjugated to monoclonal antibodies recognizing the epidermal growth factor receptor ( egfr ) expressed in human squamous cancers . these conjugates were shown to possess remarkable target-specific antitumor activity in vivo against egfr-expressing a431 tumor xenografts in severe combined immune deficiency mice", "kd_mc": "tumor-specific novel taxoid−monoclonal antibody conjugates . the main compound is <unk> . in this paragraph , can you find out the result of kd_mc ? [SEP] [CLS] what is the compound in this paper ? [SEP] tumor-specific novel taxoid−monoclonal antibody conjugates taxoids bearing methyldisulfanyl ( alkanoyl ) groups for taxoid−antibody immunoconjugates were designed , synthesized and their activities evaluated . a highly cytotoxic c-10 methyldisulfanylpropanoyl taxoid was conjugated to monoclonal antibodies recognizing the epidermal growth factor receptor ( egfr", "selectivity_mc": "methyldisulfanyl ( alkanoyl ) groups for taxoid−antibody immunoconjugates were designed , synthesized and their activities evaluated . a highly cytotoxic c-10", "kd_ce": "tumor-specific novel taxoid−monoclonal antibody conjugates . the main compound is <unk> . in this paragraph , can you find out the result of kd_ce ? [SEP] [CLS] what is the compound in this paper ? [SEP] tumor-specific novel taxoid−monoclonal antibody conjugates taxoids bearing methyldisulfanyl ( alkanoyl ) groups for taxoid−antibody immunoconjugates were designed , synthesized and their activities evaluated . a highly cytotoxic c-10", "ec50_ce": "tumor-specific novel taxoid−monoclonal antibody conjugates", "herg_ce": "tumor-specific novel taxoid−monoclonal antibody conjugates . the main compound is <unk> . in this paragraph , can you find out the result of herg_ce ? [SEP] [CLS] what is the compound in this paper ? [SEP] tumor-specific novel taxoid−monoclonal antibody conjugates taxoids bearing methyldisulfanyl ( alkanoyl ) groups for taxoid−antibody immunoconjugates were designed , synthesized and their activities evaluated . a highly cytotoxic c-10 methyldisulfanylpropanoyl taxoid was conjugated to monoclonal antibodies recognizing the epidermal growth factor receptor ( egfr ) expressed in human squamous cancers . these conjugates were shown to possess remarkable target-specific antitumor activity in vivo against egfr-expressing a431 tumor xenografts in severe combined immune deficiency mice", "solubility_ce": "<unk> . in this paragraph , can you find out the result of solubility_ce ? [SEP] [CLS] what is the compound in this paper ? [SEP] tumor-specific novel taxoid−monoclonal antibody conjugates taxoids bearing methyldisulfanyl ( alkanoyl", "ed50_an": "tumor-specific novel taxoid−monoclonal antibody conjugates . the main compound is <unk> . in this paragraph , can you find out the result of ed50_an ? [SEP] [CLS] what is the compound in this paper ?", "bioavailability_an": "tumor-specific novel taxoid−monoclonal antibody conjugates . the main compound is <unk> . in this paragraph , can you find out the result of bioavailability_an ? [SEP] [CLS] what is the compound in this paper ? [SEP] tumor-specific novel taxoid−monoclonal antibody conjugates taxoids bearing methyldisulfanyl ( alkanoyl", "compound_drug": "alkanoyl"}


{"id": 78, "paper_title": "Tumor-Specific Novel Taxoid−Monoclonal Antibody Conjugates", "paper_author": ["Iwao Ojima", "Xudong Geng", "Xinyuan Wu", "Chuanxing Qu", "Christopher P. Borella", "Hongsheng Xie", "Sharon D. Wilhelm", "Barbara A. Leece", "Laura M. Bartle", "Victor S. Goldmacher", "Ravi V. J. Chari"], "paper_year": 2002, "paper_institution": "Department of Chemistry, State University of New York at Stony Brook, Stony Brook, New York 11794-3400, and ImmunoGen, Inc., 128 Sidney Street, Cambridge, Massachusetts 02139 ", "paper_cited": 82, "doi": "10.1021/jm025540g", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2002/jmcmar.2002.45.issue-26/jm025540g/production/images/large/jm025540gn00001.jpeg", "compound_count": 30, "compound_name": "9a", "compound_name_drug": "", "compound_smiles": "", "medicinal_chemistry_metrics": {"Ki": "", "Kd": "", "IC50": "", "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": "", "IC50": "0.5 ", "EC50": "", "selectivity": "", "hERG": "", "solubility": ""}, "pharm_metrics_vivo": {"ED50": "", "AUC": "", "solubility": "", "t_half": "", "bioavailability": ""}, "clinical_statistics": {}}
articleURL: 88
10.1021/acs.jmedchem.8b01927
{"compound": "5", "ic50_mc": "5 . 20/5 . 0 5", "selectivity_ce": "1", "ed50_an": "5 in living cells .", "compound_drug": "<unk> . in this paragraph , can you find out the result of compound_drug ? [SEP] 2 . results and discussion 2 . 1 . chemistry our laboratory has been investigating the utility of porphyrin-based compounds in cancer imaging and therapy for quite some time . ( 2 5 ) in our hands , the structure–activity relationship ( sar ) and quantitative structure–activity relationship studies were extremely fruitful in selecting the most active agents in porphyrin and reduced porphyrin ( chlorin and bacteriochlorin ) systems . ( 2 6 ) we further extended this approach by preparing a series of carbohydrate ( substrate for lectin ) and crgd ( substrate for integrin ) analogues . some of the conjugates showed enhanced pdt efficacy , but the target specificity following the inhibition approach could not be confirmed . ( 2 7"}


{"id": 79, "paper_title": "Epidermal Growth Factor Receptor-Targeted Multifunctional Photosensitizers for Bladder Cancer Imaging and Photodynamic Therapy", "paper_author": ["Ravindra R. Cheruku", "Joseph Cacaccio", "Farukh A. Durrani", "Walter A. Tabaczynski", "Ramona Watson", "Aimee Marko", "Rahul Kumar", "Mohamed E. El-Khouly", "Shunichi Fukuzumi", "Joseph R. Missert", "Rutao Yao", "Munawwar Sajjad", "Dhyan Chandra", "Khurshid Guru", "Ravindra K. Pandey"], "paper_year": 2019, "paper_institution": "Photodynamic Therapy Center, Cell Stress Biology, Roswell Park Comprehensive Cancer Center, Buffalo, New York 14263, United States", "paper_cited": 12, "doi": "10.1021/acs.jmedchem.8b01927", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01927/20190308/images/large/jm-2018-01927k_0014.jpeg", "compound_count": 14, "compound_name": "5", "compound_name_drug": "", "compound_smiles": "", "medicinal_chemistry_metrics": {"Ki": "", "Kd": "", "IC50": 5.2, "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": "", "IC50": "", "EC50": "", "selectivity": "", "hERG": "", "solubility": ""}, "pharm_metrics_vivo": {"ED50": 0.005, "AUC": "", "solubility": "", "t_half": "", "bioavailability": ""}, "clinical_statistics": {}}
articleURL: 90
10.1021/jm500873e
{"compound": "mnd", "ic50_ce": "7 2 h", "solubility_ce": "5 1", "ed50_an": "7 with organic acids in methanol leads to the formation of corresponding salts ( scheme 1 ) . these compounds were tested against several cancer cell lines including mcf-7 , mda-mb231 , du-145 , ishikawa , and hela ."}


{"id": 80, "paper_title": "Thioaryl Naphthylmethanone Oxime Ether Analogs as Novel Anticancer Agents", "paper_author": ["Bandana Chakravarti", "Tahseen Akhtar", "Byanju Rai", "Manisha Yadav", "Jawed Akhtar Siddiqui", "Shailendra Kumar Dhar Dwivedi", "Ravi Thakur", "Anup Kumar Singh", "Abhishek Kumar Singh", "Harish Kumar", "Kainat Khan", "Subhashis Pal", "Srikanta Kumar Rath", "Jawahar Lal", "Rituraj Konwar", "Arun Kumar Trivedi", "Dipak Datta", "Durga Prasad Mishra", "Madan Madhav Godbole", "Sabyasachi Sanyal", "Naibedya Chattopadhyay", "Atul Kumar"], "paper_year": 2014, "paper_institution": "†Medicinal and Process Chemistry Division; ‡Endocrinology Division, §Biochemistry Division, ∥Toxicology Division, and ⊥Pharmacokinetics and Metabolism Division, CSIR-Central Drug Research Institute, Lucknow 226031, India", "paper_cited": 28, "doi": "10.1021/jm500873e", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-19/jm500873e/20141006/images/large/jm-2014-00873e_0010.jpeg", "compound_count": 27, "compound_name": "MND", "compound_name_drug": "", "compound_smiles": "", "medicinal_chemistry_metrics": {"Ki": "", "Kd": "", "IC50": "", "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": "", "IC50": 72.0, "EC50": "", "selectivity": "", "hERG": "", "solubility": 51.0}, "pharm_metrics_vivo": {"ED50": 0.007, "AUC": "", "solubility": "", "t_half": "", "bioavailability": ""}, "clinical_statistics": {}}
articleURL: 92
10.1021/acs.jmedchem.6b00276
{"compound": "8ag </b> exhibited high antiproliferative activity against panc-1 , paca-2 , a-549 , and pc-3 cell lines , with ic50 value of 0 . 0 2 μm , comparable to the positive control erlotinib . the ten most active antiproliferative compounds were assessed for mechanistic effects on brafv600e , egfr tk kinases , and tubulin polymerization , and were investigated in vitro to reverse efflux-mediated resistance developed by cancer cells . compound <b> 8af </b> exhibited the most potent brafv600e inhibitory activity with an ic50 value of 0 . 9 μm . oxime analog <b> 7o </b> displayed the most potent egfr tk inhibitory activity with an ic50 of 0 . 0 7 μm , which was analogous to the positive control . some analogs including <b> 7f", "ic50_mc": "7", "ed50_an": "7 ) ( tables 1 , 2 , and 3 ) . to synthesize the desired α , β-unsaturated carbonyl based compounds , claisene schmidt condensation was used between different ketones and suitable aryl aldehydes at a molar ratio 1:2 for cyclohexanone derivatives ( 4a–u ) and at a molar ratio 1:1 for tetralone derivatives ( 5a–ag ) ( scheme 1 ) . all synthesized compounds were characterized by using various analytical techniques and characterization data of compounds including melting point ( mp ) , 1h nmr , 13c nmr , hrms , microanalysis ( chns ) is provided in the experimental section . all compounds have a purity grade ≥95% .", "bioavailability_an": "9 0"}


{"id": 81, "paper_title": "Synthesis of α,β-Unsaturated Carbonyl-Based Compounds, Oxime and Oxime Ether Analogs as Potential Anticancer Agents for Overcoming Cancer Multidrug Resistance by Modulation of Efflux Pumps in Tumor Cells", "paper_author": ["Hua-Li Qin", "Jing Leng", "Cheng-Pan Zhang", "Ibrahim Jantan", "Muhammad Wahab Amjad", "Muhammad Sher", "Muhammad Naeem-ul-Hassan", "Muhammad Ajaz Hussain", "Syed Nasir Abbas Bukhari"], "paper_year": 2016, "paper_institution": "Department of Pharmaceutical Engineering, School of Chemistry, Chemical Engineering and Life Science, Wuhan University of Technology, 205 Luoshi Road, Wuhan 430070, P.R. China", "paper_cited": 51, "doi": "10.1021/acs.jmedchem.6b00276", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-7/acs.jmedchem.6b00276/20160414/images/large/jm-2016-00276j_0008.jpeg", "compound_count": 37, "compound_name": "8ag", "compound_name_drug": "", "compound_smiles": "", "medicinal_chemistry_metrics": {"Ki": "", "Kd": "", "IC50": 7.0, "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": "", "IC50": "μm0.02 ± 0.08", "EC50": "", "selectivity": "", "hERG": "", "solubility": ""}, "pharm_metrics_vivo": {"ED50": 0.007, "AUC": "", "solubility": "", "t_half": "", "bioavailability": 90.0}, "clinical_statistics": {}}
articleURL: 93
10.1021/jm990947f
{"compound": "2 8", "ic50_mc": "2", "ic50_ce": "6 5 1 . 0 6 . 0 0 . 5 2 . 6 3n15 . 0 5 1 . 2 0 . 4 5 4 0 . 3 3 6 . 3 7 . 8 4 8 . 5 2 8 2 0 . 0 2 5 . 2 0 . 3 3 9 . 8 4 8 . 7 6 . 5 2 4 .", "kd_ce": "3 2", "selectivity_ce": "1", "ed50_an": "2 . 3 2 and 0 . 3 2 7 μm , respectively . the poor activity of the tyrphostin type of ptk inhibitors ( gi50 generally > 1 0 0 μm ) 3 0 in this 48-h drug exposure assay may reflect the fact that these compounds require a prolonged drug exposure to exert inhibitory effects on their target enzymes and thence cell growth . also , their profile of activity does not appear to correlate with levels of egfr and erbb-2 mrna in the cells lines . 3 1 evidently the new tyrphostins tested in the present work , which are all variants of the prototypic agents , albeit at a higher oxidation level , do not have enhanced activity in this assay .", "t_half_an": "3"}


{"id": 82, "paper_title": "Structural Studies on Bioactive Compounds. 32.1 Oxidation of Tyrphostin Protein Tyrosine Kinase Inhibitors with Hypervalent Iodine Reagents", "paper_author": ["Geoffrey Wells", "Angela Seaton", "Malcolm F. G. Stevens"], "paper_year": 2000, "paper_institution": "Cancer Research Laboratories, School of Pharmaceutical Sciences, University of Nottingham, Nottingham NG7 2RD, U.K. ", "paper_cited": 40, "doi": "10.1021/jm990947f", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2000/jmcmar.2000.43.issue-8/jm990947f/production/images/large/jm990947fn00001.jpeg", "compound_count": 181, "compound_name": "28", "compound_name_drug": "", "compound_smiles": "", "medicinal_chemistry_metrics": {"Ki": "", "Kd": "", "IC50": 2.0, "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": 32.0, "IC50": "μm41.8 ", "EC50": "", "selectivity": "", "hERG": "", "solubility": ""}, "pharm_metrics_vivo": {"ED50": 2.32, "AUC": "", "solubility": "", "t_half": 3.0, "bioavailability": ""}, "clinical_statistics": {}}
articleURL: 94
10.1021/jm800637b
{"compound": "1b", "ic50_ce": "1 0 μm", "selectivity_ce": "1", "bioavailability_an": "9 6", "compound_drug": "<unk> . in this paragraph , can you find out the result of compound_drug ? [SEP] results and discussion in designing the library , we decided to combine three quinone building blocks with eight polyamines , generating a library of 2 4 compounds ( chart ) . to introduce diversity into the quinone subunit , we selected the naphthoquinone ( 1 ) of 1b , and two higher quinone homologues , anthraquinone ( 2 ) and naphtacenequinone ( 3"}


{"id": 83, "paper_title": "Parallel Synthesis and Cytotoxicity Evaluation of a Polyamine−Quinone Conjugates Library", "paper_author": ["Maria Laura Bolognesi", "Natalia Calonghi", "Chiara Mangano", "Lanfranco Masotti", "Carlo Melchiorre"], "paper_year": 2008, "paper_institution": "Department of Pharmaceutical Sciences, Alma Mater Studiorum, University of Bologna, Via Belmeloro 6, 40126 Bologna, Italy, Department of Biochemistry “G. Moruzzi”, Alma Mater Studiorum, University of Bologna, Via Irnerio 48, 40126 Bologna, Italy", "paper_cited": 28, "doi": "10.1021/jm800637b", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-17/jm800637b/production/images/large/jm-2008-00637b_0008.jpeg", "compound_count": 28, "compound_name": "1b", "compound_name_drug": "", "compound_smiles": "c1c2c(ccc1)C(=O)C=CC2=O", "medicinal_chemistry_metrics": {"Ki": "", "Kd": "", "IC50": "", "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": "", "IC50": 10000.0, "EC50": "", "selectivity": "", "hERG": "", "solubility": ""}, "pharm_metrics_vivo": {"ED50": "", "AUC": "", "solubility": "", "t_half": "", "bioavailability": 96.0}, "clinical_statistics": {}}
articleURL: 95
10.1021/acs.jmedchem.9b01167
{"compound": "", "ic50_mc": "1", "ki_mc": "0", "kd_mc": "1 3", "ic50_ce": "7", "kd_ce": "2", "herg_ce": "1 0", "ed50_an": "4 ) maximal akt activity is dependent on the phosphorylation status of both thr308 and ser473 residues . ( 1 5 )", "bioavailability_an": "1 5", "compound_drug": "<unk> . in this paragraph , can you find out the result of compound_drug ? [SEP] results and discussion promoting dephosphorylation of kinases is an attractive strategy for pharmacological intervention as many kinases have activity that is regulated by phosphorylation state . in classic examples , phosphorylation of the a-loop ( and other motifs ) increases enzymatic activity by conformational changes that lead to improved substrate binding , cellular localization , or copartner recruitment . ( 1 1 ) extracellular growth signals are propagated by kinases phosphorylating , and thus in many cases activating , downstream kinases . inducing dephosphorylation of a pathway kinase would thus simultaneously inhibit the kinase’s ability to receive and transmit an upstream signal . the pi3k/akt pathway is often overactivated in cancer cells , having a central role in cell proliferation and survival . ( 1 2 ) akt itself contains a pleckstrin homology ( ph ) domain that binds to pip3 ( phosphatidylinositol ( 3 , 4 , 5 ) -triphosphate ) in the plasma membrane with high affinity . once recruited to the plasma membrane , akt is phosphorylated by several kinases at two critical sites , threonine 3 0 8 ( thr308 , a-loop ) and serine 4 7 3 ( ser473 ) . ( 1 3 , 1 4 ) maximal akt activity is dependent on the phosphorylation status of both thr308 and ser473 residues . ( 1 5 )"}


{"id": 84, "paper_title": "Heterobifunctional Molecules Induce Dephosphorylation of Kinases–A Proof of Concept Study", "paper_author": ["Sayumi Yamazoe", "Jeffrey Tom", "Yue Fu", "Wenqiong Wu", "Liang Zeng", "Changlei Sun", "Qi Liu", "Jie Lin", "Kui Lin", "Wayne J. Fairbrother", "Steven T. Staben"], "paper_year": 2019, "paper_institution": "Discovery Chemistry , Genentech, Inc., 1 DNA Way, South San Francisco, California 94062, United States", "paper_cited": 24, "doi": "10.1021/acs.jmedchem.9b01167", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01167/20200323/images/large/jm9b01167_0008.jpeg", "compound_count": 10, "compound_name": "3", "compound_name_drug": "", "compound_smiles": "", "medicinal_chemistry_metrics": {"Ki": "", "Kd": 13.0, "IC50": 1.0, "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": 2.0, "IC50": 7.0, "EC50": "", "selectivity": "", "hERG": 10.0, "solubility": ""}, "pharm_metrics_vivo": {"ED50": 4.0, "AUC": "", "solubility": "", "t_half": "", "bioavailability": 15.0}, "clinical_statistics": {}}
articleURL: 96
10.1021/acs.jmedchem.8b00405
{"compound": "", "ic50_mc": "1", "ki_mc": "2 0", "kd_mc": "1 7", "kd_ce": "2", "ec50_ce": "7", "solubility_ce": "3", "ed50_an": "7 4 atoms , or a hydrophobic 6-aminohexonic acid linker in the α- and ξ-amino groups of the second lysine attached to cy5 . 5 ( red , figure 1 ) . the linker length was varied to determine the optimal spacing between monomers in order to maximize binding interactions to egfr and erbb2", "bioavailability_an": "8 7", "compound_drug": "<unk> . in this paragraph , can you find out the result of compound_drug ? [SEP] hydrophobic 6-aminohexonic acid linker in the α- and ξ-amino groups of the second lysine attached to cy5 . 5 ( red , figure 1"}


{"id": 85, "paper_title": "Multiplexed Targeting of Barrett’s Neoplasia with a Heterobivalent Ligand: Imaging Study on Mouse Xenograft in Vivo and Human Specimens ex Vivo", "paper_author": ["Jing Chen", "Juan Zhou", "Zhenghong Gao", "Xue Li", "Fa Wang", "Xiyu Duan", "Gaoming Li", "Bishnu P. Joshi", "Rork Kuick", "Henry D. Appelman", "Thomas D. Wang"], "paper_year": 2018, "paper_institution": "Division of Gastroenterology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan 48109, United States", "paper_cited": 7, "doi": "10.1021/acs.jmedchem.8b00405", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-12/acs.jmedchem.8b00405/20180622/images/large/jm-2018-00405p_0009.jpeg", "compound_count": 0, "compound_name": "ECFR", "compound_name_drug": "", "compound_smiles": "", "medicinal_chemistry_metrics": {"Ki": 20.0, "Kd": 17.0, "IC50": 1.0, "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": 2.0, "IC50": "", "EC50": 7.0, "selectivity": "", "hERG": "", "solubility": 3.0}, "pharm_metrics_vivo": {"ED50": 0.074, "AUC": "", "solubility": "", "t_half": "", "bioavailability": 87.0}, "clinical_statistics": {}}
articleURL: 97
10.1021/acs.jmedchem.7b01612
{"compound": "3bw", "ic50_mc": "3 0 . 6", "kd_mc": "2 . 8", "selectivity_mc": "10-fold", "ic50_ce": "3 0", "kd_ce": "2", "t_half_an": "6", "auc_an": "1 6 3 0 and 5 3 1 1", "bioavailability_an": "3 8 . 6 %", "compound_drug": "<unk> . in this paragraph , can you find out the result of compound_drug ? [SEP] results and discussion in order to identify a “hit” molecule as the starting point for the new csf1r inhibitor discovery , a random screening was performed against our in-house kinase inhibitor library . ( 30−37 ) a number of compounds displayed obvious inhibition against csf1r kinase , among which compound 2 , a previously designed irreversible egfr inhibitor , ( 3 7"}


{"id": 86, "paper_title": "Design, Synthesis, and Structure–Activity Relationship Study of 2-Oxo-3,4-dihydropyrimido[4,5-d]pyrimidines as New Colony Stimulating Factor 1 Receptor (CSF1R) Kinase Inhibitors", "paper_author": ["Qiuju Xun", "Zhang Zhang", "Jinfeng Luo", "Linjiang Tong", "Minhao Huang", "Zhen Wang", "Jian Zou", "Yingqiang Liu", "Yong Xu", "Hua Xie", "Zheng-Chao Tu", "Xiaoyun Lu", "Ke Ding"], "paper_year": 2018, "paper_institution": "State Key Laboratory of Respiratory Diseases, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, 190 Kaiyuan Avenue, Guangzhou 510530, China", "paper_cited": 11, "doi": "10.1021/acs.jmedchem.7b01612", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01612/20180315/images/large/jm-2017-01612s_0015.jpeg", "compound_count": 76, "compound_name": "3bw", "compound_name_drug": "", "compound_smiles": "C1C(N2CCN(CC2)c2c(C)cc(Nc3ncc4c(N([C@H]5CCN(C(=O)CC)C5)C(=O)N(C4)c4c(C)ccc(OC)c4)n3)cc2)CO1", "medicinal_chemistry_metrics": {"Ki": "", "Kd": 2.8, "IC50": 30.6, "selectivity": 10}, "pharm_metrics_vitro": {"Ki": "", "Kd": 2.0, "IC50": 30.0, "EC50": "", "selectivity": "", "hERG": "", "solubility": ""}, "pharm_metrics_vivo": {"ED50": "", "AUC": 1630.0, "solubility": "", "t_half": 6.0, "bioavailability": 38.6}, "clinical_statistics": {}}
articleURL: 98
10.1021/jm049892u
{"compound": "", "ic50_mc": "6", "kd_ce": "2 , 4]triazine nucleus as a new kinase inhibitor template the pyrrolo[2 , 1-f][1 , 2", "ec50_ce": "2", "solubility_ce": "2 , 4]triazine nucleus was identified as a novel kinase inhibitor template which effectively mimics the well-known quinazoline kinase inhibitor scaffold . attachment of a 4- ( ( 3-chloro-4-fluorophenyl ) amino ) substituent to the template provided potent biochemical inhibitors of the tyrosine kinase activity of egfr , as well as inhibition of cellular proliferation of the human colon tumor cell line difi . attachment of a 4- ( ( 3-hydroxy-4-methylphenyl ) amino ) substituent provided potent inhibitors of vegfr-2 which also showed effects on the vegf-dependent proliferation of human umbilical vein endothelial cells . biological activity was maintained with substitution at positions 5 or 6 ,", "ed50_an": "7 , suggesting that the former positions are promising sites for introducing side chains which modulate physicochemical properties . preliminary inhibition studies with varying atp concentrations suggest that , like the quinazoline-based kinase inhibitors , the pyrrolotriazine-based inhibitors bind in the atp pocket . . [SEP]", "bioavailability_an": "7"}


{"id": 87, "paper_title": "Discovery of the Pyrrolo[2,1-f][1,2,4]triazine Nucleus as a New Kinase Inhibitor Template", "paper_author": ["John T. Hunt", "Toomas Mitt", "Robert Borzilleri", "Johnni Gullo-Brown", "Joseph Fargnoli", "Brian Fink", "Wen-Ching Han", "Steven Mortillo", "Gregory Vite", "Barri Wautlet", "Tai Wong", "Chiang Yu", "Xiaoping Zheng", "Rajeev Bhide"], "paper_year": 2004, "paper_institution": "Departments of Oncology Chemistry, and Oncology Drug Discovery, Bristol-Myers Squibb Pharmaceutical Research Institute, P. O. Box 4000, Princeton, New Jersey 08543-4000 ", "paper_cited": 77, "doi": "10.1021/jm049892u", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2004/jmcmar.2004.47.issue-16/jm049892u/production/images/large/jm049892un00001.jpeg", "compound_count": 49, "compound_name": "f", "compound_name_drug": "", "compound_smiles": "", "medicinal_chemistry_metrics": {"Ki": "", "Kd": "", "IC50": 6.0, "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": 2.0, "IC50": "", "EC50": 2.0, "selectivity": "", "hERG": "", "solubility": 2.0}, "pharm_metrics_vivo": {"ED50": 0.007, "AUC": "", "solubility": "", "t_half": "", "bioavailability": 7.0}, "clinical_statistics": {}}
articleURL: 99
10.1021/acs.jmedchem.9b00687
{"compound": "31a", "ic50_mc": "0 . 3 5", "selectivity_mc": "9", "selectivity_ce": "1", "compound_drug": "bgb-3111"}


{"id": 88, "paper_title": "Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton’s Tyrosine Kinase", "paper_author": ["Yunhang Guo", "Ye Liu", "Nan Hu", "Desheng Yu", "Changyou Zhou", "Gongyin Shi", "Bo Zhang", "Min Wei", "Junhua Liu", "Lusong Luo", "Zhiyu Tang", "Huipeng Song", "Yin Guo", "Xuesong Liu", "Dan Su", "Shuo Zhang", "Xiaomin Song", "Xing Zhou", "Yuan Hong", "Shuaishuai Chen", "Zhenzhen Cheng", "Steve Young", "Qiang Wei", "Haisheng Wang", "Qiuwen Wang", "Lei Lv", "Fan Wang", "Haipeng Xu", "Hanzi Sun", "Haimei Xing", "Na Li", "Wei Zhang", "Zhongbo Wang", "Guodong Liu", "Zhijian Sun", "Dongping Zhou", "Wei Li", "Libin Liu", "Lai Wang", "Zhiwei Wang"], "paper_year": 2019, "paper_institution": "Department of Medicinal Chemistry, BeiGene (Beijing) Co., Ltd, No. 30 Science Park Road, Zhong-Guan-Cun Life Sciences Park, Changping District, Beijing 102206, P.R. China", "paper_cited": 60, "doi": "10.1021/acs.jmedchem.9b00687", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-17/acs.jmedchem.9b00687/20190905/images/large/jm9b00687_0019.jpeg", "compound_count": 101, "compound_name": "31a", "compound_name_drug": "BGB-3111", "compound_smiles": "C1C[C@H](n2c(N1)c(C(=O)N)c(c1ccc(Oc3ccccc3)cc1)n2)C1CCN(CC1)C(=O)C=C", "medicinal_chemistry_metrics": {"Ki": "", "Kd": "", "IC50": 0.35, "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": "", "IC50": "", "EC50": "", "selectivity": "", "hERG": "", "solubility": ""}, "pharm_metrics_vivo": {"ED50": "", "AUC": "", "solubility": "", "t_half": "", "bioavailability": ""}, "clinical_statistics": {"p1_company_num": 14, "p1_stat_company_num": [1, 0, 0, 0, 0, 0, 13, 0, 0], "p1_company": [["Ohio State University Comprehensive Cancer Center"], [], [], [], [], [], ["Peter MacCallum Cancer Centre, Australia", "BeiGene (Beijing) Co.,", "Institute of Hematology & Blood Diseases Hospital", "Lymphoma Department of Beijing University Cancer Hospital", "The First Affiliated Hospital with Nanjing Medical University", "German CLL Study Group", "Beijing Cancer Hospital", "BeiGene", "Beigne", "Department I of Internal Medicine, University Hospital Cologne", "Merck Sharp & Dohme Corp.", "Loxo Oncology", "M.D. Anderson Cancer Center"], [], []], "p1_terminate_reason": {}, "p1_withdraw_reason": {}, "p1_adverse_event": {}, "p2_company_num": 11, "p2_stat_company_num": [0, 5, 0, 0, 0, 0, 6, 0, 0], "p2_company": [[], ["Department I of Internal Medicine, University Hospital Cologne", "Merck Sharp & Dohme Corp.", "Loxo Oncology", "German CLL Study Group", "M.D. Anderson Cancer Center"], [], [], [], [], ["Peter MacCallum Cancer Centre, Australia", "BeiGene (Beijing) Co.,", "Institute of Hematology & Blood Diseases Hospital", "Lymphoma Department of Beijing University Cancer Hospital", "The First Affiliated Hospital with Nanjing Medical University", "BeiGene"], [], []], "p2_terminate_reason": {}, "p2_withdraw_reason": {}, "p2_adverse_event": {"Lymphoma Department of Beijing University Cancer Hospital": 0.2441860465116279, "The First Affiliated Hospital with Nanjing Medical University": 0.32967032967032966}, "p3_company_num": 1, "p3_stat_company_num": [0, 1, 0, 0, 0, 0, 0, 0, 0], "p3_company": [[], ["BeiGene"], [], [], [], [], [], [], []], "p3_terminate_reason": {}, "p3_withdraw_reason": {}, "p3_adverse_event": {}}}
articleURL: 100
10.1021/acs.jmedchem.6b00374
{"compound": "3 1", "ic50_mc": "1 . 5 6", "kd_mc": "0 . 0 8 4", "selectivity_mc": "1", "ic50_ce": "5 1", "ed50_an": "1 as a potent and irreversible egfr inhibitor . reviewing its profile against a panel of 2 6 kinases , we found that it showed only moderate inhibition against flt3 . an explanation of this observation could be that the interaction modes of the lead compound with flt3 and egfr share a high degree of similarity ( figure 1a ) . the predicted binding mode shown in figure 1a was obtained through docking the lead compound into flt3 homology model built in an active conformation . the structure of egfr ( pdb code 3ika ) was aligned to the flt3 homology model . in both structures , the aminopyrimidine ring interacts with the residue ( flt3 , cys694; egfr , met793 ) at hinge region through classical bidentate hydrogen bonding . a hydrophobic sandwich with the pteridin-7 ( 8h ) -one core and a floor leucine residue and a ceiling alanine residue ( flt3 , ala642 and leu818; egfr , ala743 and leu844 ) is formed , further stabilizing the binding interactions between lead scaffold and target . the most noticeable difference within the two inhibitor–kinase complexes is the distinct interaction between the michael acceptor and the target . the electrophilic group forms a covalent bond with the thiol of cys797 of egfr , and this has been widely reported ( 24-27 ) as a vital contribution to egfr binding affinity and selectivity .", "compound_drug": "<unk> . in this paragraph , can you find out the result of compound_drug ? [SEP] results and discussion binding mode analysis previously , we reported the discovery of the lead compound 1 as a potent and irreversible egfr inhibitor . reviewing its profile against a panel of 2 6 kinases , we found that it showed only moderate inhibition against flt3 . an explanation of this observation could be that the interaction modes of the lead compound with flt3 and egfr share a high degree of similarity ( figure 1a ) . the predicted binding mode shown in figure 1a was obtained through docking the lead compound into flt3 homology model built in an active conformation . the structure of egfr ( pdb code 3ika ) was aligned to the flt3 homology model . in both structures , the aminopyrimidine ring interacts with the residue ( flt3 , cys694; egfr , met793 ) at hinge region through classical bidentate hydrogen bonding . a hydrophobic sandwich with the pteridin-7 ( 8h ) -one core and a floor leucine residue and a ceiling alanine residue ( flt3 , ala642 and leu818; egfr , ala743"}


{"id": 89, "paper_title": "Discovery and Rational Design of Pteridin-7(8H)-one-Based Inhibitors Targeting FMS-like Tyrosine Kinase 3 (FLT3) and Its Mutants", "paper_author": ["Deheng Sun", "Yu Yang", "Jiankun Lyu", "Wei Zhou", "Wenlin Song", "Zhenjiang Zhao", "Zhuo Chen", "Yufang Xu", "Honglin Li"], "paper_year": 2016, "paper_institution": "State Key Laboratory of Bioreactor Engineering, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science & Technology, Shanghai 200237, China", "paper_cited": 16, "doi": "10.1021/acs.jmedchem.6b00374", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00374/20160708/images/large/jm-2016-00374p_0007.jpeg", "compound_count": 36, "compound_name": "31", "compound_name_drug": "", "compound_smiles": "", "medicinal_chemistry_metrics": {"Ki": "", "Kd": 0.084, "IC50": 1.56, "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": "", "IC50": 51.0, "EC50": "", "selectivity": "", "hERG": "", "solubility": ""}, "pharm_metrics_vivo": {"ED50": 0.001, "AUC": "", "solubility": "", "t_half": "", "bioavailability": ""}, "clinical_statistics": {}}
articleURL: 101
10.1021/acs.jmedchem.0c01677
{"compound": "", "ic50_mc": "0 . 5 6 in", "ki_mc": "1 0 . 0 vs 8 . 0", "kd_mc": "1 0 . 0", "selectivity_mc": "25-fold", "kd_ce": "2", "ec50_ce": "1 0 0 and 4 0 0 μm", "selectivity_ce": "1", "herg_ce": "1 0", "ed50_an": "7 ) and h2n-cmyiealdkyac-conh2 ( labeled ebp ) , which could target egfr-overexpressed colon carcinoma cells . ( 3 8 ) they were prepared manually according to our previously described procedure . ( 1 9 ) the bifunctional linker 1 was prepared by treating 1 , 3 , 5-tris ( bromomethyl ) benzene with one equiv of sodium cyclopentadienylide . for the photosensitizer part , a zinc ( ii ) phthalocyanine core was used due to its superior photophysical properties and", "bioavailability_an": "4 1 ) the target maleimide-substituted phthalocyanine 2 was synthesized according to our previously described procedure . ( 3 4", "compound_drug": "ht29"}


{"id": 90, "paper_title": "Facile Synthesis of Cyclic Peptide–Phthalocyanine Conjugates for Epidermal Growth Factor Receptor-Targeted Photodynamic Therapy", "paper_author": ["Jacky C. H. Chu", "Wing-Ping Fong", "Clarence T. T. Wong", "Dennis K. P. Ng"], "paper_year": 2021, "paper_institution": "Department of Chemistry, The Chinese University of Hong Kong, Shatin, N.T., Hong Kong, China", "paper_cited": -1, "doi": "10.1021/acs.jmedchem.0c01677", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01677/20210218/images/large/jm0c01677_0013.jpeg", "compound_count": 7, "compound_name": "5", "compound_name_drug": "", "compound_smiles": "", "medicinal_chemistry_metrics": {"Ki": 10.0, "Kd": 10.0, "IC50": 0.56, "selectivity": 25}, "pharm_metrics_vitro": {"Ki": "", "Kd": 2.0, "IC50": "", "EC50": 100000.0, "selectivity": "", "hERG": 10.0, "solubility": ""}, "pharm_metrics_vivo": {"ED50": 0.007, "AUC": "", "solubility": "", "t_half": "", "bioavailability": 41.0}, "clinical_statistics": {}}
articleURL: 103
10.1021/jm990482t
{"compound": "", "ic50_mc": "1 . 1 8", "kd_mc": "1", "ic50_ce": "9", "kd_ce": "2 0 inhibition were classified as reversible . for compounds capable of rapid and complete alkylation of the enzyme , the ic50 values derive essentially from titrating the enzyme activity in a stoichiometric manner and for this reason are designated as apparent ic50s ( ic50[app] ) . 1 4 the concentration of egfr in the isolated enzyme assays is calculated at 1", "ec50_ce": "7", "herg_ce": "1 0 0", "solubility_ce": "2", "ed50_an": "1 . 1 3 to 1 . 9 9 × 10-6 cm/s for b→a studies .", "bioavailability_an": "1 4 0 . 6 9 2 . 7 irrev 7 . 3 16b o ( ch2 ) 3morph f br 171−173 1 . 8 4 . 7 irrev 8 . 2 17b h f cl ref 1 4 0 . 7 5 3 . 1 irrev 4 . 3 18b o ( ch2 ) 3morph f cl 188−190 1 . 5 7 . 4 irrev 9 . 0 19b [o ( ch2 ) 2]2 ( ch2 ) 2oh f cl 131−132 1 . 7 nd nd 20c h h ref 1 4 0 . 7 5 1 8 irrev 1 2 21c chch ( ch2", "compound_drug": "ci 1 0 3 3"}


{"id": 91, "paper_title": "Tyrosine Kinase Inhibitors. 17. Irreversible Inhibitors of the Epidermal Growth Factor Receptor:  4-(Phenylamino)quinazoline- and 4-(Phenylamino)pyrido[3,2-d]pyrimidine-6-acrylamides Bearing Additional Solubilizing Functions", "paper_author": ["Jeff B. Smaill", "Gordon W. Rewcastle", "Joseph A. Loo", "Kenneth D. Greis", "O. Helen Chan", "Eric L. Reyner", "Elke Lipka", "H. D. Hollis Showalter", "Patrick W. Vincent", "William L. Elliott", "William A. Denny"], "paper_year": 2000, "paper_institution": "Auckland Cancer Society Research Centre, Faculty of Medical and Health Sciences, The University of Auckland, Private Bag 92019, Auckland, New Zealand, and Parke-Davis Pharmaceutical Research, Division of Warner-Lambert Company, 2800 Plymouth Road, Ann Arbor, Michigan 48106-1047 ", "paper_cited": 204, "doi": "10.1021/jm990482t", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2000/jmcmar.2000.43.issue-7/jm990482t/production/images/large/jm990482tn00001.jpeg", "compound_count": 189, "compound_name": "N", "compound_name_drug": "", "compound_smiles": "C1N(CCOC1)CCCOc1c(NC(=O)C=C)cc2c(Nc3ccc(F)c(Cl)c3)ncnc2c1", "medicinal_chemistry_metrics": {"Ki": "", "Kd": 1.0, "IC50": 1.18, "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": 20.0, "IC50": 9.0, "EC50": 7.0, "selectivity": "", "hERG": 100.0, "solubility": 2.0}, "pharm_metrics_vivo": {"ED50": 1.13, "AUC": "", "solubility": "", "t_half": "", "bioavailability": ""}, "clinical_statistics": {}}
articleURL: 105
10.1021/jm070654j
{"compound": "3", "selectivity_mc": "1", "ed50_an": "3 . 3 ± 3 . 6 ( table 5 ) ."}


{"id": 92, "paper_title": "Discovery of Kinase Inhibitors by High-Throughput Docking and Scoring Based on a Transferable Linear Interaction Energy Model", "paper_author": ["Peter Kolb", "Danzhi Huang", "Fabian Dey", "Amedeo Caflisch"], "paper_year": 2008, "paper_institution": "Department of Biochemistry, University of Zürich, Winterthurerstrasse 190, CH-8057 Zürich, Switzerland", "paper_cited": 46, "doi": "10.1021/jm070654j", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-5/jm070654j/production/images/large/jm-2007-00654j_0007.jpeg", "compound_count": 15, "compound_name": "3", "compound_name_drug": "", "compound_smiles": "", "medicinal_chemistry_metrics": {"Ki": "", "Kd": "", "IC50": "", "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": "", "IC50": "", "EC50": "", "selectivity": "", "hERG": "", "solubility": ""}, "pharm_metrics_vivo": {"ED50": 3.3, "AUC": "", "solubility": "", "t_half": "", "bioavailability": ""}, "clinical_statistics": {}}
articleURL: 106
10.1021/acs.jmedchem.6b01915
{"compound": "21b", "ic50_mc": "2 . 3", "selectivity_ce": "1", "ed50_an": "7 ) was also well tolerated by the clk1 binding site . on the other hand , the modifications in 3 0 , also including a replacement of the free hydroxyl group by methoxy , had decreased the potency toward dyrk1a . hence 3 0 was identified as moderately selective hit for clk1 ( 9-fold selectivity over dyrk1a ) , with an ic50 of about 1 0 0 nm . ( 1 7 ) in order to optimize the hit compound , molecular modeling was performed based on the clk1 cocrystal structure with hymenialdisine ( pdb code 1z57 ) ; ( 4 ) the binding model suggested that the ether oxygen of 3 0 might interact with the backbone nh of leu244 and the amide carbonyl with the ε-amino function of lys191 ( cf . figure 1 ) . in the resulting binding orientation , the side chains of phe172 , asp325 , and asn293 , as well as several backbone amides , were all located within reach of the amide-linked moieties , potentially enabling a variety of interactions ( figure 1 ) . on the basis of this model", "compound_drug": "<unk> . in this paragraph , can you find out the result of compound_drug ? [SEP] results and discussion compound design in a previous study , we described the development of the fragment-like hydroxybenzothiophene ketone 2 9 ( 1 7"}


{"id": 93, "paper_title": "Development of Selective Clk1 and -4 Inhibitors for Cellular Depletion of Cancer-Relevant Proteins", "paper_author": ["Ahmed K. ElHady", "Mohammad Abdel-Halim", "Ashraf H. Abadi", "Matthias Engel"], "paper_year": 2017, "paper_institution": "Department of Pharmaceutical Chemistry, Faculty of Pharmacy and Biotechnology, German University in Cairo, Cairo 11835, Egypt", "paper_cited": 19, "doi": "10.1021/acs.jmedchem.6b01915", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.6b01915/20170707/images/large/jm-2016-019157_0008.jpeg", "compound_count": 34, "compound_name": "21b", "compound_name_drug": "", "compound_smiles": "", "medicinal_chemistry_metrics": {"Ki": "", "Kd": "", "IC50": 2.3, "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": "", "IC50": "μm2.2", "EC50": "", "selectivity": "", "hERG": "", "solubility": ""}, "pharm_metrics_vivo": {"ED50": 0.007, "AUC": "", "solubility": "", "t_half": "", "bioavailability": ""}, "clinical_statistics": {}}
articleURL: 107
10.1021/jm010888h
{"compound": "1", "herg_ce": "2", "ed50_an": "2 . 5 μm , figure 2 ) . figure 2 inhibition of ige-germline promoter activity in bl-2 cells by 1 ( ○ , duplicates ) . parallel cultures were quantitated for cell viability ( × , duplicates ) in the presence of 1 . high resolution imagedownload ms powerpoint slide", "compound_drug": "<unk> . in this paragraph , can you find out the result of compound_drug ? [SEP] resolution imagedownload ms powerpoint slide"}


{"id": 94, "paper_title": "S(+)-4-(1-Phenylethylamino)quinazolines as Inhibitors of Human Immunoglobuline E Synthesis:  Potency Is Dictated by Stereochemistry and Atomic Point Charges at N-1", "paper_author": ["Michael Berger", "Bettina Albrecht", "Attila Berces", "Peter Ettmayer", "Wolfgang Neruda", "Maximilian Woisetschläger"], "paper_year": 2001, "paper_institution": "Novartis Forschungsinstitut, Brunnerstrasse 59, Vienna A-1235, Austria ", "paper_cited": 23, "doi": "10.1021/jm010888h", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2001/jmcmar.2001.44.issue-18/jm010888h/production/images/large/jm010888hn00001.jpeg", "compound_count": 42, "compound_name": "1", "compound_name_drug": "", "compound_smiles": "C1C2c3ccccc3/C(=N\\C=C(/C(=N)C2)\\C1)/N[C@H](c1c2ccccc2ccc1)C", "medicinal_chemistry_metrics": {"Ki": "", "Kd": "", "IC50": "127 ± 14 (19) ", "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": "", "IC50": "", "EC50": "", "selectivity": "", "hERG": 2.0, "solubility": ""}, "pharm_metrics_vivo": {"ED50": 2.5, "AUC": "", "solubility": "", "t_half": "", "bioavailability": ""}, "clinical_statistics": {}}
articleURL: 108
10.1021/jm2007744
{"compound": "2 2", "selectivity_mc": "1", "ic50_ce": "2 1", "kd_ce": "2", "herg_ce": "1 μm", "ed50_an": "3 ) exhibited strong pdk2 inhibitory activity , i . e . selectivity in facilitating akt ser-473 dephosphorylation without affecting that of thr-308 , while other agents showed low or no appreciable activities in mediating akt dephosphorylation at either residue ( figure 2a ) . as these two structurally related compounds differ only in the n-alkyl moiety , i . e . , methyl versus ethyl , 2 2 was used as the lead agent for mechanistic validation .", "compound_drug": "<unk> . in this paragraph , can you find out the result of compound_drug ? [SEP] results identification of putative pdk2 inhibitors by screening a focused compound library of the 5 3 compounds examined , 2 2 and n-ethyl-3- ( 1- ( 4- ( piperazin-1-yl ) phenyl ) -5- ( 4′- ( trifluoromethyl ) -[1 , 1′-biphenyl]-4-yl ) -1h-pyrazol-3-yl ) propanamide ( 2 3"}


{"id": 95, "paper_title": "Identification and Characterization of a Novel Integrin-Linked Kinase Inhibitor", "paper_author": ["Su-Lin Lee", "En-Chi Hsu", "Chih-Chien Chou", "Hsiao-Ching Chuang", "Li-Yuan Bai", "Samuel K. Kulp", "Ching-Shih Chen"], "paper_year": 2011, "paper_institution": "Division of Medicinal Chemistry, College of Pharmacy and Comprehensive Cancer Center, The Ohio State University, 336 Parks Hall, 500 West 12th Avenue, Columbus, OH 43210, United States", "paper_cited": 52, "doi": "10.1021/jm2007744", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm2007744/production/images/large/jm-2011-007744_0010.jpeg", "compound_count": 11, "compound_name": "22", "compound_name_drug": "", "compound_smiles": "", "medicinal_chemistry_metrics": {"Ki": "", "Kd": "", "IC50": "", "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": 2.0, "IC50": 21.0, "EC50": "", "selectivity": "", "hERG": 1.0, "solubility": ""}, "pharm_metrics_vivo": {"ED50": 0.003, "AUC": "", "solubility": "", "t_half": "", "bioavailability": ""}, "clinical_statistics": {}}
articleURL: 109
10.1021/acs.jmedchem.7b00076
{"compound": "3m", "ic50_mc": "3", "kd_mc": "2", "ic50_ce": "2 4 . 8", "bioavailability_an": "6 0 %", "compound_drug": "25-33 ) the crystal structure of fgfr1 in complex with potency inhibitor 1 5 ( pdb id: 3tt0 ) ( 3 4"}


{"id": 96, "paper_title": "Design, Synthesis, and Pharmacological Evaluation of Novel Multisubstituted Pyridin-3-amine Derivatives as Multitargeted Protein Kinase Inhibitors for the Treatment of Non-Small Cell Lung Cancer", "paper_author": ["Wei Zhu", "Hui Chen", "Yulan Wang", "Jiang Wang", "Xia Peng", "Xianjie Chen", "Yinglei Gao", "Chunpu Li", "Yulong He", "Jing Ai", "Meiyu Geng", "Mingyue Zheng", "Hong Liu"], "paper_year": 2017, "paper_institution": "†State Key Laboratory of Drug Research and ‡CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zu Chong Zhi Road, Shanghai, 201203, China", "paper_cited": 14, "doi": "10.1021/acs.jmedchem.7b00076", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-14/acs.jmedchem.7b00076/20170721/images/large/jm-2017-00076u_0015.jpeg", "compound_count": 73, "compound_name": "3m", "compound_name_drug": "", "compound_smiles": "", "medicinal_chemistry_metrics": {"Ki": "", "Kd": 2.0, "IC50": 3.0, "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": "", "IC50": 24.8, "EC50": "", "selectivity": "", "hERG": "", "solubility": ""}, "pharm_metrics_vivo": {"ED50": "", "AUC": "", "solubility": "", "t_half": "", "bioavailability": 60.0}, "clinical_statistics": {}}
articleURL: 110
10.1021/acs.jmedchem.9b01392
{"compound": "2 1", "ic50_mc": "0 . 0 2 μm", "selectivity_mc": "1", "herg_ce": "1 0 0", "ed50_an": "0 . 0 2 μm , 120-fold selectivity of jak1 over jak2 ) . to rationalize the observed selectivity , an x-ray crystal structure of 2 bound to the kinase domain of jak1 was solved ( figure 1a ) .", "t_half_an": "6", "bioavailability_an": "1 0 0 %", "compound_drug": "azd4205"}


{"id": 97, "paper_title": "Discovery of (2R)-N-[3-[2-[(3-Methoxy-1-methyl-pyrazol-4-yl)amino]pyrimidin-4-yl]-1H-indol-7-yl]-2-(4-methylpiperazin-1-yl)propenamide (AZD4205) as a Potent and Selective Janus Kinase 1 Inhibitor", "paper_author": ["Qibin Su", "Erica Banks", "Geraldine Bebernitz", "Kirsten Bell", "Cassandra F. Borenstein", "Huawei Chen", "Claudio E. Chuaqui", "Nanhua Deng", "Andrew D. Ferguson", "Sameer Kawatkar", "Neil P. Grimster", "Linette Ruston", "Paul D. Lyne", "Jon A. Read", "Xianyou Peng", "Xiaohui Pei", "Stephen Fawell", "Zhanlei Tang", "Scott Throner", "Melissa M. Vasbinder", "Haoyu Wang", "Jon Winter-Holt", "Richard Woessner", "Allan Wu", "Wenzhan Yang", "Michael Zinda", "Jason G. Kettle"], "paper_year": 2020, "paper_institution": "Oncology R&D, AstraZeneca R&D, Waltham, Massachusetts 02451, United States", "paper_cited": 5, "doi": "10.1021/acs.jmedchem.9b01392", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01392/20200507/images/large/jm9b01392_0013.jpeg", "compound_count": 24, "compound_name": "21", "compound_name_drug": "AZD4205", "compound_smiles": "", "medicinal_chemistry_metrics": {"Ki": "", "Kd": "", "IC50": 20.0, "selectivity": "μm>214"}, "pharm_metrics_vitro": {"Ki": "", "Kd": "", "IC50": "", "EC50": "", "selectivity": "", "hERG": 100.0, "solubility": ""}, "pharm_metrics_vivo": {"ED50": 0.02, "AUC": "", "solubility": "", "t_half": 6.0, "bioavailability": 100.0}, "clinical_statistics": {"p1_company_num": 4, "p1_stat_company_num": [0, 0, 0, 0, 0, 0, 4, 0, 0], "p1_company": [[], [], [], [], [], [], ["Frontage Clinical Services, Inc.", "Pharmaron CPC", "Samsung Medical Center", "Dizal (Jiangsu) Pharmaceutical Co., Ltd."], [], []], "p1_terminate_reason": {}, "p1_withdraw_reason": {}, "p1_adverse_event": {}, "p2_company_num": 2, "p2_stat_company_num": [0, 1, 0, 0, 0, 0, 1, 0, 0], "p2_company": [[], ["Samsung Medical Center"], [], [], [], [], ["Dizal (Jiangsu) Pharmaceutical Co., Ltd."], [], []], "p2_terminate_reason": {}, "p2_withdraw_reason": {}, "p2_adverse_event": {}, "p3_company_num": 0, "p3_stat_company_num": [0, 0, 0, 0, 0, 0, 0, 0, 0], "p3_company": [[], [], [], [], [], [], [], [], []], "p3_terminate_reason": {}, "p3_withdraw_reason": {}, "p3_adverse_event": {}}}
articleURL: 112
10.1021/jm990199u
{"compound": "6", "ic50_mc": "7 7 nm", "kd_mc": "7 7", "selectivity_mc": "7 7 nm and >1000-fold", "selectivity_ce": "1 6", "bioavailability_an": "1 6 </b> ) has an ic50 value of 7 7 nm and >1000-fold selectivity with respect to nr1a/2a and nr1a/2c receptors . potency at α1 adrenergic receptors is low for the four cinnamides tested . inhibition of nr1a/2b receptors does not correlate with egfr and erbb2/neu tyrosine kinase inhibitor activity . the n- ( phenylalkyl", "compound_drug": "<unk> . in this paragraph , can you find out the result of compound_drug ? [SEP] [CLS] what is the compound in this paper ? [SEP] structure−activity relationship of n- ( phenylalkyl ) cinnamides as novel nr2b subtype-selective nmda receptor antagonists a novel series of n- ( phenylalkyl ) cinnamides related to n- ( 4-phenylbutyl ) -3 , 4-dihydroxy-β-cyanocinnamide ( <b> 6 </b> , an egfr-k inhibitor with high antiproliferative activity ) was synthesized and tested for antagonism at n-methyl-d-aspartate ( nmda ) receptor subtypes . potency and subunit selectivity were assayed by electrical recordings in xenopus oocytes expressing three binary combinations of cloned rat nmda receptor subunits: nr1a expressed in combination with either nr2a , nr2b , or nr2c . the n- ( phenylalkyl"}


{"id": 98, "paper_title": "Structure−Activity Relationship of N-(Phenylalkyl)cinnamides as Novel NR2B Subtype-Selective NMDA Receptor Antagonists", "paper_author": ["Amir P. Tamiz", "Sui Xiong Cai", "Zhang-Lin Zhou", "Po-Wai Yuen", "Robert M. Schelkun", "Edward R. Whittemore", "Eckard Weber", "Richard M. Woodward", "John F. W. Keana"], "paper_year": 1999, "paper_institution": "Department of Chemistry, University of Oregon, Eugene, Oregon 97403, CoCensys Inc., 213 Technology Drive, Irvine, California 92618, and Parke-Davis Pharmaceutical Research, 2800 Plymouth Road, Ann Arbor, Michigan 48106 ", "paper_cited": 30, "doi": "10.1021/jm990199u", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/1999/jmcmar.1999.42.issue-17/jm990199u/production/images/large/jm990199un00001.jpeg", "compound_count": 116, "compound_name": "6", "compound_name_drug": "", "compound_smiles": "", "medicinal_chemistry_metrics": {"Ki": "", "Kd": 77.0, "IC50": 77.0, "selectivity": 1000}, "pharm_metrics_vitro": {"Ki": "", "Kd": "", "IC50": "", "EC50": "", "selectivity": "", "hERG": "", "solubility": ""}, "pharm_metrics_vivo": {"ED50": "", "AUC": "", "solubility": "", "t_half": "", "bioavailability": 16.0}, "clinical_statistics": {}}
articleURL: 114
10.1021/jm4013888
{"compound": "2 3", "ic50_mc": "5 . 9", "selectivity_mc": "58-fold", "ic50_ce": "2 2", "solubility_ce": "2"}


{"id": 99, "paper_title": "Discovery of Mer Specific Tyrosine Kinase Inhibitors for the Treatment and Prevention of Thrombosis", "paper_author": ["Weihe Zhang", "Andrew L. McIver", "Michael A. Stashko", "Deborah DeRyckere", "Brian R. Branchford", "Debra Hunter", "Dmitri Kireev", "Michael J. Miley", "Jacqueline Norris-Drouin", "Wendy M. Stewart", "Minjung Lee", "Susan Sather", "Yingqiu Zhou", "Jorge A. Di Paola", "Mischa Machius", "William P. Janzen", "H. Shelton Earp", "Douglas K. Graham", "Stephen V. Frye", "Xiaodong Wang"], "paper_year": 2013, "paper_institution": "†Center for Integrative Chemical Biology and Drug Discovery ‡Division of Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy §Department of Pharmacology ∥Lineberger Comprehensive Cancer Center, Department of Medicine, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States", "paper_cited": 34, "doi": "10.1021/jm4013888", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-23/jm4013888/production/images/large/jm-2013-013888_0017.jpeg", "compound_count": 49, "compound_name": "23", "compound_name_drug": "", "compound_smiles": "c1(CC)ccc(C)cc1", "medicinal_chemistry_metrics": {"Ki": "", "Kd": "", "IC50": 5.9, "selectivity": 58}, "pharm_metrics_vitro": {"Ki": "", "Kd": "", "IC50": 22.0, "EC50": "", "selectivity": "", "hERG": "", "solubility": 2.0}, "pharm_metrics_vivo": {"ED50": "", "AUC": "", "solubility": "", "t_half": "", "bioavailability": ""}, "clinical_statistics": {}}
articleURL: 118
10.1021/jm8003653
{"compound": "2b", "ic50_mc": "3 . 8 4", "ed50_an": "3 . 8 4 , which is almost one unit less than that of 2b and might increase its aqueous solubility .", "compound_drug": "mpi-0441138"}


{"id": 100, "paper_title": "Discovery of 2-Chloro-N-(4-methoxyphenyl)-N-methylquinazolin-4-amine (EP128265, MPI-0441138) as a Potent Inducer of Apoptosis with High In Vivo Activity", "paper_author": ["Nilantha Sirisoma", "Shailaja Kasibhatla", "Azra Pervin", "Hong Zhang", "Songchun Jiang", "J. Adam Willardsen", "Mark B. Anderson", "Vijay Baichwal", "Gary G. Mather", "Kevin Jessing", "Raouf Hussain", "Khanh Hoang", "Christopher M. Pleiman", "Ben Tseng", "John Drewe", "Sui Xiong Cai"], "paper_year": 2008, "paper_institution": "EpiCept Corporation, 6650 Nancy Ridge Drive, San Diego, California 92121, Myriad Pharmaceuticals, Inc., 320 Wakara Way, Salt Lake City, Utah 84108", "paper_cited": 45, "doi": "10.1021/jm8003653", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-15/jm8003653/production/images/large/jm-2008-003653_0002.jpeg", "compound_count": 51, "compound_name": "2b", "compound_name_drug": "MPI-0441138", "compound_smiles": "c1(C)nc(nc2c1cccc2)Cl", "medicinal_chemistry_metrics": {"Ki": "", "Kd": "", "IC50": 3.84, "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": "", "IC50": "", "EC50": "μm0.002 ± 0.0001", "selectivity": "", "hERG": "", "solubility": ""}, "pharm_metrics_vivo": {"ED50": 3.84, "AUC": "", "solubility": "", "t_half": "", "bioavailability": ""}, "clinical_statistics": {}}
articleURL: 119
10.1021/acs.jmedchem.1c00373
{"compound": "brigatinib degrader siais164018 with destroying metastasis-related oncoproteins and a reshuffling kinome profile proteolysis-targeting chimera ( protac ) is an attractive technology in drug discovery . canonically , targets act as a basic starting point in the most previous protac design . here , we designed degraders considering from the view of clinical benefits . with this novel design , brigatinib was turned into a degrader siais164018 and endowed with unique features . first , siais164018 could degrade not only alk fusion proteins in activating or g1202r-mutated form", "ic50_mc": "6 . 8", "selectivity_mc": "1", "ic50_ce": "5 0 0 nm", "ed50_an": "6 ( siais164018 ) degraded alk significantly at 1 0 nm and it had been identified as a potent brigatinib-based degrader (", "compound_drug": "mda-mb-231"}


{"id": 101, "paper_title": "Discovery of a Brigatinib Degrader SIAIS164018 with Destroying Metastasis-Related Oncoproteins and a Reshuffling Kinome Profile", "paper_author": ["Chaowei Ren", "Ning Sun", "Haixia Liu", "Ying Kong", "Renhong Sun", "Xing Qiu", "Jinju Chen", "Yan Li", "Jianshui Zhang", "Yuedong Zhou", "Hui Zhong", "Qianqian Yin", "Xiaoling Song", "Xiaobao Yang", "Biao Jiang"], "paper_year": 2021, "paper_institution": "Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai 201210, China", "paper_cited": -1, "doi": "10.1021/acs.jmedchem.1c00373", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00373/20210629/images/large/jm1c00373_0012.jpeg", "compound_count": 6, "compound_name": "1–11", "compound_name_drug": "Brigatinib Degrader SIAIS164018", "compound_smiles": "", "medicinal_chemistry_metrics": {"Ki": "", "Kd": "", "IC50": 6.8, "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": "", "IC50": 500.0, "EC50": "", "selectivity": "", "hERG": "", "solubility": ""}, "pharm_metrics_vivo": {"ED50": 0.006, "AUC": "", "solubility": "", "t_half": "", "bioavailability": ""}, "clinical_statistics": {}}
articleURL: 120
10.1021/jm000285q
{"compound": "2c", "selectivity_mc": "1", "ec50_ce": "3 0 0 nm", "compound_drug": "<unk> . in this paragraph , can you find out the result of compound_drug ? [SEP] results and discussion chemistry . a series of 3 , 6-diaryl-2 , 5-dihydroxybenzoquinones were prepared using the general route previously described for the synthesis of our natural product lead 1 ( scheme 1"}


{"id": 102, "paper_title": "Discovery of a Potent, Highly Selective, and Orally Efficacious Small-Molecule Activator of the Insulin Receptor", "paper_author": ["Kun Liu", "Libo Xu", "Deborah Szalkowski", "Zhihua Li", "Victor Ding", "Gloria Kwei", "Su Huskey", "David E. Moller", "James V. Heck", "Bei B. Zhang", "A. Brian Jones"], "paper_year": 2000, "paper_institution": "Merck Research Laboratories, P.O. Box 2000, Rahway, New Jersey 07065 ", "paper_cited": 64, "doi": "10.1021/jm000285q", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2000/jmcmar.2000.43.issue-19/jm000285q/production/images/large/jm000285qn00001.jpeg", "compound_count": 47, "compound_name": "2c", "compound_name_drug": "", "compound_smiles": "", "medicinal_chemistry_metrics": {"Ki": "", "Kd": "", "IC50": "", "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": "", "IC50": "", "EC50": 300.0, "selectivity": "", "hERG": "", "solubility": ""}, "pharm_metrics_vivo": {"ED50": "", "AUC": "", "solubility": "", "t_half": "", "bioavailability": ""}, "clinical_statistics": {}}
articleURL: 121
10.1021/jm030427r
{"compound": "6ab", "ic50_mc": "0 . 9 0", "selectivity_mc": "1", "ic50_ce": "1 0 0 0 0", "ed50_an": "7 6hh 4-me 0 . 5 3 6 8 6ih 2-no219 6 . 8 9 6jh 3-no21 . 1 1 8 1 0 6kh 4-no25 ."}


{"id": 103, "paper_title": "Novel Potent Orally Active Selective VEGFR-2 Tyrosine Kinase Inhibitors:  Synthesis, Structure−Activity Relationships, and Antitumor Activities of N-Phenyl-N‘-{4-(4-quinolyloxy)phenyl}ureas", "paper_author": ["Kazuo Kubo", "Toshiyuki Shimizu", "Shin-ichi Ohyama", "Hideko Murooka", "Akemi Iwai", "Kazuhide Nakamura", "Kazumasa Hasegawa", "Yoshiko Kobayashi", "Noriko Takahashi", "Kazumi Takahashi", "Shinichiro Kato", "Toshio Izawa", "Toshiyuki Isoe"], "paper_year": 2005, "paper_institution": "Pharmaceutical Research and Development Laboratories, Kirin Brewery Co., Ltd., 3 Miyahara-cho, Takasaki-shi, Gunma 370-1295, Japan ", "paper_cited": 108, "doi": "10.1021/jm030427r", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2005/jmcmar.2005.48.issue-5/jm030427r/production/images/large/jm030427rn00001.jpeg", "compound_count": 79, "compound_name": "6ab", "compound_name_drug": "", "compound_smiles": "", "medicinal_chemistry_metrics": {"Ki": "", "Kd": "", "IC50": 0.9, "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": "", "IC50": 10000.0, "EC50": "", "selectivity": "", "hERG": "", "solubility": ""}, "pharm_metrics_vivo": {"ED50": 76.0, "AUC": "", "solubility": "", "t_half": "", "bioavailability": ""}, "clinical_statistics": {}}
articleURL: 122
10.1021/jm401387j
{"compound": "1 0", "ic50_mc": "9 . 8", "selectivity_mc": "38-fold", "ed50_an": "7 , 9a , 1 3 ) the ic50 value of 2 was 1 8 nm , which was in the same range as that of the parent pyrazolopyrimidine compound 1 . replacing the trans-4-aminocyclohexylmethylamino substitution in 2 with a trans-4-hydroxycyclohexylamino group also resulted in a potent mer inhibitor 3 . this will likely diminish the undesired herg activity present in 1 as previously demonstrated with unc1062 . ( 7 ) in contrast , the mer activity decreased dramatically when the intramolecular hydrogen bond was disrupted either by moving the nitrogen of 2-pyridinyl to the c6 position of the pyridine ring ( 4 , 34-fold ) or by replacing it with a ch group ( 5 , 56-fold ) . the complete removal of the 2-pyridinyl substitution also rendered the corresponding 6 much less active ( 890-fold ) . collectively , these results validate that the pseudo-ring design through an intramolecular hydrogen bond maintains a conformation similar to the pyrazolopyrimidine . compared to 1 , compounds 2 and 3 are also more selective for mer relative to axl ( 38-fold and 67-fold , respectively ) and tyro3 ( 10-fold and 37-fold , respectively ) . this enhanced selectivity was fortuitous", "compound_drug": "unc2250"}


{"id": 104, "paper_title": "Pseudo-Cyclization through Intramolecular Hydrogen Bond Enables Discovery of Pyridine Substituted Pyrimidines as New Mer Kinase Inhibitors", "paper_author": ["Weihe Zhang", "Dehui Zhang", "Michael A. Stashko", "Deborah DeRyckere", "Debra Hunter", "Dmitri Kireev", "Michael J. Miley", "Christopher Cummings", "Minjung Lee", "Jacqueline Norris-Drouin", "Wendy M. Stewart", "Susan Sather", "Yingqiu Zhou", "Gregory Kirkpatrick", "Mischa Machius", "William P. Janzen", "H. Shelton Earp", "Douglas K. Graham", "Stephen V. Frye", "Xiaodong Wang"], "paper_year": 2013, "paper_institution": "†Center for Integrative Chemical Biology and Drug Discovery and ‡Division of Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States", "paper_cited": 40, "doi": "10.1021/jm401387j", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-23/jm401387j/production/images/large/jm-2013-01387j_0012.jpeg", "compound_count": 55, "compound_name": "10", "compound_name_drug": "", "compound_smiles": "", "medicinal_chemistry_metrics": {"Ki": "", "Kd": "", "IC50": 9.8, "selectivity": 38}, "pharm_metrics_vitro": {"Ki": "", "Kd": "", "IC50": "", "EC50": "", "selectivity": "", "hERG": "", "solubility": ""}, "pharm_metrics_vivo": {"ED50": 0.007, "AUC": "", "solubility": "", "t_half": "", "bioavailability": ""}, "clinical_statistics": {}}
articleURL: 125
10.1021/jm4011753
{"compound": "2 1", "ic50_mc": "1 . 9", "kd_mc": "1", "ic50_ce": "1 5 0", "solubility_ce": "2", "t_half_an": "1 8", "bioavailability_an": "2 0", "compound_drug": "<unk> . in this paragraph , can you find out the result of compound_drug ? [SEP] 3 results and discussion biological activity on isolated enzymes the first series of hydroxamates , compounds 2–13 , were tested in vitro for their ability to inhibit human recombinant adam-17 , mmp-1 , -2 , -9 , and -14 by a fluorimetric assay , which uses a fluorogenic peptide ( 1 5 ) as the substrate ( table 1 ) . compound 1 4 , ( 1 6"}


{"id": 105, "paper_title": "Selective Arylsulfonamide Inhibitors of ADAM-17: Hit Optimization and Activity in Ovarian Cancer Cell Models", "paper_author": ["Elisa Nuti", "Francesca Casalini", "Salvatore Santamaria", "Marina Fabbi", "Grazia Carbotti", "Silvano Ferrini", "Luciana Marinelli", "Valeria La Pietra", "Ettore Novellino", "Caterina Camodeca", "Elisabetta Orlandini", "Susanna Nencetti", "Armando Rossello"], "paper_year": 2013, "paper_institution": "Dipartimento di Farmacia, Università di Pisa, Via Bonanno 6, 56126 Pisa, Italy", "paper_cited": 13, "doi": "10.1021/jm4011753", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-20/jm4011753/production/images/large/jm-2013-011753_0013.jpeg", "compound_count": 81, "compound_name": "21", "compound_name_drug": "", "compound_smiles": "c1c(cc(Br)cc1Br)COc1ccc(cc1)S(=O)(=O)N[C@@H](C(=O)NO)CCCNC(=O)N", "medicinal_chemistry_metrics": {"Ki": "", "Kd": 1.0, "IC50": 1.9, "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": "", "IC50": 150.0, "EC50": "", "selectivity": "", "hERG": "", "solubility": 2.0}, "pharm_metrics_vivo": {"ED50": "", "AUC": "", "solubility": "", "t_half": 18.0, "bioavailability": 20.0}, "clinical_statistics": {}}
articleURL: 127
10.1021/jm0307943
{"compound": "7", "ic50_mc": "1", "ed50_an": "8 thus , we proceeded to construct a library via solution-phase synthesis . the general design of the library of nakijiquinones analogues was guided by the modular composition of these natural products .", "compound_drug": "<unk> . in this paragraph , can you find out the result of compound_drug ? [SEP] results for the synthesis of a nakijiquinone analogue library , initially a solid-phase approach was considered . attachment to the solid support via the amino acid part of the molecule appeared to be advantageous for variation of the diterpene , the quinoid , and the amino acid parts of the parent compound . unfortunately , the bond between the amino acid and the quinone is very base labile , a fact learned from initial failures encountered in the synthesis of the natural product itself . 1 8 thus , we proceeded to construct a library via solution-phase synthesis . the general design of the library of nakijiquinones analogues was guided by the modular composition of these natural products ."}


{"id": 106, "paper_title": "Development of Natural Product-Derived Receptor Tyrosine Kinase Inhibitors Based on Conservation of Protein Domain Fold", "paper_author": ["Lars Kissau", "Petra Stahl", "Ralph Mazitschek", "Athannasios Giannis", "Herbert Waldmann"], "paper_year": 2003, "paper_institution": "Max-Planck-Institut für molekulare Physiologie, Abteilung Chemische Biologie, Otto-Hahn-Strasse 11, 44227 Dortmund, Germany and Universität Dortmund, Fachbereich 3, Organische Chemie, 44221 Dortmund, Germany, and Institut für Organische Chemie, Universität Leipzig, Johannisallee 29, 04103 Leipzig, Germany ", "paper_cited": 54, "doi": "10.1021/jm0307943", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2003/jmcmar.2003.46.issue-14/jm0307943/production/images/large/jm0307943n00001.jpeg", "compound_count": 109, "compound_name": "7", "compound_name_drug": "", "compound_smiles": "", "medicinal_chemistry_metrics": {"Ki": "", "Kd": "", "IC50": 1.0, "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": "", "IC50": "", "EC50": "", "selectivity": "", "hERG": "", "solubility": ""}, "pharm_metrics_vivo": {"ED50": 8.0, "AUC": "", "solubility": "", "t_half": "", "bioavailability": ""}, "clinical_statistics": {}}
articleURL: 128
10.1021/jm011022e
{"compound": "2", "ic50_mc": "1", "t_half_an": "1 . 3", "compound_drug": "<unk> . in this paragraph , can you find out the result of compound_drug ? [SEP] results and discussion i . inhibition of receptor kinase activity in vitro . as previously reported , 1 8 one of the preferred patterns of substitution of the aniline ring to optimize inhibition of the target enzymes consists of a small lipophilic , electron-deficient substituent at the c-2‘ position combined with a larger lipophilic , electron-withdrawing atom at the c-4‘ position such as chlorine or bromine . the same patterns were apparent with basic c-7 side chains . as shown by comparison of the 4‘-cyano and 4‘-bromo derivatives 1 2 and 1 1 ( table 1"}


{"id": 107, "paper_title": "Novel 4-Anilinoquinazolines with C-7 Basic Side Chains:  Design and Structure Activity Relationship of a Series of Potent, Orally Active, VEGF Receptor Tyrosine Kinase Inhibitors", "paper_author": ["Laurent F. Hennequin", "Elaine S. E. Stokes", "Andrew P. Thomas", "Craig Johnstone", "Patrick A. Plé", "Donald J. Ogilvie", "Michael Dukes", "Stephen R. Wedge", "Jane Kendrew", "Jon O. Curwen"], "paper_year": 2002, "paper_institution": "AstraZeneca, Centre de Recherches, Z.I. La Pompelle, B.P. 1050, Chemin de Vrilly, 51689 Reims, Cedex 2, France, and AstraZeneca Pharmaceuticals, Alderley Park, Macclesfield, Cheshire SK10 4TG, United Kingdom ", "paper_cited": 217, "doi": "10.1021/jm011022e", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2002/jmcmar.2002.45.issue-6/jm011022e/production/images/large/jm011022en00001.jpeg", "compound_count": 136, "compound_name": "2", "compound_name_drug": "", "compound_smiles": "", "medicinal_chemistry_metrics": {"Ki": "", "Kd": "", "IC50": 1.0, "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": "", "IC50": "", "EC50": "", "selectivity": "", "hERG": "", "solubility": ""}, "pharm_metrics_vivo": {"ED50": "", "AUC": "", "solubility": "", "t_half": 1.3, "bioavailability": ""}, "clinical_statistics": {}}
articleURL: 134
10.1021/jm201391u
{"compound": "6a", "ic50_mc": "1 4", "selectivity_mc": "1", "ic50_ce": "2", "ed50_an": "1 , 3-dipolar cycloaddition of diazoalkanes or nitrile imines with olefins or alkynes . ( 1 1 ) recently , a novel regioselective synthesis of 1 , 3 , 4-trisubstituted pyrazoles has been successfully employed . ( 4 )", "compound_drug": "6a–h"}


{"id": 108, "paper_title": "Tri- and Tetrasubstituted Pyrazole Derivates: Regioisomerism Switches Activity from p38MAP Kinase to Important Cancer Kinases", "paper_author": ["Bassam Abu Thaher", "Martina Arnsmann", "Frank Totzke", "Jan E. Ehlert", "Michael H. G. Kubbutat", "Christoph Schächtele", "Markus O. Zimmermann", "Pierre Koch", "Frank M. Boeckler", "Stefan A. Laufer"], "paper_year": 2011, "paper_institution": "Faculty of Science, Chemistry Department, Islamic University of Gaza, Gaza Strip, Palestine", "paper_cited": 58, "doi": "10.1021/jm201391u", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-2/jm201391u/production/images/large/jm-2011-01391u_0009.jpeg", "compound_count": 24, "compound_name": "6a", "compound_name_drug": "", "compound_smiles": "", "medicinal_chemistry_metrics": {"Ki": "", "Kd": "", "IC50": 14.0, "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": "", "IC50": 2.0, "EC50": "", "selectivity": "", "hERG": "", "solubility": ""}, "pharm_metrics_vivo": {"ED50": 1.0, "AUC": "", "solubility": "", "t_half": "", "bioavailability": ""}, "clinical_statistics": {}}
articleURL: 137
10.1021/acs.jmedchem.9b00576
{"compound": "1", "ic50_mc": "3 . 8", "ic50_ce": "4 9 . 9"}


{"id": 109, "paper_title": "Structure-Based Design of 5-Methylpyrimidopyridone Derivatives as New Wild-Type Sparing Inhibitors of the Epidermal Growth Factor Receptor Triple Mutant (EGFRL858R/T790M/C797S)", "paper_author": ["Jiayi Shen", "Tao Zhang", "Su-Jie Zhu", "Min Sun", "Linjiang Tong", "Mengzhen Lai", "Rong Zhang", "Wei Xu", "Ruibo Wu", "Jian Ding", "Cai-Hong Yun", "Hua Xie", "Xiaoyun Lu", "Ke Ding"], "paper_year": 2019, "paper_institution": "International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Discovery of Chinese Ministry of Education (MOE), Guangzhou City Key Laboratory of Precision Chemical Drug Development, School of Pharmacy, Jinan University, 601 Huangpu Avenue West, Guangzhou 510632, China", "paper_cited": 14, "doi": "10.1021/acs.jmedchem.9b00576", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-15/acs.jmedchem.9b00576/20190801/images/large/jm-2019-005766_0008.jpeg", "compound_count": 45, "compound_name": "1", "compound_name_drug": "", "compound_smiles": "C1CN(CCN1C)c1c(C)cc(Nc2nc3n([C@@H]4CCCN(C(=O)CC)C4)c(=O)c(c(c3cn2)C)[C@H]2C=CCC(F)[C@H]2Cl)cc1", "medicinal_chemistry_metrics": {"Ki": "", "Kd": "", "IC50": 3.8, "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": "", "IC50": 49.9, "EC50": "", "selectivity": "", "hERG": "", "solubility": ""}, "pharm_metrics_vivo": {"ED50": "", "AUC": "", "solubility": "", "t_half": "", "bioavailability": ""}, "clinical_statistics": {}}
articleURL: 146
10.1021/jm2013453
{"compound": "2 ( vegfr-2 ) tyrosine kinase inhibitors . a quantitative structure–activity relationship analysis was conducted to rationalize the structure–activity relationship and to predict how similar the inhibitor-binding profiles of two protein kinases are likely to be on the basis of the docking of lead coumpounds into the atp-binding site", "ic50_mc": "6", "ki_mc": "growth factor receptor 2 ( vegfr-2 ) tyrosine kinase inhibitors . a quantitative structure–activity relationship analysis was conducted to rationalize the structure–activity relationship and to predict how similar the inhibitor-binding profiles of two protein kinases are likely to be on the basis of the docking of lead coumpounds into the atp-binding site . this model was used to direct the synthesis of new compounds . a series of n- ( aromatic ) -n′-{4-[ ( 6 , 7-dimethoxyquinazolin-4-yl ) oxy]phenyl}urea were identified as potent and selective inhibitors of the tyrosine kinase activity of vegfr-2 ( fetal liver kinase 1 , kinase insert domain-containing receptor ) . an efficient route was developed that enabled the synthesis of a wide variety of analogues with substitution on several positions of the template . substitution of diarylurea , competitive with atp , afforded several analogues with low nanomolar inhibition of enzymatic activity of vegfr-2 . in this paper", "kd_ce": "2 ( vegfr-2 ) tyrosine kinase inhibitors . a quantitative structure–activity relationship analysis was conducted to rationalize the structure–activity relationship and to predict how similar the inhibitor-binding profiles of two protein kinases are likely to be on the basis of the docking of lead coumpounds into the atp-binding site . this model was used to direct the synthesis of new compounds . a series of n- ( aromatic ) -n′-{4-[ ( 6 , 7-dimethoxyquinazolin-4-yl", "ec50_ce": "2 ( vegfr-2 ) tyrosine kinase inhibitors . a quantitative structure–activity relationship analysis was conducted to rationalize the structure–activity relationship and to predict how similar the inhibitor-binding profiles of two protein kinases are likely to be on the basis of the docking of lead coumpounds into the atp-binding site . this model was used to direct the synthesis of new compounds . a series of n- ( aromatic ) -n′-{4-[ ( 6 , 7-dimethoxyquinazolin-4-yl ) oxy]phenyl}urea were identified as potent and selective inhibitors of the tyrosine kinase activity of vegfr-2 ( fetal liver kinase 1 , kinase insert domain-containing receptor", "selectivity_ce": "7-dimethoxyquinazolin-4-yl", "herg_ce": "1 , kinase insert domain-containing receptor ) . an efficient route was developed that enabled the synthesis of a wide variety of analogues with substitution on several positions of the template . substitution of diarylurea , competitive with atp , afforded several analogues with low nanomolar inhibition of enzymatic activity of vegfr-2 . in this paper , we describe the synthesis , structure–activity relationships", "ed50_an": "2 ( vegfr-2 ) tyrosine kinase inhibitors . a quantitative structure–activity relationship analysis was conducted to rationalize the structure–activity relationship and to predict how similar the inhibitor-binding profiles of two protein kinases are likely to be on the basis of the docking of lead coumpounds into the atp-binding site . this model was used to direct the synthesis of new compounds . a series of n- ( aromatic ) -n′-{4-[ ( 6 , 7-dimethoxyquinazolin-4-yl ) oxy]phenyl}urea were identified as potent and selective inhibitors of the tyrosine kinase activity of vegfr-2 ( fetal liver kinase 1 , kinase insert domain-containing receptor ) . an efficient route was developed that enabled the synthesis of a wide variety of analogues with substitution on several positions of the template . substitution of diarylurea , competitive with atp , afforded several analogues with low nanomolar inhibition of enzymatic activity of vegfr-2 . in this paper , we describe the synthesis , structure–activity relationships , and pharmacological characterization of the series . . [SEP]"}


{"id": 110, "paper_title": "Synthesis and Structure–Activity Relationships of (Aryloxy)quinazoline Ureas as Novel, Potent, and Selective Vascular Endothelial Growth Factor Receptor-2 Inhibitors", "paper_author": ["Antonio Garofalo", "Amaury Farce", "Séverine Ravez", "Amélie Lemoine", "Perrine Six", "Philippe Chavatte", "Laurence Goossens", "Patrick Depreux"], "paper_year": 2012, "paper_institution": "Univ. Lille Nord de France, F-59000 Lille, France", "paper_cited": 45, "doi": "10.1021/jm2013453", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-3/jm2013453/production/images/large/jm-2011-013453_0004.jpeg", "compound_count": 41, "compound_name": "7", "compound_name_drug": "", "compound_smiles": "", "medicinal_chemistry_metrics": {"Ki": 2.0, "Kd": "", "IC50": 6.0, "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": 2.0, "IC50": "", "EC50": 2.0, "selectivity": "", "hERG": 0.001, "solubility": ""}, "pharm_metrics_vivo": {"ED50": 0.002, "AUC": "", "solubility": "", "t_half": "", "bioavailability": ""}, "clinical_statistics": {}}
articleURL: 253
10.1021/jm9011142
{"compound": ". the synthesis of these compounds involved the nucleophilic displacement of the common intermediate 5-chloro-9h-pyrimido[4 , 5-b]indole-2 , 4-diamine with appropriate benzenethiols . the inhibitory potency of both these single agents against vegfr-2 , pdgfr-β , and hts is better than or close to standards . in a colo-205 xenograft mouse model , one of the analogs significantly decreased tumor growth ( tumor growth inhibition ( tgi ) = 7", "ic50_mc": "7 6", "ki_mc": "7 6 % at 3 5", "kd_mc": "7", "ec50_ce": "7 6 % at 3 5 mg/kg", "herg_ce": "3 5", "compound_drug": "<unk> . in this paragraph , can you find out the result of compound_drug ? [SEP] [CLS] what is the compound in this paper ? [SEP] single agents with designed combination chemotherapy potential: synthesis and evaluation of substituted pyrimido[4 , 5-b]indoles as receptor tyrosine kinase and thymidylate synthase inhibitors and as antitumor agents combinations of antiangiogenic agents ( aas ) with cytotoxic agents have shown significant promise in cancer treatment , and several such clinical trials are currently underway . we have designed , synthesized , and evaluated two compounds that each inhibit vascular endothelial growth factor receptor-2 ( vegfr-2"}


{"id": 111, "paper_title": "Single Agents with Designed Combination Chemotherapy Potential: Synthesis and Evaluation of Substituted Pyrimido[4,5-b]indoles as Receptor Tyrosine Kinase and Thymidylate Synthase Inhibitors and as Antitumor Agents", "paper_author": ["Aleem Gangjee", "Nilesh Zaware", "Sudhir Raghavan", "Michael Ihnat", "Satyendra Shenoy", "Roy L. Kisliuk"], "paper_year": 2010, "paper_institution": "Division of Medicinal Chemistry, Graduate School of Pharmaceutical Sciences, Duquesne University, 600 Forbes Avenue, Pittsburgh, Pennsylvania 15282", "paper_cited": 40, "doi": "10.1021/jm9011142", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm9011142/production/images/large/jm-2009-011142_0005.jpeg", "compound_count": 16, "compound_name": "1", "compound_name_drug": "", "compound_smiles": "", "medicinal_chemistry_metrics": {"Ki": 76.0, "Kd": 7.0, "IC50": 76.0, "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": "", "IC50": "", "EC50": 76.0, "selectivity": "", "hERG": 35.0, "solubility": ""}, "pharm_metrics_vivo": {"ED50": "", "AUC": "", "solubility": "", "t_half": "", "bioavailability": ""}, "clinical_statistics": {}}
articleURL: 262
10.1021/jm301085w
{"compound": "", "ki_mc": "growth factor ( vegf ) receptors: drugs and new inhibitors the recent launch onto the market of five vegfr inhibitors indicates the therapeutic value of these agents and the importance of the research in the field of angiogenesis inhibitors for future oncologic therapy . in this perspective we briefly report the inhibitors that are in clinical use , while we dedicate two wider sections to the compounds that are in clinical trials", "selectivity_mc": "launch onto the market of five vegfr inhibitors indicates the therapeutic value of these agents and the importance of the research in the field of angiogenesis inhibitors for future oncologic therapy . in this perspective we briefly report the inhibitors that are in clinical use , while we dedicate two wider sections to the compounds that are in clinical trials", "ic50_ce": "two wider", "herg_ce": "we briefly report the inhibitors that are in clinical use", "ed50_an": "we briefly report the inhibitors that are in clinical use , while we dedicate two wider sections to the compounds that are in clinical trials and to the new derivatives appearing in the literature . we especially consider the medicinal chemistry aspect of the topic and report the structure–activity relationship studies and the binding mode of some inhibitors as well as the biological data of the compounds discovered in the past 5 years . . [SEP]", "bioavailability_an": "dedicate two wider sections to the compounds that are in clinical trials and to the new derivatives appearing in the literature . we especially consider the medicinal chemistry aspect of the topic and report the structure–activity relationship studies and the binding mode of some inhibitors as well as the biological data of the compounds discovered in the past 5 years . . [SEP]", "compound_drug": "<unk> . in this paragraph , can you find out the result of compound_drug ? [SEP] [CLS] what is the compound in this paper ? [SEP] vascular endothelial growth factor ( vegf ) receptors: drugs and new inhibitors the recent launch onto the market of five vegfr inhibitors indicates the therapeutic value of these agents and the importance of the research in the field of angiogenesis inhibitors for future oncologic therapy . in this perspective we briefly report the inhibitors that are in clinical use , while we dedicate two wider sections to the compounds that are in clinical trials and to the new derivatives appearing in the literature . we especially consider the medicinal chemistry aspect of the topic and report the structure–activity relationship studies and the binding mode of some inhibitors as well as the biological data of the compounds discovered in the past 5 years . . [SEP]"}


{"id": 112, "paper_title": "Vascular Endothelial Growth Factor (VEGF) Receptors: Drugs and New Inhibitors", "paper_author": ["Francesca Musumeci", "Marco Radi", "Chiara Brullo", "Silvia Schenone"], "paper_year": 2012, "paper_institution": "Dipartimento di Farmacia, University of Genoa, Viale Benedetto XV 3, 16132 Genova, Italy", "paper_cited": 105, "doi": "10.1021/jm301085w", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301085w/production/images/large/jm-2012-01085w_0019.jpeg", "compound_count": 66, "compound_name": "1", "compound_name_drug": "", "compound_smiles": "", "medicinal_chemistry_metrics": {"Ki": "", "Kd": "", "IC50": "", "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": "", "IC50": "", "EC50": "", "selectivity": "", "hERG": "", "solubility": ""}, "pharm_metrics_vivo": {"ED50": 0.005, "AUC": "", "solubility": "", "t_half": "", "bioavailability": 5.0}, "clinical_statistics": {}}
articleURL: 355
10.1021/jm040099a
{"compound": "1 5", "ic50_mc": "0 . 0 1 7 μm", "ki_mc": "growth factor receptor-2 inhibitors . the main compound is <unk> . in this paragraph", "selectivity_mc": "1", "ic50_ce": "0 . 0 0 5 ± 0 . 0 0 3", "ed50_an": "7 in a literature review , discovery and lead optimization efforts have provided many cdk inhibitors over the past decade;38 two of these agents , flavopiridol and ucn-01 , have advanced to clinical evaluation . 3 9 , 4 0 however , both flavopiridol41 and ucn-0142 proved to be potent but nonselective cdk inhibitors . recently , a high-affinity cdk1 inhibitor ( cgp-60474 , ic50 = 0 . 0 1 7 μm , scheme 1 ) with better selectivity toward other kinases was reported . 4 3 therefore , we decided to take advantage of the recent advances in palladium-catalyzed c−c bond , c−n bond formation reactions to assemble diverse biheteroaryl molecules ( scheme 1 ) , which might be difficult to synthesize otherwise , with the goal to identify a cdk1 inhibitor with optimized potency , selectivity , and pharmacokinetic profiles"}


{"id": 113, "paper_title": "Synthesis and Discovery of Pyrazine−Pyridine Biheteroaryl as a Novel Series of Potent Vascular Endothelial Growth Factor Receptor-2 Inhibitors", "paper_author": ["Gee-Hong Kuo", "Aihua Wang", "Stuart Emanuel", "Alan DeAngelis", "Rui Zhang", "Peter J. Connolly", "William V. Murray", "Robert H. Gruninger", "Jan Sechler", "Angel Fuentes-Pesquera", "Dana Johnson", "Steven A. Middleton", "Linda Jolliffe", "Xin Chen"], "paper_year": 2004, "paper_institution": "Drug Discovery Division, Johnson & Johnson Pharmaceutical Research and Development, L.L.C., 1000 Route 202, P.O. Box 300, Raritan, New Jersey 08869 ", "paper_cited": 27, "doi": "10.1021/jm040099a", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2005/jmcmar.2005.48.issue-6/jm040099a/production/images/large/jm040099an00001.jpeg", "compound_count": 180, "compound_name": "15", "compound_name_drug": "", "compound_smiles": "", "medicinal_chemistry_metrics": {"Ki": "", "Kd": "", "IC50": 17.0, "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": "", "IC50": 0.005, "EC50": "", "selectivity": "", "hERG": "", "solubility": ""}, "pharm_metrics_vivo": {"ED50": 7.0, "AUC": "", "solubility": "", "t_half": "", "bioavailability": ""}, "clinical_statistics": {}}
articleURL: 357
10.1021/jm050559f
{"compound": ". unequivocal evidence , from mass spectral studies , indicates that these inhibitors form a covalent interaction with cys-1045 .", "ic50_mc": "4] benzoquinone derivatives that function as potent covalent-binding , irreversible inhibitors of the kinase domain of vascular endothelial growth factor receptor-2 ( vegfr-2 ) has been prepared by ceric ammonium nitrate oxidation of substituted ( 2 , 5-dimethoxyphenyl ) ( 6 , 7-disubstituted-quinazolin-4-yl ) amines and by displacement of the chlorine atom of substituted 2-chloro-5- ( 6 , 7-disubstituted-quinazolin-4-ylamino ) -[1 , 4]benzoquinones with various amines , anilines , phenols , and alcohols . enzyme studies were conducted in the absence and presence of glutathione and plasma . several of the compounds inhibit vegf-stimulated autophosphorylation in intact cells . kinetic experiments were performed to study the reactivity of selected inhibitors toward glutathione . reactivities correlated with lumo energies calculated as averages of those of individual conformers weighted by the boltzmann distribution . these results and molecular modeling were used to rationalize the biological observations", "ki_mc": "6 , 7-disubstituted-quinazolin-4-ylamino ) -[1 , 4]benzoquinones with various amines , anilines , phenols , and alcohols", "kd_mc": "6", "ic50_ce": "2- ( quinazolin-4-ylamino ) -[1 , 4]benzoquinones as covalent-binding , irreversible inhibitors of the kinase domain of vascular endothelial growth factor receptor-2 a series of 2- ( quinazolin-4-ylamino ) -[1 , 4] benzoquinone derivatives that function as potent covalent-binding , irreversible inhibitors of the kinase domain of vascular endothelial growth factor receptor-2 ( vegfr-2 ) has been prepared by ceric ammonium nitrate oxidation of substituted ( 2 , 5-dimethoxyphenyl ) ( 6 , 7-disubstituted-quinazolin-4-yl ) amines and by displacement of the chlorine atom of substituted 2-chloro-5- ( 6 , 7-disubstituted-quinazolin-4-ylamino ) -[1 , 4]benzoquinones with various amines , anilines , phenols , and alcohols . enzyme studies were conducted in the absence and presence of glutathione and plasma . several of the compounds inhibit vegf-stimulated autophosphorylation in intact cells . kinetic experiments were performed to study the reactivity of selected inhibitors toward glutathione . reactivities correlated with lumo energies calculated as averages of those of individual conformers weighted by the boltzmann distribution . these results and molecular modeling were used to rationalize the biological observations . the compounds behave as non-atp-competitive inhibitors . unequivocal evidence , from mass spectral studies", "kd_ce": "2 , 5-dimethoxyphenyl ) ( 6 , 7-disubstituted-quinazolin-4-yl ) amines and by displacement of the chlorine atom of substituted 2-chloro-5- ( 6", "ec50_ce": "2 , 5-dimethoxyphenyl ) ( 6", "selectivity_ce": "<unk> . in this paragraph , can you find out the result of selectivity_ce ? [SEP] [CLS] what is the compound in this paper ? [SEP] 2- ( quinazolin-4-ylamino ) -[1 , 4]benzoquinones as covalent-binding , irreversible inhibitors of the kinase domain of vascular endothelial growth factor receptor-2 a series of 2- ( quinazolin-4-ylamino ) -[1 , 4] benzoquinone derivatives that function as potent covalent-binding , irreversible inhibitors of the kinase domain of vascular endothelial growth factor receptor-2 ( vegfr-2 ) has been prepared by ceric ammonium nitrate oxidation of substituted ( 2 , 5-dimethoxyphenyl", "ed50_an": "7-disubstituted-quinazolin-4-yl ) amines and by displacement of the chlorine atom of substituted 2-chloro-5- ( 6 , 7-disubstituted-quinazolin-4-ylamino ) -[1 , 4]benzoquinones with various amines , anilines , phenols , and alcohols . enzyme studies were conducted in the absence and presence of glutathione and plasma . several of the compounds inhibit vegf-stimulated autophosphorylation in intact cells . kinetic experiments were performed to study the reactivity of selected inhibitors toward glutathione . reactivities correlated with lumo energies calculated as averages of those of individual conformers weighted by the boltzmann distribution . these results and molecular modeling were used to rationalize the biological observations . the compounds behave as non-atp-competitive inhibitors . unequivocal evidence , from mass spectral studies , indicates that these inhibitors form a covalent interaction with cys-1045 . one member of this series displays antitumor activity in an in vivo model . . [SEP]", "t_half_an": "6 , 7-disubstituted-quinazolin-4-yl ) amines and by displacement of the chlorine atom of substituted 2-chloro-5- ( 6 , 7-disubstituted-quinazolin-4-ylamino ) -[1 , 4]benzoquinones with various amines , anilines , phenols , and alcohols . enzyme studies were conducted in the absence and presence of glutathione and plasma . several of the compounds inhibit vegf-stimulated autophosphorylation in intact cells . kinetic experiments were performed to study the reactivity of selected inhibitors toward glutathione . reactivities correlated with lumo energies calculated as averages of those of individual conformers weighted by the boltzmann distribution . these results and molecular modeling were used to rationalize the biological observations", "compound_drug": "<unk> . in this paragraph , can you find out the result of compound_drug ? [SEP] [CLS] what is the compound in this paper ? [SEP] 2- ( quinazolin-4-ylamino ) -[1 , 4]benzoquinones as covalent-binding , irreversible inhibitors of the kinase domain of vascular endothelial growth factor receptor-2 a series of 2- ( quinazolin-4-ylamino ) -[1 , 4] benzoquinone derivatives that function as potent covalent-binding , irreversible inhibitors of the kinase domain of vascular endothelial growth factor receptor-2 ( vegfr-2"}


{"id": 114, "paper_title": "2-(Quinazolin-4-ylamino)-[1,4]benzoquinones as Covalent-Binding, Irreversible Inhibitors of the Kinase Domain of Vascular Endothelial Growth Factor Receptor-2", "paper_author": ["Allan Wissner", "M. Brawner Floyd", "Bernard D. Johnson", "Heidi Fraser", "Charles Ingalls", "Thomas Nittoli", "Russell G. Dushin", "Carolyn Discafani", "Ramaswamy Nilakantan", "Joseph Marini", "Malini Ravi", "Kinwang Cheung", "Xingzhi Tan", "Sylvia Musto", "Tami Annable", "Marshall M. Siegel", "Frank Loganzo"], "paper_year": 2005, "paper_institution": "Chemical and Screening Sciences and Oncology Research, Wyeth Research, 401 N. Middletown Road, Pearl River, New York 10965 ", "paper_cited": 43, "doi": "10.1021/jm050559f", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2005/jmcmar.2005.48.issue-24/jm050559f/production/images/large/jm050559fn00001.jpeg", "compound_count": 215, "compound_name": "16", "compound_name_drug": ".unequivocalevidence,frommassspectralstudies,indicatesthattheseinhibitorsformacovalentinteractionwithcys-1045.", "compound_smiles": "C1CC(CCN1)COc1c(OC)cc2c(C)ncnc2c1", "medicinal_chemistry_metrics": {"Ki": 6.0, "Kd": 6.0, "IC50": 2.0, "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": 2.0, "IC50": 2.0, "EC50": 2.0, "selectivity": "", "hERG": "", "solubility": ""}, "pharm_metrics_vivo": {"ED50": 0.006, "AUC": "", "solubility": "", "t_half": 6.0, "bioavailability": ""}, "clinical_statistics": {}}
articleURL: 365
10.1021/acs.jmedchem.9b01336
{"compound": "npa101 . 3 , lacking the structural liability for demethylation . npa101 . 3 showed a selective inhibitory profile and an inhibitory concentration 5", "ic50_mc": "3", "selectivity_ce": "1", "ed50_an": "1 and data not shown ) . hydrolysis and initial oxidation occur in the selectivity region , which is the region of pz-1 that enters the allosteric pocket of both ret and vegfr2 . any modification to slow metabolism in this region can alter selectivity and inhibitory profiles and , therefore , is likely to alter the optimized ret/vegfr2 inhibitory profile", "compound_drug": "pz-1"}


{"id": 115, "paper_title": "Bioisosteric Discovery of NPA101.3, a Second-Generation RET/VEGFR2 Inhibitor Optimized for Single-Agent Polypharmacology", "paper_author": ["Marialuisa Moccia", "Brendan Frett", "Lingtian Zhang", "Naga Rajiv Lakkaniga", "David C. Briggs", "Rakhee Chauhan", "Annalisa Brescia", "Giorgia Federico", "Wei Yan", "Massimo Santoro", "Neil Q. McDonald", "Hong-yu Li", "Francesca Carlomagno"], "paper_year": 2020, "paper_institution": "Dipartimento di Medicina Molecolare e Biotecnologie Mediche, Università di Napoli “Federico II”, 80131 Napoli, Italy", "paper_cited": 6, "doi": "10.1021/acs.jmedchem.9b01336", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01336/20210220/images/large/jm9b01336_0007.jpeg", "compound_count": 0, "compound_name": "RETNEGFRZ", "compound_name_drug": "", "compound_smiles": "S(=O)(=O)(c1ccc(cc1)c1ccc2c(ncn2c2ccc(cc2)CC(=O)Nc2cc(C(C)(C)C)on2)c1)C", "medicinal_chemistry_metrics": {"Ki": "", "Kd": "", "IC50": 3.0, "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": "", "IC50": "", "EC50": "", "selectivity": "", "hERG": "", "solubility": ""}, "pharm_metrics_vivo": {"ED50": 1.0, "AUC": "", "solubility": "", "t_half": "", "bioavailability": ""}, "clinical_statistics": {}}
articleURL: 383
10.1021/jm058205b
{"compound": "", "ic50_mc": "2 . 2 7 7 μm", "ki_mc": "0 . 7 4 μm", "kd_mc": "0 . 1 6 8 μm ) reduced the binding affinity about 2-fold , the sterically bulkier 3-methoxyanilino-pyrazine 1 5 ( ic50 = 0 . 7 4 μm ) decreased the binding affinity almost 10-fold . replacing the 3-chloroaniline of 7 with 2-chloroaniline reduced the potency about 12-fold ( 1", "selectivity_mc": "2 0 with 3 , 4-dichloroaniline only decreased the potency about 2-fold ( 2 8 , ic50 = 0 . 1 8 9 μm ) . these examples suggested that 3-chloro-substitution seems to be highly favorable to the binding affinity . in addition , replacement of the 3-chloroaniline of 7 with a benzylamine group also resulted in 13-fold", "ic50_ce": "8 4 μm", "kd_ce": "2", "selectivity_ce": "1", "herg_ce": "1 . 0 1 μm ) . in a parallel study , we found out that replacing the hydroxyl group in the lower side chain of 7 with a 4-pyridine ring gave compound 2 0 with comparable potency ( ic50 = 0 . 0 7 6 μm ) . we thus synthesized two other analogues in compound 2 0 series in comparison to compound 7 series . replacing the 3-chloroaniline of 2 0 with 4-chloroaniline reduced the potency about 13-fold ( 2 4 , ic50 = 1 . 0 μm ) . on the other hand , replacement of the 3-chloroaniline of 2 0 with 3 , 4-dichloroaniline only decreased the potency about 2-fold ( 2 8 , ic50 = 0 . 1 8 9", "solubility_ce": "2 0 with comparable potency ( ic50 = 0 . 0 7 6 μm ) . we thus synthesized two other analogues in compound 2 0 series in comparison to compound 7 series . replacing the 3-chloroaniline of 2 0 with 4-chloroaniline reduced the potency about 13-fold ( 2 4 , ic50 = 1 . 0 μm ) . on the other hand , replacement of the 3-chloroaniline of 2", "ed50_an": "1 . 0 μm ) . on the other hand , replacement of the 3-chloroaniline of 2 0 with 3 , 4-dichloroaniline only decreased the potency about 2-fold ( 2 8 , ic50 = 0 . 1 8 9 μm ) . these examples suggested that 3-chloro-substitution seems to be highly favorable to the binding", "t_half_an": "3", "bioavailability_an": "7 2 5 as the vegfr-2 lead molecule in hand ( ic50 = 0 . 0 8 4 μm , table 1 ) , we first examined the binding affinities of other substituents at the upper-right position . while a smaller 3-fluoroanilino-pyrazine 1 1 ( ic50 = 0 . 1 6 8 μm ) reduced the binding affinity about 2-fold , the sterically bulkier 3-methoxyanilino-pyrazine 1 5 ( ic50 = 0 . 7 4 μm ) decreased the binding affinity almost 10-fold . replacing the 3-chloroaniline of 7 with 2-chloroaniline reduced the potency about 12-fold ( 1 9 , ic50 = 1 . 0 1 μm ) . in a parallel study , we found out that replacing the hydroxyl group in the lower side chain of 7 with a 4-pyridine ring gave compound 2 0 with comparable potency ( ic50 = 0 . 0 7 6 μm ) . we thus synthesized two other analogues in compound 2 0 series in comparison to compound 7 series . replacing the 3-chloroaniline of 2 0 with 4-chloroaniline reduced the potency about 13-fold ( 2 4 , ic50 = 1 . 0 μm ) . on the other hand , replacement of the 3-chloroaniline of 2 0 with 3 , 4-dichloroaniline only decreased the potency about 2-fold ( 2 8 , ic50 = 0 . 1 8 9 μm )", "compound_drug": "<unk> . in this paragraph , can you find out the result of compound_drug ? [SEP] results and discussion lead optimization . with 3-chloroanilino-pyrazine-pyridine-biheteroaryl 7 2 5"}


{"id": 116, "paper_title": "Synthesis and Structure−Activity Relationships of Pyrazine-Pyridine Biheteroaryls as Novel, Potent, and Selective Vascular Endothelial Growth Factor Receptor-2 Inhibitors", "paper_author": ["Gee-Hong Kuo", "Catherine Prouty", "Aihua Wang", "Stuart Emanuel", "Alan DeAngelis", "Yan Zhang", "Fengbin Song", "Lawrence Beall", "Peter J. Connolly", "Prahba Karnachi", "Xin Chen", "Robert H. Gruninger", "Jan Sechler", "Angel Fuentes-Pesquera", "Steven A. Middleton", "Linda Jolliffe", "William V. Murray"], "paper_year": 2005, "paper_institution": "Drug Discovery Division, Johnson & Johnson Pharmaceutical Research and Development, L.L.C., 1000 Route 202, P.O. Box 300, Raritan, New Jersey 08869 ", "paper_cited": 24, "doi": "10.1021/jm058205b", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2005/jmcmar.2005.48.issue-15/jm058205b/production/images/large/jm058205bn00001.jpeg", "compound_count": 243, "compound_name": "41", "compound_name_drug": "", "compound_smiles": "", "medicinal_chemistry_metrics": {"Ki": 740.0, "Kd": 168.0, "IC50": 2277.0, "selectivity": 2}, "pharm_metrics_vitro": {"Ki": "", "Kd": 2.0, "IC50": 84000.0, "EC50": "", "selectivity": "", "hERG": 1.01, "solubility": 20.0}, "pharm_metrics_vivo": {"ED50": 1.0, "AUC": "", "solubility": "", "t_half": 3.0, "bioavailability": 725.0}, "clinical_statistics": {}}
articleURL: 387
10.1021/jm401358b
{"compound": "10a", "ic50_mc": "5 2 . 5 μm", "ic50_ce": "2 2 . 0 ± 2 . 0 μm", "ed50_an": "5 2 . 5 μm against vegfr2 was obtained and the ability of clm3 to halve the kinase activity of ret was verified ( table 1 ) , we then clarified its mode of binding to both of the target proteins , exploiting preliminary docking calculations . in the case of vegfr2 , glide software ( 3 0 ) positioned clm3 into the x-ray structure of the protein ( pdb code 4ag8 ( 3 1 ) ) so that the n2 of the pyrazolopyrimidine ring can establish an h-bond with the c919 backbone , the phenylethanamine moiety is surrounded by v848 , k868 , a866 , l889 , l1035 , and v916 side chains , while the phenylethyl group forms hydrophobic contact with l840 and f918 residues . as highlighted in figure 1 , the short substitution pattern on position 4 of the heterocyclic core prevents clm3 from reaching the vegfr2 regulatory domain pocket ( rdp ) , represented by the cleft enclosed by the juxtamembrane domain of the receptor refolding into the catalytic site . accordingly , interactions with key e885 and d1046 residues , often hooked by known vegfr2 inhibitors from the literature , like sorafenib , ( 3 1 ) are", "t_half_an": "3"}


{"id": 117, "paper_title": "Structure-Based Optimization of Tyrosine Kinase Inhibitor CLM3. Design, Synthesis, Functional Evaluation, and Molecular Modeling Studies.", "paper_author": ["Stefania Sartini", "Vito Coviello", "Agostino Bruno", "Valeria La Pietra", "Luciana Marinelli", "Francesca Simorini", "Sabrina Taliani", "Silvia Salerno", "Anna Maria Marini", "Anna Fioravanti", "Paola Orlandi", "Alessandro Antonelli", "Federico Da Settimo", "Ettore Novellino", "Guido Bocci", "Concettina La Motta"], "paper_year": 2014, "paper_institution": "Dipartimento di Farmacia, Università di Pisa, Via Bonanno 6, 56126 Pisa, Italy", "paper_cited": 15, "doi": "10.1021/jm401358b", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-4/jm401358b/production/images/large/jm-2013-01358b_0008.jpeg", "compound_count": 32, "compound_name": "10a", "compound_name_drug": "", "compound_smiles": "", "medicinal_chemistry_metrics": {"Ki": "", "Kd": "", "IC50": 52500.0, "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": "", "IC50": 22000.0, "EC50": "", "selectivity": "", "hERG": "", "solubility": ""}, "pharm_metrics_vivo": {"ED50": 52.5, "AUC": "", "solubility": "", "t_half": 3.0, "bioavailability": ""}, "clinical_statistics": {}}
articleURL: 388
10.1021/jm301217c
{"compound": "", "ic50_mc": "1", "ki_mc": "1 0", "ic50_ce": "2", "ec50_ce": "7 0", "ed50_an": "3 ) this procedure results in good yields and appeared to be efficient concerning the tolerance of functional groups . scheme 3 shows the maleimide formation , carried out in a one-pot reaction with azaindole glyoxyl esters ( 10d , 11a–c ) and arylacetamide derivatives ( 12a–c ) in the presence of potassium tert-butoxide ( tbuok ) and activated molecular sieves in dry thf . ( 1 4 ) arylacetamides 12a–c are readily available from the corresponding acetic acids , which are converted to the acid chloride by reacting with phosphorus pentachloride and hydrolyzed with ammonia .", "bioavailability_an": "6 1 %", "compound_drug": "dmfdea ) and reduction with palladium/c , h2 ( scheme 1 ) . 7-azaindole ( 9d"}


{"id": 118, "paper_title": "Novel 3-Azaindolyl-4-arylmaleimides Exhibiting Potent Antiangiogenic Efficacy, Protein Kinase Inhibition, and Antiproliferative Activity", "paper_author": ["Christopher Ganser", "Eva Lauermann", "Annett Maderer", "Torsten Stauder", "Jan-Peter Kramb", "Stanislav Plutizki", "Thomas Kindler", "Markus Moehler", "Gerd Dannhardt"], "paper_year": 2012, "paper_institution": "†Department of Pharmacy, ‡Department of Internal Medicine I, and §Department of Internal Medicine III, Johannes Gutenberg University of Mainz, Mainz, Germany", "paper_cited": 26, "doi": "10.1021/jm301217c", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-22/jm301217c/production/images/large/jm-2012-01217c_0005.jpeg", "compound_count": 31, "compound_name": "18", "compound_name_drug": "", "compound_smiles": "", "medicinal_chemistry_metrics": {"Ki": 10.0, "Kd": "", "IC50": 1.0, "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": "", "IC50": 2.0, "EC50": 70.0, "selectivity": "", "hERG": "", "solubility": ""}, "pharm_metrics_vivo": {"ED50": 0.003, "AUC": "", "solubility": "", "t_half": "", "bioavailability": 61.0}, "clinical_statistics": {}}
articleURL: 420
10.1021/jm051106d
{"compound": "1 2", "ic50_mc": "<unk> . in this paragraph , can you find out the result of ic50_mc ? [SEP] [CLS] what is the compound in this paper ? [SEP] discovery and preclinical studies of ( r ) -1- ( 4- ( 4-fluoro-2-methyl-1h-indol-5-yloxy ) -5- methylpyrrolo[2 , 1-f][1 , 2 , 4]triazin-6-yloxy ) propan- 2-ol ( bms-540215 ) , an in vivo active potent vegfr-2 inhibitor a series of substituted 4- ( 4-fluoro-1h-indol-5-yloxy ) pyrrolo[2 , 1-f][1 , 2 , 4]triazine-based inhibitors of vascular endothelial growth factor receptor-2 kinase is reported . structure−activity relationship studies revealed that a methyl group at the 5-position and a substituted alkoxy group at the 6-position of the pyrrolo[2 , 1-f][1 , 2 , 4]triazine core gave potent compounds . biochemical potency , kinase selectivity , and pharmacokinetics of the series were optimized and in vitro safety liabilities were minimized to afford bms-540215 ( <b> 1 2", "ic50_ce": "2", "kd_ce": "2 , 4]triazine core gave potent compounds . biochemical potency , kinase selectivity , and pharmacokinetics of the series were optimized and in vitro safety liabilities were minimized to afford bms-540215 ( <b> 1 2 </b> ) , which demonstrated robust preclinical in vivo activity in human tumor xenograft models . the l-alanine prodrug of <b> 1 2 </b> , bms-582664 ( <b> 2", "compound_drug": "bms-540215"}


{"id": 119, "paper_title": "Discovery and Preclinical Studies of (R)-1-(4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5- methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan- 2-ol (BMS-540215), an In Vivo Active Potent VEGFR-2 Inhibitor", "paper_author": ["Rajeev S. Bhide", "Zhen-Wei Cai", "Yong-Zheng Zhang", "Ligang Qian", "Donna Wei", "Stephanie Barbosa", "Louis J. Lombardo", "Robert M. Borzilleri", "Xiaoping Zheng", "Laurence I. Wu", "Joel C. Barrish", "Soong-Hoon Kim", "Kenneth Leavitt", "Arvind Mathur", "Leslie Leith", "Sam Chao", "Barri Wautlet", "Steven Mortillo", "Robert Jeyaseelan", "Daniel Kukral", "John T. Hunt", "Amrita Kamath", "Aberra Fura", "Viral Vyas", "Punit Marathe", "Celia D'Arienzo", "George Derbin", "Joseph Fargnoli"], "paper_year": 2006, "paper_institution": "Bristol-Myers Squibb, Pharmaceutical Research Institute, Princeton, New Jersey 08543-4000 ", "paper_cited": 97, "doi": "10.1021/jm051106d", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2006/jmcmar.2006.49.issue-7/jm051106d/production/images/large/jm051106dn00001.jpeg", "compound_count": 20, "compound_name": "12", "compound_name_drug": "", "compound_smiles": "", "medicinal_chemistry_metrics": {"Ki": "", "Kd": "", "IC50": 2.0, "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": 2.0, "IC50": 2.0, "EC50": "", "selectivity": "", "hERG": "", "solubility": ""}, "pharm_metrics_vivo": {"ED50": "", "AUC": "", "solubility": "", "t_half": "", "bioavailability": ""}, "clinical_statistics": {}}
articleURL: 428
10.1021/jm049538w
{"compound": "3 9", "ic50_mc": "1", "ic50_ce": "7 3 . 2 0 304-cl 0 . 0 8 1 0 . 9 3 314-f 0 . 0 7 9 0 . 3 0 324-cn 0 . 0 5 1 0 . 4 9 334-conh20 . 0 1 8 0 . 21a"}


{"id": 120, "paper_title": "Discovery and Evaluation of 2-Anilino-5-aryloxazoles as a Novel Class of VEGFR2 Kinase Inhibitors", "paper_author": ["Philip A. Harris", "Mui Cheung", "Robert N. Hunter", "Matthew L. Brown", "James M. Veal", "Robert T. Nolte", "Liping Wang", "Wendy Liu", "Renae M. Crosby", "Jennifer H. Johnson", "Andrea H. Epperly", "Rakesh Kumar", "Deirdre K. Luttrell", "Jeffrey A. Stafford"], "paper_year": 2005, "paper_institution": "GlaxoSmithKline, Five Moore Drive, Research Triangle Park, North Carolina 27709 ", "paper_cited": 84, "doi": "10.1021/jm049538w", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2005/jmcmar.2005.48.issue-5/jm049538w/production/images/large/jm049538wn00001.jpeg", "compound_count": 135, "compound_name": "39", "compound_name_drug": "", "compound_smiles": "", "medicinal_chemistry_metrics": {"Ki": "", "Kd": "", "IC50": 1.0, "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": "", "IC50": 73.20304, "EC50": "", "selectivity": "", "hERG": "", "solubility": ""}, "pharm_metrics_vivo": {"ED50": "", "AUC": "", "solubility": "", "t_half": "", "bioavailability": ""}, "clinical_statistics": {}}
articleURL: 430
10.1021/jm701397k
{"compound": "34a", "ic50_mc": "4", "ki_mc": "1 . 4 mg/kg", "selectivity_mc": "1 . 4", "kd_ce": "4-n , n′-diphenyl ) ureas that potently inhibited a panel of vascular endothelial growth factor receptor ( vegfr ) and platelet-derived growth factor receptor ( pdgfr ) kinases . several of these compounds , such as <b> 34a </b> , are potent inhibitors of kinase insert domain-containing receptor tyrosine kinase ( kdr ) both enzymatically ( <10 nm ) and cellularly ( <10 nm ) . in addition , compound <b> 34a </b> possesses a favorable pharmacokinetic profile and demonstrates efficacy in the estradiol-induced murine uterine edema ( ue ) model ( ed50 = 1", "solubility_ce": "7-aminopyrazolo[1 , 5-a]pyrimidine urea receptor tyrosine kinase inhibitors have been discovered . investigation of structure−activity relationships of the pyrazolo[1 , 5-a]pyrimidine nucleus led to a series of 6- ( 4-n , n′-diphenyl ) ureas that potently inhibited a panel of vascular endothelial growth factor receptor ( vegfr ) and platelet-derived growth factor receptor ( pdgfr ) kinases . several of these compounds , such as <b> 34a </b> , are potent inhibitors of kinase insert domain-containing receptor tyrosine kinase ( kdr ) both enzymatically ( <10", "t_half_an": "1", "compound_drug": "<unk> . in this paragraph , can you find out the result of compound_drug ? [SEP] [CLS] what is the compound in this paper ? [SEP] 7-aminopyrazolo[1 , 5-a]pyrimidines as potent multitargeted receptor tyrosine kinase inhibitors 7-aminopyrazolo[1 , 5-a]pyrimidine urea receptor tyrosine kinase inhibitors have been discovered . investigation of structure−activity relationships of the pyrazolo[1 , 5-a]pyrimidine nucleus led to a series of 6- ( 4-n , n′-diphenyl ) ureas that potently inhibited a panel of vascular endothelial growth factor receptor ( vegfr ) and platelet-derived growth factor receptor ( pdgfr ) kinases . several of these compounds , such as <b> 34a"}


{"id": 121, "paper_title": "7-Aminopyrazolo[1,5-a]pyrimidines as Potent Multitargeted Receptor Tyrosine Kinase Inhibitors", "paper_author": ["Robin R. Frey", "Michael L. Curtin", "Daniel H. Albert", "Keith B. Glaser", "Lori J. Pease", "Niru B. Soni", "Jennifer J. Bouska", "David Reuter", "Kent D. Stewart", "Patrick Marcotte", "Gail Bukofzer", "Junling Li", "Steven K. Davidsen", "Michael R. Michaelides"], "paper_year": 2008, "paper_institution": "Global Pharmaceutical Research and Development, Abbott Laboratories, 100 Abbott Park Road, Abbott Park, Illinois 60064-6100", "paper_cited": 34, "doi": "10.1021/jm701397k", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-13/jm701397k/production/images/large/jm-2007-01397k_0019.jpeg", "compound_count": 53, "compound_name": "34a", "compound_name_drug": "", "compound_smiles": "n1(cc(c2cnn3c2ncc(c3C)c2ccc(C)cc2)cn1)C", "medicinal_chemistry_metrics": {"Ki": 1.4, "Kd": "", "IC50": 4.0, "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": 1.0, "IC50": "", "EC50": "", "selectivity": "", "hERG": "", "solubility": ""}, "pharm_metrics_vivo": {"ED50": "", "AUC": "10.6", "solubility": "", "t_half": 1.0, "bioavailability": "∼100"}, "clinical_statistics": {}}
articleURL: 440
10.1021/jm049538w
{"compound": "3 9", "ic50_mc": "1", "ic50_ce": "7 3 . 2 0 304-cl 0 . 0 8 1 0 . 9 3 314-f 0 . 0 7 9 0 . 3 0 324-cn 0 . 0 5 1 0 . 4 9 334-conh20 . 0 1 8 0 . 21a"}


{"id": 122, "paper_title": "Discovery and Evaluation of 2-Anilino-5-aryloxazoles as a Novel Class of VEGFR2 Kinase Inhibitors", "paper_author": ["Philip A. Harris", "Mui Cheung", "Robert N. Hunter", "Matthew L. Brown", "James M. Veal", "Robert T. Nolte", "Liping Wang", "Wendy Liu", "Renae M. Crosby", "Jennifer H. Johnson", "Andrea H. Epperly", "Rakesh Kumar", "Deirdre K. Luttrell", "Jeffrey A. Stafford"], "paper_year": 2005, "paper_institution": "GlaxoSmithKline, Five Moore Drive, Research Triangle Park, North Carolina 27709 ", "paper_cited": 84, "doi": "10.1021/jm049538w", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2005/jmcmar.2005.48.issue-5/jm049538w/production/images/large/jm049538wn00001.jpeg", "compound_count": 135, "compound_name": "39", "compound_name_drug": "", "compound_smiles": "", "medicinal_chemistry_metrics": {"Ki": "", "Kd": "", "IC50": 1.0, "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": "", "IC50": 73.20304, "EC50": "", "selectivity": "", "hERG": "", "solubility": ""}, "pharm_metrics_vivo": {"ED50": "", "AUC": "", "solubility": "", "t_half": "", "bioavailability": ""}, "clinical_statistics": {}}
articleURL: 442
10.1021/jm701397k
{"compound": "34a", "ic50_mc": "4", "ki_mc": "1 . 4 mg/kg", "selectivity_mc": "1 . 4", "kd_ce": "4-n , n′-diphenyl ) ureas that potently inhibited a panel of vascular endothelial growth factor receptor ( vegfr ) and platelet-derived growth factor receptor ( pdgfr ) kinases . several of these compounds , such as <b> 34a </b> , are potent inhibitors of kinase insert domain-containing receptor tyrosine kinase ( kdr ) both enzymatically ( <10 nm ) and cellularly ( <10 nm ) . in addition , compound <b> 34a </b> possesses a favorable pharmacokinetic profile and demonstrates efficacy in the estradiol-induced murine uterine edema ( ue ) model ( ed50 = 1", "solubility_ce": "7-aminopyrazolo[1 , 5-a]pyrimidine urea receptor tyrosine kinase inhibitors have been discovered . investigation of structure−activity relationships of the pyrazolo[1 , 5-a]pyrimidine nucleus led to a series of 6- ( 4-n , n′-diphenyl ) ureas that potently inhibited a panel of vascular endothelial growth factor receptor ( vegfr ) and platelet-derived growth factor receptor ( pdgfr ) kinases . several of these compounds , such as <b> 34a </b> , are potent inhibitors of kinase insert domain-containing receptor tyrosine kinase ( kdr ) both enzymatically ( <10", "t_half_an": "1", "compound_drug": "<unk> . in this paragraph , can you find out the result of compound_drug ? [SEP] [CLS] what is the compound in this paper ? [SEP] 7-aminopyrazolo[1 , 5-a]pyrimidines as potent multitargeted receptor tyrosine kinase inhibitors 7-aminopyrazolo[1 , 5-a]pyrimidine urea receptor tyrosine kinase inhibitors have been discovered . investigation of structure−activity relationships of the pyrazolo[1 , 5-a]pyrimidine nucleus led to a series of 6- ( 4-n , n′-diphenyl ) ureas that potently inhibited a panel of vascular endothelial growth factor receptor ( vegfr ) and platelet-derived growth factor receptor ( pdgfr ) kinases . several of these compounds , such as <b> 34a"}


{"id": 123, "paper_title": "7-Aminopyrazolo[1,5-a]pyrimidines as Potent Multitargeted Receptor Tyrosine Kinase Inhibitors", "paper_author": ["Robin R. Frey", "Michael L. Curtin", "Daniel H. Albert", "Keith B. Glaser", "Lori J. Pease", "Niru B. Soni", "Jennifer J. Bouska", "David Reuter", "Kent D. Stewart", "Patrick Marcotte", "Gail Bukofzer", "Junling Li", "Steven K. Davidsen", "Michael R. Michaelides"], "paper_year": 2008, "paper_institution": "Global Pharmaceutical Research and Development, Abbott Laboratories, 100 Abbott Park Road, Abbott Park, Illinois 60064-6100", "paper_cited": 34, "doi": "10.1021/jm701397k", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-13/jm701397k/production/images/large/jm-2007-01397k_0019.jpeg", "compound_count": 53, "compound_name": "34a", "compound_name_drug": "", "compound_smiles": "n1(cc(c2cnn3c2ncc(c3C)c2ccc(C)cc2)cn1)C", "medicinal_chemistry_metrics": {"Ki": 1.4, "Kd": "", "IC50": 4.0, "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": 1.0, "IC50": "", "EC50": "", "selectivity": "", "hERG": "", "solubility": ""}, "pharm_metrics_vivo": {"ED50": "", "AUC": "10.6", "solubility": "", "t_half": 1.0, "bioavailability": "∼100"}, "clinical_statistics": {}}
articleURL: 449
10.1021/acs.jmedchem.5b01582
{"compound": "3", "kd_mc": "2 ( vegfr2 ) tyrosine kinase inhibitors . in biochemical and cellular assays , the compounds exhibit single-digit nanomolar potency toward vegfr2 . compounds of this series show good exposure in rodents when dosed orally . they potently inhibit vegf-driven angiogenesis in a chamber model and rodent tumor models at daily doses of less than 3", "ec50_ce": "2 ( vegfr2 ) tyrosine kinase inhibitors . in biochemical and cellular assays , the compounds exhibit single-digit nanomolar potency toward vegfr2 . compounds of this series show good exposure in rodents when dosed orally . they potently inhibit vegf-driven angiogenesis in a chamber model and rodent tumor models at daily doses of less than 3 mg/kg by targeting the tumor vasculature as demonstrated by elisa for tie-2 in lysates or by immunohistochemical analysis", "selectivity_ce": "<unk> . in this paragraph , can you find out the result of selectivity_ce ? [SEP] [CLS] what is the compound in this paper ? [SEP] a novel potent oral series of vegfr2 inhibitors abrogate tumor growth by inhibiting angiogenesis this paper describes the identification of 6- ( pyrimidin-4-yloxy ) -naphthalene-1-carboxamides as a new class of potent and selective human vascular endothelial growth factor receptor 2 ( vegfr2 ) tyrosine kinase inhibitors . in biochemical and cellular assays , the compounds exhibit single-digit nanomolar potency toward vegfr2 . compounds of this series show good exposure in rodents when dosed orally . they potently inhibit vegf-driven angiogenesis in a chamber model and rodent tumor models at daily doses of less than 3 mg/kg by targeting the tumor vasculature as demonstrated by elisa for tie-2 in lysates or by immunohistochemical analysis . this novel series of compounds shows a potential for the treatment of solid tumors and other diseases where angiogenesis plays an important role .", "t_half_an": "3 mg/kg by targeting the tumor vasculature as demonstrated by elisa for tie-2 in lysates or by immunohistochemical analysis", "bioavailability_an": "2 ( vegfr2 ) tyrosine kinase inhibitors . in biochemical and cellular assays , the compounds exhibit single-digit nanomolar potency toward vegfr2 . compounds of this series show good exposure in rodents when dosed orally . they potently inhibit vegf-driven angiogenesis in a chamber model and rodent tumor models at daily doses of less than 3 mg/kg by targeting the tumor vasculature as demonstrated by elisa for tie-2 in lysates or by immunohistochemical analysis . this novel series of compounds shows a potential for the treatment of solid tumors and other diseases where angiogenesis plays an important role . . [SEP]"}


{"id": 124, "paper_title": "A Novel Potent Oral Series of VEGFR2 Inhibitors Abrogate Tumor Growth by Inhibiting Angiogenesis", "paper_author": ["Guido Bold", "Christian Schnell", "Pascal Furet", "Paul McSheehy", "Josef Brüggen", "Jürgen Mestan", "Paul W. Manley", "Peter Drückes", "Marion Burglin", "Ursula Dürler", "Jacqueline Loretan", "Robert Reuter", "Markus Wartmann", "Andreas Theuer", "Beatrice Bauer-Probst", "Georg Martiny-Baron", "Peter Allegrini", "Arnaud Goepfert", "Jeanette Wood", "Amanda Littlewood-Evans"], "paper_year": 2015, "paper_institution": "Oncology Research, Novartis Institutes for BioMedical Research, 4002 Basel, Switzerland", "paper_cited": 22, "doi": "10.1021/acs.jmedchem.5b01582", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01582/20160113/images/large/jm-2015-01582p_0015.jpeg", "compound_count": 14, "compound_name": "3", "compound_name_drug": "", "compound_smiles": "C(c1cccc(NC(=O)c2c3ccc(Oc4ncnc(c4)CO)cc3ccc2)c1)(F)(F)F", "medicinal_chemistry_metrics": {"Ki": "", "Kd": 2.0, "IC50": "", "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": "", "IC50": "", "EC50": 2.0, "selectivity": "", "hERG": "", "solubility": ""}, "pharm_metrics_vivo": {"ED50": "", "AUC": "", "solubility": "", "t_half": 3.0, "bioavailability": 2.0}, "clinical_statistics": {}}
articleURL: 473
10.1021/acs.jmedchem.7b01091
{"compound": "2 3", "ic50_mc": "5 ) combined with molecular docking and sitemap analysis , ( 2 6 ) the binding site of vegfr-2 can be divided into four important regions ( figure 2 ) . sorafenib , for example , binds to the active site cavity of vegfr-2 in a dfg-out ( inactive ) conformation , which enables the appropriately substituted inhibitor to penetrate into the extended hydrophobic pocket . the n-methyl picolinamide/n-methyl-2-pyridinecarboxamide part binds to the hinge region by forming two hydrogen bonds with the backbone amide nh and carbonyl oxygen of cys919 , which are the predominant forces that maintain inhibitor activity . the hydrogen bond-rich region indicates where hydrogen acceptors or donors are favorable . an effective inhibitor ( here the amide group of sorafenib ) will form two to three hydrogen bonds with the side chain of glu885 and the backbone nh of asp1046 , two residues that have also been implicated as important contributors to both hydrogen bonding and nonbonding interactions for inhibitor binding by ftmap analysis . ( 2 7 , 2 8", "kd_mc": "2 5 ) combined with molecular docking and sitemap analysis , ( 2 6 ) the binding site of vegfr-2 can be divided into four important regions ( figure 2 ) . sorafenib , for example , binds to the active site cavity of vegfr-2 in a dfg-out ( inactive ) conformation , which enables the appropriately substituted inhibitor to penetrate into the extended hydrophobic pocket . the n-methyl picolinamide/n-methyl-2-pyridinecarboxamide part binds to the hinge region by forming two hydrogen bonds with the backbone amide nh and carbonyl oxygen of cys919 , which are the predominant forces that maintain inhibitor activity . the hydrogen bond-rich region indicates where hydrogen acceptors or donors are favorable . an effective inhibitor ( here the amide group of sorafenib ) will form two to three hydrogen bonds with the side chain of glu885 and the backbone nh of asp1046 , two residues that have also been implicated as important contributors to both hydrogen bonding and nonbonding interactions for inhibitor binding by ftmap analysis . ( 2 7", "ic50_ce": "2 5", "ec50_ce": "7", "herg_ce": "2 ) . sorafenib , for example , binds to the active site cavity of vegfr-2 in a dfg-out ( inactive ) conformation", "ed50_an": "6 ) the binding site of vegfr-2 can be divided into four important regions ( figure 2 ) . sorafenib , for example , binds to the active site cavity of vegfr-2 in a dfg-out ( inactive ) conformation , which enables the appropriately substituted inhibitor to penetrate into the extended hydrophobic pocket . the n-methyl picolinamide/n-methyl-2-pyridinecarboxamide part binds to the hinge region by forming two hydrogen bonds with the backbone amide nh and carbonyl oxygen of cys919 , which are the predominant forces that maintain inhibitor activity . the hydrogen bond-rich region indicates where hydrogen acceptors or donors are favorable . an effective inhibitor ( here the amide group of sorafenib ) will form two to three hydrogen bonds with the side chain of glu885 and the backbone nh of asp1046 , two residues that have also been implicated as important contributors to both hydrogen bonding and nonbonding interactions for inhibitor binding by ftmap analysis . ( 2 7 , 2 8 ) however , we focused instead on the two important hydrophobic regions . hydrophobic region i , occupied by the central phenyl ring in sorafenib , is surrounded by several hydrophobic amino acids , including ala866 , leu840 , gly841 , and", "t_half_an": "6 ) the binding site of vegfr-2 can be divided into four important regions ( figure 2 ) . sorafenib , for example , binds to the active site cavity of vegfr-2 in a dfg-out ( inactive ) conformation , which enables the appropriately substituted inhibitor to penetrate into the extended hydrophobic pocket . the n-methyl picolinamide/n-methyl-2-pyridinecarboxamide part binds to the hinge region by forming two hydrogen bonds with the backbone amide nh and carbonyl oxygen of cys919 , which are the predominant forces that maintain inhibitor activity . the hydrogen bond-rich region indicates where hydrogen acceptors or donors are favorable . an effective inhibitor ( here the amide group of sorafenib ) will form two to three hydrogen bonds with the side chain of glu885 and the backbone nh of asp1046 , two residues that have also been implicated as important contributors to both hydrogen bonding and nonbonding interactions for inhibitor binding by ftmap analysis . ( 2 7", "bioavailability_an": "2 7", "compound_drug": "<unk> . in this paragraph , can you find out the result of compound_drug ? [SEP] results and discussion binding site analysis and sar summarization previously , we constructed a three-dimensional quantitative structure activity relationship ( 3d-qsar ) model and summarized a sar map for vegfr-2 . ( 2 5"}


{"id": 125, "paper_title": "Discovery of Novel Potent VEGFR-2 Inhibitors Exerting Significant Antiproliferative Activity against Cancer Cell Lines", "paper_author": ["Yanmin Zhang", "Yadong Chen", "Danfeng Zhang", "Lu Wang", "Tao Lu", "Yu Jiao"], "paper_year": 2017, "paper_institution": "Laboratory of Molecular Design and Drug Discovery, School of Science, China Pharmaceutical University, 639 Longmian Avenue, Nanjing 211198, China", "paper_cited": 34, "doi": "10.1021/acs.jmedchem.7b01091", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-1/acs.jmedchem.7b01091/20180110/images/large/jm-2017-01091x_0018.jpeg", "compound_count": 27, "compound_name": "23", "compound_name_drug": "", "compound_smiles": "", "medicinal_chemistry_metrics": {"Ki": "", "Kd": 25.0, "IC50": 5.0, "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": "", "IC50": 25.0, "EC50": 7.0, "selectivity": "", "hERG": 2.0, "solubility": ""}, "pharm_metrics_vivo": {"ED50": 0.006, "AUC": "", "solubility": "", "t_half": 6.0, "bioavailability": 27.0}, "clinical_statistics": {}}
articleURL: 482
10.1021/jm070034i
{"compound": "2 2", "ic50_mc": "in this paragraph", "ki_mc": "0 . 2 nm", "ic50_ce": "3 2 . 4 nm", "ed50_an": "6 . 3 mg/kg", "compound_drug": "<unk> . in this paragraph , can you find out the result of compound_drug ? [SEP] results and discussion in an effort to improve the solubility and potentially improve cellular potency of the 2-aminobenzimidazoles , analogs containing a basic amine were investigated ( table 2 ) . guided by the structural information , we attached the amine from the 3-position of the phenyl ring with a 2- to 4-atom tether to direct the group toward bulk solvent . as exemplified by compound 7"}


{"id": 126, "paper_title": "Design, Synthesis, and Evaluation of Orally Active Benzimidazoles and Benzoxazoles as Vascular Endothelial Growth Factor-2 Receptor Tyrosine Kinase Inhibitors", "paper_author": ["Michele H. Potashman", "James Bready", "Angela Coxon", "Thomas M. DeMelfi,", "Lucian DiPietro", "Nicholas Doerr", "Daniel Elbaum", "Juan Estrada", "Paul Gallant", "Julie Germain", "Yan Gu", "Jean-Christophe Harmange", "Stephen A. Kaufman", "Rick Kendall", "Joseph L. Kim", "Gondi N. Kumar", "Alexander M. Long", "Seshadri Neervannan", "Vinod F. Patel", "Anthony Polverino", "Paul Rose", "Simon van der Plas", "Douglas Whittington", "Roger Zanon", "Huilin Zhao"], "paper_year": 2007, "paper_institution": "Department of Medicinal Chemistry, Amgen Inc., One Kendall Square, Building 1000, Cambridge, Massachusetts 02139, and Oncology Research, Pharmaceutics, and Pharmacokinetic Drug Metabolism, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799 ", "paper_cited": 110, "doi": "10.1021/jm070034i", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2007/jmcmar.2007.50.issue-18/jm070034i/production/images/large/jm070034in00001.jpeg", "compound_count": 303, "compound_name": "22", "compound_name_drug": "", "compound_smiles": "O=C(c1cc(Oc2ccc3oc(nc3c2)Nc2ccc(Cl)c(OC[C@H]3NCCC3)c2)ccn1)C", "medicinal_chemistry_metrics": {"Ki": 0.2, "Kd": "", "IC50": "", "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": "", "IC50": 32.4, "EC50": "", "selectivity": "", "hERG": "", "solubility": ""}, "pharm_metrics_vivo": {"ED50": 6300.0, "AUC": "", "solubility": "", "t_half": "", "bioavailability": ""}, "clinical_statistics": {}}
articleURL: 496
10.1021/acs.jmedchem.7b01843
{"compound": "9g", "ic50_mc": "3 0 . 9 nm", "selectivity_mc": "1", "ic50_ce": "2 9 3 . 5", "compound_drug": "<unk> . in this paragraph , can you find out the result of compound_drug ? [SEP] results and discussion design and sar ( structure–activity relationship ) exploration commonly , covalent inhibitors have been developed by structure-guided attachment of an electrophilic moiety to a reversible inhibitor . ( 3 4 ) to identify an appropriate chemical scaffold for our covalent design , a set of clinical molecules with various binding modes were inspected , which emphasized the adenine region and hydrophobic region i ( figure 1c ) as the two pivotal binding sites that played important roles in binding fgfr inhibitors . it was reasonable to assume that chemical entities capable of occupying the two regions would provide acceptable binding affinity that is beneficial for covalent design . ( 3 5"}


{"id": 127, "paper_title": "Discovery of Potent Irreversible Pan-Fibroblast Growth Factor Receptor (FGFR) Inhibitors", "paper_author": ["Yuming Wang", "Lijun Li", "Jun Fan", "Yang Dai", "Alan Jiang", "Meiyu Geng", "Jing Ai", "Wenhu Duan"], "paper_year": 2018, "paper_institution": "Department of Medicinal Chemistry, Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences, 555 Zu Chong Zhi Road, Shanghai 201203, P. R. China", "paper_cited": 15, "doi": "10.1021/acs.jmedchem.7b01843", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01843/20181019/images/large/jm-2017-01843j_0020.jpeg", "compound_count": 108, "compound_name": "9g", "compound_name_drug": "", "compound_smiles": "", "medicinal_chemistry_metrics": {"Ki": "", "Kd": "", "IC50": 30.9, "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": "", "IC50": 293.5, "EC50": "", "selectivity": "", "hERG": "", "solubility": ""}, "pharm_metrics_vivo": {"ED50": "", "AUC": "277", "solubility": "", "t_half": "1.73", "bioavailability": ""}, "clinical_statistics": {}}
articleURL: 502
10.1021/jm020899q
{"compound": "7", "selectivity_mc": "9", "solubility_ce": "2", "bioavailability_an": "5 2 nm , respectively . at 3- to 5-fold higher concentrations , they also inhibit vegfr-1 and , although they possess some activity against other members of the pdgfr kinase family at submicromolar concentrations ( ckit , csf-1r , and pdgfr-β ) , they do not significantly inhibit any of the other kinases tested at concentrations <10 μm ( table 1 ) . the aniline 4 and the ester 6 were devoid of activity ( data not shown ) . in this respect , compounds 5 and 7 possess a comparable selectivity profile in comparison to clinical development compounds such as ptk787/zk222584 , su5416 , and zd6474 ( table 1"}


{"id": 128, "paper_title": "Anthranilic Acid Amides:  A Novel Class of Antiangiogenic VEGF Receptor Kinase Inhibitors", "paper_author": ["Paul W. Manley", "Pascal Furet", "Guido Bold", "Josef Brüggen", "Jürgen Mestan", "Thomas Meyer", "Christian R. Schnell", "Jeanette Wood", "Martin Haberey", "Andreas Huth", "Martin Krüger", "Andreas Menrad", "Eckhard Ottow", "Dieter Seidelmann", "Gerhard Siemeister", "Karl-Heinz Thierauch"], "paper_year": 2002, "paper_institution": "Oncology Research, Novartis Pharma AG, CH-4057 Basel, Switzerland ", "paper_cited": 78, "doi": "10.1021/jm020899q", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2002/jmcmar.2002.45.issue-26/jm020899q/production/images/large/jm020899qn00001.jpeg", "compound_count": 19, "compound_name": "7", "compound_name_drug": "", "compound_smiles": "Cc1cccc(C(F)(F)F)c1", "medicinal_chemistry_metrics": {"Ki": "", "Kd": "", "IC50": "", "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": "", "IC50": "1.16 ± 0.12 (n = 7) ", "EC50": "", "selectivity": "", "hERG": "", "solubility": 2.0}, "pharm_metrics_vivo": {"ED50": "", "AUC": "", "solubility": "", "t_half": "", "bioavailability": 52.0}, "clinical_statistics": {}}
articleURL: 516
10.1021/jm900159g
{"compound": "c4", "ic50_mc": "1", "ic50_ce": "2 0", "ed50_an": "7 ) nuclear magnetic resonance analysis ( nmr ) of the fat/vegfr-3 peptide complex localized chemical shift of residue histidine 1 0 2 5 on the fat domain ( prutzman and campbell , unpublished data ) , so we hypothesized that a small molecule binding to this site could disrupt the fak−vegfr-3 interaction . therefore , we used the crystal structure of the fat domain of fak ( 3 4 ) to dock small molecules from the nci/dtp database to the binding region in silico ( figure 1a , b ) . we selected compounds with the highest binding affinities to fak for functional testing and selected compound 1 ( figure 1b , c ) for its profound inhibitory effect on cell growth . figure 1b illustrates the binding mode of 1 with the fak fat domain . in a panel of breast , colon , lung , osteosarcoma , melanoma , and pancreas cancer cells , the ic50 of 1 varied between 1 and 2 0 μμ ( figure 1d ) . because 1 was an orally bioavailable antihistamine that inhibited cell survival , we selected it for further mechanistic analyses , focusing on human breast cancer ."}


{"id": 129, "paper_title": "Small Molecule Chloropyramine Hydrochloride (C4) Targets the Binding Site of Focal Adhesion Kinase and Vascular Endothelial Growth Factor Receptor 3 and Suppresses Breast Cancer Growth in Vivo", "paper_author": ["Elena V. Kurenova", "Darell L. Hunt", "Dihua He", "Andrew T. Magis", "David A. Ostrov", "William G. Cance"], "paper_year": 2009, "paper_institution": "Department of Surgical Oncology, Roswell Park Cancer Institute, Buffalo, New York 14263", "paper_cited": 43, "doi": "10.1021/jm900159g", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-15/jm900159g/production/images/large/jm-2009-00159g_0007.jpeg", "compound_count": 2, "compound_name": "c4", "compound_name_drug": "", "compound_smiles": "", "medicinal_chemistry_metrics": {"Ki": "", "Kd": "", "IC50": 1.0, "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": "", "IC50": 20.0, "EC50": "", "selectivity": "", "hERG": "", "solubility": ""}, "pharm_metrics_vivo": {"ED50": 0.007, "AUC": "", "solubility": "", "t_half": "", "bioavailability": ""}, "clinical_statistics": {}}
articleURL: 520
10.1021/jm0500931
{"compound": "", "ic50_mc": "1", "ki_mc": "5 0", "kd_mc": "5", "selectivity_mc": "10-fold", "ic50_ce": "9 3 . 4 15nh", "kd_ce": "3", "solubility_ce": "4", "ed50_an": "7-substituted 1 , 6-naphthyridines 16−26 , 2 8 , 3 0 , 3 1 and 33−37 ( together with the previously reported41 , 4 2 analogues 1 4 , 1 5 , 2 7 , 2 9 , 3 2 ) listed in table 1 were evaluated for their ability to prevent phosphorylation of a model glutamate−tyrosine copolymer substrate by isolated human bfgf receptor ( fgfr-1 ) , 3 8 mouse pdgf-β receptor ( pdgfr ) , and avian c-src tyrosine kinase ( all full length enzymes ) , using published methods . 3 8 , 6 3 , 6 4 the compounds were additionally evaluated against highly purified and phosphorylated kinase constructs of the cytoplasmic domains of human fgfr-1 kinase ( designated fgf# in table 1 ) and of human vegfr-2 ( lacking 5 0 residues in the kinase insert domain65 ) using assays in delfia ( dissociation-enhanced lanthanide fluoroimmunoassay ) format . ic50 is defined as the concentration of inhibitor that reduces by 5 0 % the level of 32p ( from added [32p]-atp ) incorporated into the copolymer substrate .", "bioavailability_an": "2 2", "compound_drug": "<unk> . in this paragraph , can you find out the result of compound_drug ? [SEP] results and discussion the 3- ( 3 , 5-dimethoxyphenyl ) analogues 14−26 were all highly selective ( >100-fold , often much greater ) for fgfr and vegfr over both pdgfr and c-src ( table 1 ) . compounds with 2-amino substituents ( 1 5 , 2 1"}


{"id": 130, "paper_title": "Synthesis and Structure−Activity Relationships of Soluble 7-Substituted 3-(3,5-Dimethoxyphenyl)-1,6-naphthyridin-2-amines and Related Ureas as Dual Inhibitors of the Fibroblast Growth Factor Receptor-1 and Vascular Endothelial Growth Factor Receptor-2 Tyrosine Kinases", "paper_author": ["Andrew M. Thompson", "Amy M. Delaney", "James M. Hamby", "Mel C. Schroeder", "Teresa A. Spoon", "Sheila M. Crean", "H. D. Hollis Showalter", "William A. Denny"], "paper_year": 2005, "paper_institution": "Auckland Cancer Society Research Centre, School of Medical Sciences, The University of Auckland, Private Bag 92019, Auckland 1000, New Zealand, and Pfizer Global Research and Development, Ann Arbor Laboratories, 2800 Plymouth Road, Ann Arbor, Michigan 48106-1047 ", "paper_cited": 41, "doi": "10.1021/jm0500931", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2005/jmcmar.2005.48.issue-14/jm0500931/production/images/large/jm0500931n00001.jpeg", "compound_count": 258, "compound_name": "N", "compound_name_drug": "", "compound_smiles": "", "medicinal_chemistry_metrics": {"Ki": 50.0, "Kd": 5.0, "IC50": 1.0, "selectivity": 10}, "pharm_metrics_vitro": {"Ki": "", "Kd": 3.0, "IC50": 93.415, "EC50": "", "selectivity": "", "hERG": "", "solubility": 4.0}, "pharm_metrics_vivo": {"ED50": 0.001, "AUC": "", "solubility": "", "t_half": "", "bioavailability": 22.0}, "clinical_statistics": {}}
articleURL: 568
10.1021/jm501562a
{"compound": "bibf1120", "ki_mc": "idiopathic pulmonary", "ed50_an": "three major signaling pathways involved in angiogenesis . nintedanib targets proangiogenic and pro-fibrotic pathways mediated by the vegfr family , the fibroblast growth factor receptor ( fgfr ) family , the platelet-derived growth factor receptor ( pdgfr ) family , as well as src and flt-3 kinases . the compound was identified during a lead optimization program for small-molecule inhibitors of angiogenesis and has since undergone extensive clinical investigation for the treatment of various solid tumors , and in patients with the debilitating lung disease idiopathic pulmonary fibrosis ( ipf ) . recent clinical evidence from phase iii studies has shown that nintedanib has significant efficacy in the treatment of nsclc , ovarian cancer , and ipf . this review article provides a comprehensive summary of the preclinical and clinical research and development of nintedanib from the initial drug discovery process to the latest available clinical trial data . . [SEP]"}


{"id": 131, "paper_title": "Nintedanib: From Discovery to the Clinic", "paper_author": ["Gerald J. Roth", "Rudolf Binder", "Florian Colbatzky", "Claudia Dallinger", "Rozsa Schlenker-Herceg", "Frank Hilberg", "Stefan-Lutz Wollin", "Rolf Kaiser"], "paper_year": 2014, "paper_institution": "†Department of Medicinal Chemistry; §Department of Drug Metabolism and Pharmacokinetics; ‡Department of Non-Clinical Drug Safety; ∥Department of Translational Medicine and Clinical Pharmacology; ⊥Department of Respiratory Diseases Research; and #Corporate Division Medicine, TA Oncology, Boehringer Ingelheim Pharma GmbH & Co. KG, 88397 Biberach an der Riss, Germany", "paper_cited": 134, "doi": "10.1021/jm501562a", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-3/jm501562a/20150206/images/large/jm-2014-01562a_0006.jpeg", "compound_count": 15, "compound_name": "bibf1120", "compound_name_drug": "", "compound_smiles": "C(NC)CNCC(=O)C", "medicinal_chemistry_metrics": {"Ki": "", "Kd": "", "IC50": "", "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": "", "IC50": "", "EC50": "", "selectivity": "", "hERG": "", "solubility": ""}, "pharm_metrics_vivo": {"ED50": "", "AUC": "", "solubility": "", "t_half": "", "bioavailability": ""}, "clinical_statistics": {}}
articleURL: 608
10.1021/jm301537p
{"compound": "3 3", "ic50_mc": "3", "selectivity_ce": "1", "herg_ce": "1 0 μm", "ed50_an": "3 . 1 sar of pyrazolo[3 , 4-d]pyrimidine derivatives using cell- and transgenic-zebrafish-based assays for sar analysis , cell- and transgenic-zebrafish-based assays were used . to screen flt3 kinase inhibitors , two tumor cell lines , mv4-11 and hela , were chosen . mv4-11 is a human aml cell line whose viability depends on the activation of mutated flt3 kinase ( flt3-itd ) . ( 34-37 ) hela is a human cancerous cervical tumor cell line whose viability is independent of flt3; hela cells were used to rule out activity due to non-flt3-mediated effects ( “off-target” or cellular toxic effects ) . compounds are likely better flt3 inhibitors if they have high potency against mv4-11 cells but low or no activity against hela cells . to screen vegfr2 kinase inhibitors , an in vivo live fluorescent transgenic zebrafish ( flk-1:egfp ) assay was adopted; vegfr2 is one of the key regulators of angiogenesis , and the transgenic zebrafish assay has been utilized as a less costly and more rapid in vivo method for the screening of agents with antiangiogenic activity . ( 38-41 ) the combination of cell- and transgenic-zebrafish-based assays is an effective method for identifying dual inhibitors of flt3 and vegfr2 . there are some advantages of performing sar analysis with cell- and transgenic-zebrafish-based assays rather than enzymatic assays for hit/lead optimization . for example , sar analysis based on cellular assays may permit the evaluation of both the intrinsic activity of the compounds", "t_half_an": "3 . 1", "auc_an": "3 1 8 8 1", "bioavailability_an": "3 5 . 8", "compound_drug": "<unk> . in this paragraph , can you find out the result of compound_drug ? [SEP] 3 results and discussion 3 . 1 sar of pyrazolo[3 , 4-d]pyrimidine derivatives using cell- and transgenic-zebrafish-based assays for sar analysis , cell- and transgenic-zebrafish-based assays were used . to screen flt3 kinase inhibitors , two tumor cell lines , mv4-11"}


{"id": 132, "paper_title": "Structure–Activity Relationship Studies of Pyrazolo[3,4-d]pyrimidine Derivatives Leading to the Discovery of a Novel Multikinase Inhibitor That Potently Inhibits FLT3 and VEGFR2 and Evaluation of Its Activity against Acute Myeloid Leukemia in Vitro and in Vivo", "paper_author": ["Ling-Ling Yang", "Guo-Bo Li", "Shuang Ma", "Chan Zou", "Shu Zhou", "Qi-Zheng Sun", "Chuan Cheng", "Xin Chen", "Li-Jiao Wang", "Shan Feng", "Lin-Li Li", "Sheng-Yong Yang"], "paper_year": 2013, "paper_institution": "†State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medical School, and ‡College of Chemical Engineering, Sichuan University, Sichuan 610041, China", "paper_cited": 47, "doi": "10.1021/jm301537p", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-4/jm301537p/production/images/large/jm-2012-01537p_0019.jpeg", "compound_count": 38, "compound_name": "33", "compound_name_drug": "", "compound_smiles": "n1cnc(c(c1Oc1ccc(NC(=O)Nc2cc(C(F)(F)F)c(Cl)cc2)cc1)C=N)N", "medicinal_chemistry_metrics": {"Ki": "", "Kd": "", "IC50": 3.0, "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": "", "IC50": "μm0.039", "EC50": "", "selectivity": "", "hERG": 10.0, "solubility": ""}, "pharm_metrics_vivo": {"ED50": 0.0031, "AUC": 31881.0, "solubility": "", "t_half": 3.1, "bioavailability": 35.8}, "clinical_statistics": {}}
articleURL: 653
10.1021/jm701098w
{"compound": "2 2", "ic50_ce": "2 0 , and 2 2", "selectivity_ce": "1", "ed50_an": "0 . 0 1 mg/kg", "bioavailability_an": "7 3"}


{"id": 133, "paper_title": "Evaluation of a Series of Naphthamides as Potent, Orally Active Vascular Endothelial Growth Factor Receptor-2 Tyrosine Kinase Inhibitors¶", "paper_author": ["Matthew M. Weiss", "Jean-Christophe Harmange", "Anthony J. Polverino", "David Bauer", "Loren Berry", "Virginia Berry", "George Borg", "James Bready", "Danlin Chen", "Deborah Choquette", "Angela Coxon", "Tom DeMelfi", "Nicholas Doerr", "Juan Estrada", "Julie Flynn", "Russell F. Graceffa", "Shawn P. Harriman", "Stephen Kaufman", "Daniel S. La", "Alexander Long", "Sesha Neervannan", "Vinod F. Patel", "Michele Potashman", "Kelly Regal", "Phillip M. Roveto", "Michael L. Schrag", "Charlie Starnes", "Andrew Tasker", "Yohannes Teffera", "Douglas A. Whittington", "Roger Zanon"], "paper_year": 2008, "paper_institution": "Department of Medicinal Chemistry, Department of Molecular Structure, and Department of Pharmacokinetics and Drug Metabolism, Amgen Inc., One Kendall Square, Building 1000, Cambridge, Massachusetts 02139, and Department of Oncology Research, Department of Toxicology, and Department of Pharmaceutics, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320", "paper_cited": 26, "doi": "10.1021/jm701098w", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-6/jm701098w/production/images/large/jm-2007-01098w_0012.jpeg", "compound_count": 29, "compound_name": "22", "compound_name_drug": "", "compound_smiles": "O(c1c(OC)cc2c(Oc3ccc4c(C(=O)C)cccc4c3)ccnc2c1)C", "medicinal_chemistry_metrics": {"Ki": "", "Kd": "", "IC50": "", "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": "", "IC50": 20.0, "EC50": "", "selectivity": "", "hERG": "", "solubility": ""}, "pharm_metrics_vivo": {"ED50": 10.0, "AUC": "224c", "solubility": "", "t_half": "7", "bioavailability": 73.0}, "clinical_statistics": {}}
articleURL: 689
10.1021/jm400778d
{"compound": "8b", "ic50_ce": "4 9", "selectivity_ce": "1", "ed50_an": "7 0 nm ) compared to that of compound 2 . the ratio of vegfr2 ic50 to braf ic50 ( v/b ratio ) is a useful metric in discussing the selectivity of our braf inhibitors . introduction of a nitro group at the c-7 position ( 3b ) improved braf selectivity ( v/b ratio for no2 , 2 . 8; for h , 0 . 5 6 ) . furthermore , the cellular inhibitory activity of 3b toward mek phosphorylation ( ic50 = 2 9 nm ) was approximately 8-fold more potent than that for 2 .", "bioavailability_an": "1 0 8"}


{"id": 134, "paper_title": "Discovery of a Selective Kinase Inhibitor (TAK-632) Targeting Pan-RAF Inhibition: Design, Synthesis, and Biological Evaluation of C-7-Substituted 1,3-Benzothiazole Derivatives", "paper_author": ["Masanori Okaniwa", "Masaaki Hirose", "Takeo Arita", "Masato Yabuki", "Akito Nakamura", "Terufumi Takagi", "Tomohiro Kawamoto", "Noriko Uchiyama", "Akihiko Sumita", "Shunichirou Tsutsumi", "Tsuneaki Tottori", "Yoshitaka Inui", "Bi-Ching Sang", "Jason Yano", "Kathleen Aertgeerts", "Sei Yoshida", "Tomoyasu Ishikawa"], "paper_year": 2013, "paper_institution": "Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1 Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan", "paper_cited": 62, "doi": "10.1021/jm400778d", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-16/jm400778d/production/images/large/jm-2013-00778d_0019.jpeg", "compound_count": 57, "compound_name": "8b", "compound_name_drug": "", "compound_smiles": "", "medicinal_chemistry_metrics": {"Ki": "", "Kd": "", "IC50": "2.4 (0.45–12)", "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": "", "IC50": 49.0, "EC50": "", "selectivity": "", "hERG": "", "solubility": ""}, "pharm_metrics_vivo": {"ED50": 0.07, "AUC": "", "solubility": "", "t_half": "", "bioavailability": 108.0}, "clinical_statistics": {}}
articleURL: 709
10.1021/jm0501275
{"compound": "5 0", "ic50_mc": "4 . 8 nm", "ic50_ce": "5 0 0 nm", "ed50_an": "1−4 were initially screened and optimized for inhibition of human vegfr-2 tyrosine kinase activity . potent analogues ( ic50 < 1 0 0 nm ) identified in the primary biochemical assay23 were then evaluated for inhibition of fgfr-1 kinase activity . select compounds were subsequently screened for enzyme inhibition against a small panel of rtks [flk-1 , pdgfr-β , her-1 ( egfr ) , her-2 , igf-1r] utilizing a previously reported assay format . 2 3 in each case , the entire cytoplasmic domain sequence of the rtk was fused to glutathione s-transferase and the biological activity was determined by quantitation of the amount of radioactive phosphate transferred to an artificial poly ( glu4/tyr ) substrate . procedures for measuring activity against the representative nonreceptor kinase lck and the serine-threonine kinases pkcα and cdk2 have also been described previously . 3 4 , 3 5 the most potent and selective vegfr-2 and fgfr-1 inhibitors were evaluated for their ability to inhibit growth-factor-stimulated cellular proliferation of human umbilical vein endothelial cells ( huvecs ) using either vegf or fgf as the mitogen . 2 3 as a positive control for general cytotoxicity , compounds evaluated in the huvec assays were also tested for their ability to inhibit the proliferation of the l2987 human lung carcinoma cell line . in all cases , the pyrrolotriazine analogues described herein provided ic50 values", "bioavailability_an": "7 9 %", "compound_drug": "<unk> . in this paragraph , can you find out the result of compound_drug ? [SEP] , 1 0 ) had minimal effect on the intrinsic activity , while the bromide analogue 1 1 ( r2 = br ) was >2-fold less potent than the parent hydroxamate derivative 9 . incorporation of a fluorine atom at r2 was well-tolerated , although the fluorine atom of analogue 1 3 ( r1 = f"}


{"id": 135, "paper_title": "Design, Synthesis, and Evaluation of Orally Active 4-(2,4-Difluoro-5-(methoxycarbamoyl)phenylamino)pyrrolo[2,1-f][1,2,4]triazines as Dual Vascular Endothelial Growth Factor Receptor-2 and Fibroblast Growth Factor Receptor-1 Inhibitors", "paper_author": ["Robert M. Borzilleri", "Xiaoping Zheng", "Ligang Qian", "Christopher Ellis", "Zhen-wei Cai", "Barri S. Wautlet", "Steve Mortillo", "Robert Jeyaseelan,", "Daniel W. Kukral", "Aberra Fura", "Amrita Kamath", "Viral Vyas", "John S. Tokarski", "Joel C. Barrish", "John T. Hunt", "Louis J. Lombardo", "Joseph Fargnoli", "Rajeev S. Bhide"], "paper_year": 2005, "paper_institution": "Departments of Oncology Chemistry, Discovery Biology, Metabolism and Pharmacokinetics, and Structural Biology and Modeling, Bristol-Myers Squibb Pharmaceutical Research Institute, P.O. Box 4000, Princeton, New Jersey 08543-4000 ", "paper_cited": 52, "doi": "10.1021/jm0501275", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2005/jmcmar.2005.48.issue-12/jm0501275/production/images/large/jm0501275n00001.jpeg", "compound_count": 207, "compound_name": "50", "compound_name_drug": "", "compound_smiles": "", "medicinal_chemistry_metrics": {"Ki": "", "Kd": "", "IC50": 4.8, "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": "", "IC50": 500.0, "EC50": "", "selectivity": "", "hERG": "", "solubility": ""}, "pharm_metrics_vivo": {"ED50": 0.1, "AUC": "", "solubility": "", "t_half": "", "bioavailability": 79.0}, "clinical_statistics": {}}
articleURL: 740
10.1021/jm300126x
{"compound": "6d", "ic50_mc": "3 . 1 and 4 3", "ic50_ce": "0 . 5 3", "kd_ce": "3", "selectivity_ce": "1", "ed50_an": "3 . 1 and 4 3 nm , respectively . however , western blotting assay for assessing the phosphorylation level of the downstream mek1/2 ( pmek ) in ht-29 colon cancer cells revealed that its cellular activity based on braf ( v600e ) inhibition was insufficient ( ic50 = 3 8 0 0 nm ) . thus , our initial medicinal chemistry efforts were directed at exploring the alkylamide side chain ( r1 ) and hydrophobic “back pocket” benzamide moiety ( r3 ) using the imidazo[1 , 2-b]pyridazine scaffold 1 to enhance both braf ( v600e ) and cellular pmek inhibitory activities .", "bioavailability_an": "7 0 . 5 %", "compound_drug": "v600e"}


{"id": 136, "paper_title": "Design and Synthesis of Novel DFG-Out RAF/Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) Inhibitors. 1. Exploration of [5,6]-Fused Bicyclic Scaffolds", "paper_author": ["Masanori Okaniwa", "Masaaki Hirose", "Takashi Imada", "Tomohiro Ohashi", "Youko Hayashi", "Tohru Miyazaki", "Takeo Arita", "Masato Yabuki", "Kazuyo Kakoi", "Juran Kato", "Terufumi Takagi", "Tomohiro Kawamoto", "Shuhei Yao", "Akihiko Sumita", "Shunichirou Tsutsumi", "Tsuneaki Tottori", "Hideyuki Oki", "Bi-Ching Sang", "Jason Yano", "Kathleen Aertgeerts", "Sei Yoshida", "Tomoyasu Ishikawa"], "paper_year": 2012, "paper_institution": "Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-Chome, Fujisawa, Kanagawa 251-8555, Japan", "paper_cited": 41, "doi": "10.1021/jm300126x", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-7/jm300126x/production/images/large/jm-2012-00126x_0028.jpeg", "compound_count": 95, "compound_name": "6d", "compound_name_drug": "", "compound_smiles": "", "medicinal_chemistry_metrics": {"Ki": "", "Kd": "", "IC50": 3.1, "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": 3.0, "IC50": 0.53, "EC50": "", "selectivity": "", "hERG": "", "solubility": ""}, "pharm_metrics_vivo": {"ED50": 0.0031, "AUC": "", "solubility": "", "t_half": "", "bioavailability": 70.5}, "clinical_statistics": {}}
